var title_f28_50_29472="Neonate with gastroschisi";
var content_f28_50_29472=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F60889&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F60889&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Neonate with gastroschisis, showing eviscerated bowel",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 292px; height: 258px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Ana Monteagudo, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f28_50_29472=[""].join("\n");
var outline_f28_50_29472=null;
var title_f28_50_29473="Patient information: Bunion (The Basics)";
var content_f28_50_29473=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div>",
"   &nbsp;",
"  </div>",
"  <div id=\"basicsTopicMinWidth\">",
"   <div id=\"basicsTopicRight\">",
"    <div id=\"placeholder\">",
"     <div id=\"basics-graphics\">",
"      <span class=\"basics-box-top\">",
"      </span>",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-graphics-title.png\"/>",
"       <span class=\"openRelatedGraphics\" id=\"PI/17212\" rel=\"graphic_box\">",
"        <a href=\"#\" title=\"View All Related Graphics\">",
"         View All",
"        </a>",
"       </span>",
"      </h4>",
"      <ul>",
"       <li>",
"        <a class=\"graphic graphic_figure\" href=\"UTD.htm?16/28/16847\">",
"         Bunion",
"        </a>",
"        <li>",
"         <a class=\"graphic graphic_picture\" href=\"UTD.htm?1/32/1537\">",
"          Night splint to treat a bunion",
"         </a>",
"        </li>",
"       </li>",
"      </ul>",
"      <a href=\"#\" id=\"basics-seeall\">",
"       See All Graphics",
"      </a>",
"     </div>",
"     <script type=\"text/javascript\">",
"      if ($(\"#basics-graphics li\").length &lt;= 4) {",
"				$(\"#basics-seeall\").remove();",
"			} else {",
"				$(\"#basics-graphics li:gt(3)\").addClass(\"hidden\");",
"				$(\"#basics-seeall\").click(function(){",
"					$(\"#basics-graphics li.hidden\").removeClass(\"hidden\");",
"					$(this).remove();",
"					return false;",
"				});",
"			}",
"     </script>",
"     <div class=\"ieSpacer\">",
"     </div>",
"     <div id=\"basics-more\">",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-more-title.png\"/>",
"      </h4>",
"      <dl>",
"       <dt class=\"basics\">",
"        The Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?0/52/834\">",
"         Patient information: Corns and calluses (The Basics)",
"        </a>",
"       </dd>",
"      </dl>",
"      <div id=\"tooltipper\">",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"   <div id=\"basicsTopicLeft\">",
"    <div id=\"topicTitle\">",
"     Patient information: Bunion (The Basics)",
"    </div>",
"    <span class=\"view\">",
"     View in",
"     <a class=\"lang\" href=\"./es-419/bunion-the-basics?source=topic_page\">",
"      Spanish",
"     </a>",
"    </span>",
"    <a class=\"contributor contributor_credentials\" href=\"./authors-and-editors/patient-information\">",
"     Written by the doctors and editors at UpToDate",
"    </a>",
"    <div id=\"topicText\">",
"     <p class=\"headingAnchor\" id=\"H16326120\">",
"      <span class=\"h1\">",
"       What is a bunion?",
"      </span>",
"      &nbsp;&mdash;&nbsp;A bunion is a bony bump on the joint at the base of your big toe (",
"      <a class=\"graphic graphic_figure graphicRef72906 \" href=\"UTD.htm?16/28/16847\">",
"       figure 1",
"      </a>",
"      ). It happens when your big toe points toward your second toe.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H16326135\">",
"      <span class=\"h1\">",
"       What are the symptoms of a bunion?",
"      </span>",
"      &nbsp;&mdash;&nbsp;The symptoms include:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        A bony bump on the joint at the base of the big toe",
"       </li>",
"       <li>",
"        Pain around the big toe joint",
"       </li>",
"       <li>",
"        Trouble moving the big toe",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      Your big toe might also turn red and swollen. &nbsp;",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H16326150\">",
"      <span class=\"h1\">",
"       Is there a test for a bunion?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Maybe. Your doctor or nurse should be able to tell if you have it by learning about your symptoms and doing an exam. But you might need an X-ray to see if the joint in your toe is damaged.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H16326165\">",
"      <span class=\"h1\">",
"       Is there anything I can do on my own to feel better?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Yes. You might feel better if you:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Wear wide, low-heeled shoes, or special shoes designed to have extra space around the big toe.",
"       </li>",
"       <li>",
"        Do stretching exercises &ndash; This helps the toe and foot joints move better.",
"       </li>",
"       <li>",
"        Wear a bunion pad &ndash; This is a small cushion that keeps the big toe from rubbing against your shoe.",
"       </li>",
"       <li>",
"        Put a cold gel pack, bag of ice, or bag of frozen vegetables on the bunion for 20 to 30 minutes after exercising. Put a thin towel between the ice (or other cold object) and your skin.",
"       </li>",
"       <li>",
"        Take medicine to reduce the pain, such as",
"        <a class=\"drug drug_patient\" href=\"UTD.htm?19/35/20021?source=see_link\">",
"         acetaminophen",
"        </a>",
"        (brand name: Tylenol&reg;) or",
"        <a class=\"drug drug_patient\" href=\"UTD.htm?14/17/14614?source=see_link\">",
"         ibuprofen",
"        </a>",
"        (sample brand names: Advil&reg;, Motrin&reg;)",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H16326180\">",
"      <span class=\"h1\">",
"       How is a bunion treated?",
"      </span>",
"      &nbsp;&mdash;&nbsp;If the treatments you have tried on your own don&rsquo;t help, you doctor might refer you to a foot doctor, called a &ldquo;podiatrist.&rdquo; A podiatrist can fit you with:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        A special shoe insert (called an &ldquo;orthotic&rdquo;) to align and support your toe during the day.",
"       </li>",
"       <li>",
"        A foot splint to help to straighten the toe at night while you sleep (",
"        <a class=\"graphic graphic_picture graphicRef51796 \" href=\"UTD.htm?1/32/1537\">",
"         picture 1",
"        </a>",
"        ). &nbsp;",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      If you have severe pain or trouble walking, your doctor can refer you to a foot surgeon. There are many different types of surgery to realign the toe and remove the bony bump of a bunion.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H16326195\">",
"      <span class=\"h1\">",
"       Can a bunion be prevented?",
"      </span>",
"      &nbsp;&mdash;&nbsp;You might be less likely to get a bunion if you avoid wearing shoes that squeeze or put pressure on your toes.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H13526910\">",
"      <span class=\"h1\">",
"       More on this topic",
"      </span>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?0/52/834?source=see_link\">",
"       Patient information: Corns and calluses (The Basics)",
"      </a>",
"     </p>",
"    </div>",
"    <div id=\"reviewProcess\">",
"     <span>",
"      All topics are updated as new evidence becomes available and our",
"      <a class=\"policy policy_editorialpolicy\" href=\"/home/editorial-policy\">",
"       peer review process",
"      </a>",
"      is complete.",
"     </span>",
"    </div>",
"    <div id=\"topicRetrievedDate\">",
"     <span class=\"emphasis\">",
"      This topic retrieved from UpToDate on:",
"     </span>",
"     Apr 20, 2013.",
"    </div>",
"    <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"     <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"      Find",
"     </a>",
"     <a class=\"toolbutton printicon\" href=\"UTD.htm?28/50/29473?view=print\" title=\"Print This Topic\">",
"      Print",
"     </a>",
"     <a class=\"toolbutton emailicon etacLink\" href=\"#\" title=\"Email This Topic\">",
"      Email",
"     </a>",
"    </div>",
"    <div id=\"disclaimer\">",
"     The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions.",
"The use of UpToDate content is governed by the",
"     <a class=\"legal legal_termsofuse\" href=\"/home/terms-use\" target=\"_blank\">",
"      UpToDate Terms of Use",
"     </a>",
"     . &copy;2013 UpToDate, Inc. All rights reserved.",
"    </div>",
"    <div id=\"topicVersionRevision\">",
"     Topic 17212 Version 3.0",
"    </div>",
"   </div>",
"   <!--  basicsTopicLeft -->",
"  </div>",
"  <!-- basicsTopicMinWidth -->",
" </div>",
" <!-- topicContent -->",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-183.166.191.243-84F2B57B49-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f28_50_29473=[""].join("\n");
var outline_f28_50_29473=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16326120\">",
"      What is a bunion?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16326135\">",
"      What are the symptoms of a bunion?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16326150\">",
"      Is there a test for a bunion?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16326165\">",
"      Is there anything I can do on my own to feel better?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16326180\">",
"      How is a bunion treated?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16326195\">",
"      Can a bunion be prevented?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13526910\">",
"      More on this topic",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PI/17212\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li>",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?16/28/16847\">",
"      Bunion",
"     </a>",
"     <li>",
"      <a class=\"graphic graphic_picture\" href=\"UTD.htm?1/32/1537\">",
"       Night splint to treat a bunion",
"      </a>",
"     </li>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?0/52/834?source=related_link\">",
"      Patient information: Corns and calluses (The Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f28_50_29474="Patient information: Knee replacement (The Basics)";
var content_f28_50_29474=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"0\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div>",
"   &nbsp;",
"  </div>",
"  <div id=\"basicsTopicMinWidth\">",
"   <div id=\"basicsTopicRight\">",
"    <div id=\"placeholder\">",
"     <div id=\"basics-graphics\">",
"      <span class=\"basics-box-top\">",
"      </span>",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-graphics-title.png\"/>",
"       <span class=\"openRelatedGraphics\" id=\"PI/15809\" rel=\"graphic_box\">",
"        <a href=\"#\" title=\"View All Related Graphics\">",
"         View All",
"        </a>",
"       </span>",
"      </h4>",
"      <ul>",
"       <li>",
"        <a class=\"graphic graphic_figure\" href=\"UTD.htm?17/11/17584\">",
"         Right knee",
"        </a>",
"       </li>",
"      </ul>",
"      <a href=\"#\" id=\"basics-seeall\">",
"       See All Graphics",
"      </a>",
"     </div>",
"     <script type=\"text/javascript\">",
"      if ($(\"#basics-graphics li\").length &lt;= 4) {",
"				$(\"#basics-seeall\").remove();",
"			} else {",
"				$(\"#basics-graphics li:gt(3)\").addClass(\"hidden\");",
"				$(\"#basics-seeall\").click(function(){",
"					$(\"#basics-graphics li.hidden\").removeClass(\"hidden\");",
"					$(this).remove();",
"					return false;",
"				});",
"			}",
"     </script>",
"     <div class=\"ieSpacer\">",
"     </div>",
"     <div id=\"basics-more\">",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-more-title.png\"/>",
"      </h4>",
"      <dl>",
"       <dt class=\"basics\">",
"        The Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?1/3/1075\">",
"         Patient information: Deep vein thrombosis (blood clots in the legs) (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?42/3/43058\">",
"         Patient information: Osteoarthritis (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?16/31/16883\">",
"         Patient information: Rheumatoid arthritis (The Basics)",
"        </a>",
"       </dd>",
"       <dt class=\"beyondthebasics\">",
"        Beyond the Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?12/44/12998\">",
"         Patient information: Deep vein thrombosis (DVT) (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?18/21/18769\">",
"         Patient information: Joint infection (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?24/4/24642\">",
"         Patient information: Knee pain (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?21/13/21717\">",
"         Patient information: Total knee replacement (arthroplasty) (Beyond the Basics)",
"        </a>",
"       </dd>",
"      </dl>",
"      <div id=\"tooltipper\">",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"   <div id=\"basicsTopicLeft\">",
"    <div id=\"topicTitle\">",
"     Patient information: Knee replacement (The Basics)",
"    </div>",
"    <span class=\"view\">",
"     View in",
"     <a class=\"lang\" href=\"./es-419/knee-replacement-the-basics?source=topic_page\">",
"      Spanish",
"     </a>",
"    </span>",
"    <a class=\"contributor contributor_credentials\" href=\"./authors-and-editors/patient-information\">",
"     Written by the doctors and editors at UpToDate",
"    </a>",
"    <div id=\"topicText\">",
"     <p class=\"headingAnchor\" id=\"H1717207\">",
"      <span class=\"h1\">",
"       What is knee replacement?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Knee replacement is a type of surgery in which a doctor replaces parts of a person&rsquo;s knee joint with man-made parts.",
"     </p>",
"     <p>",
"      The knee joint is made up of the lower part of the thigh bone, the knee cap, and the top part of the lower leg bone (",
"      <a class=\"graphic graphic_figure graphicRef57878 \" href=\"UTD.htm?17/11/17584\">",
"       figure 1",
"      </a>",
"      ).",
"     </p>",
"     <p>",
"      When people have problems with their knee joint, the knee can be painful, swollen, stiff, or have trouble moving normally. Different conditions can cause problems with the knee joint. One of the most common causes is osteoarthritis, a type of arthritis that often comes with age.",
"     </p>",
"     <p>",
"      Knee replacement is a treatment that can reduce knee pain and improve the way the knee works.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H1717214\">",
"      <span class=\"h1\">",
"       When are knee problems treated with knee replacement?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Knee problems might or might not be treated with knee replacement right away. Doctors sometimes suggest trying other treatments first. These can include weight loss, medicines, knee braces, or physical therapy. If these treatments do not help enough, doctors then suggest knee replacement.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H1717221\">",
"      <span class=\"h1\">",
"       What happens during knee replacement surgery?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Knee replacement takes place in an operating room in a hospital. A doctor will give you medicines to make you sleep and to numb your body. Then your doctor will make a cut down the center on the front of the knee. He or she will replace parts of your knee joint with man-made parts made out of metal, ceramic, or plastic.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H1717228\">",
"      <span class=\"h1\">",
"       What happens after surgery?",
"      </span>",
"      &nbsp;&mdash;&nbsp;After surgery, most people stay in the hospital for 2 to 4 days. While you are in the hospital, you will get:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Medicines to treat your pain",
"       </li>",
"       <li>",
"        Antibiotic medicines to prevent infections",
"       </li>",
"       <li>",
"        Medicines to prevent blood clots in the legs",
"       </li>",
"       <li>",
"        Special boots or stockings to prevent blood clots in the legs",
"       </li>",
"       <li>",
"        Physical therapy &ndash; Most people are able to stand and walk (with help) within 1 day after surgery. The physical therapist will teach you exercises to make the muscles in your leg stronger. He or she will also work with you on bending, walking, and climbing stairs so that you can move normally.",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H1717235\">",
"      <span class=\"h1\">",
"       What problems can people have from knee replacement?",
"      </span>",
"      &nbsp;&mdash;&nbsp;People can have different problems right after knee replacement surgery, but serious problems are uncommon. Problems from knee replacement can include:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Blood clots in the legs &ndash; This can cause leg pain and swelling.",
"       </li>",
"       <li>",
"        Infections &ndash; Symptoms of an infection can include fever, chills, pain in the knee that gets worse and worse, or knee swelling.",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      If you have any of these symptoms, let your doctor or nurse know.",
"     </p>",
"     <p>",
"      People who have a knee replaced sometimes find that the new knee is stiff and does not bend as well as their own knee used to. This can make it hard to climb stairs or get up from a low chair.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H1717242\">",
"      <span class=\"h1\">",
"       Where do I go after I leave the hospital?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Many people go home. But some people stay in a nursing home or rehabilitation facility for a short time in order to get stronger before going home. Wherever you go, you will need to do your exercises and have physical therapy.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H1717249\">",
"      <span class=\"h1\">",
"       When will I be able to do my usual activities again?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Most people can do their usual activities again within 3 to 6 weeks of knee replacement. Your doctor or nurse will tell you if there are any activities that you should avoid.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H1717256\">",
"      <span class=\"h1\">",
"       How do I know if knee replacement is right for me?",
"      </span>",
"      &nbsp;&mdash;&nbsp;To help you decide if knee replacement is right for you, talk with your doctor or nurse. You can ask him or her:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        What are the benefits of knee replacement?",
"       </li>",
"       <li>",
"        What are the downsides to knee replacement?",
"       </li>",
"       <li>",
"        Are there other options besides knee replacement?",
"       </li>",
"       <li>",
"        What happens if I do not have knee replacement?",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H1717263\">",
"      <span class=\"h1\">",
"       More on this topic",
"      </span>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?42/3/43058?source=see_link\">",
"       Patient information: Osteoarthritis (The Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?16/31/16883?source=see_link\">",
"       Patient information: Rheumatoid arthritis (The Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?1/3/1075?source=see_link\">",
"       Patient information: Deep vein thrombosis (blood clots in the legs) (The Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?21/13/21717?source=see_link\">",
"       Patient information: Total knee replacement (arthroplasty) (Beyond the Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?24/4/24642?source=see_link\">",
"       Patient information: Knee pain (Beyond the Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?18/21/18769?source=see_link\">",
"       Patient information: Joint infection (Beyond the Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?12/44/12998?source=see_link\">",
"       Patient information: Deep vein thrombosis (DVT) (Beyond the Basics)",
"      </a>",
"     </p>",
"    </div>",
"    <div id=\"reviewProcess\">",
"     <span>",
"      All topics are updated as new evidence becomes available and our",
"      <a class=\"policy policy_editorialpolicy\" href=\"/home/editorial-policy\">",
"       peer review process",
"      </a>",
"      is complete.",
"     </span>",
"    </div>",
"    <div id=\"topicRetrievedDate\">",
"     <span class=\"emphasis\">",
"      This topic retrieved from UpToDate on:",
"     </span>",
"     Apr 20, 2013.",
"    </div>",
"    <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"     <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"      Find",
"     </a>",
"     <a class=\"toolbutton printicon\" href=\"UTD.htm?28/50/29474?view=print\" title=\"Print This Topic\">",
"      Print",
"     </a>",
"     <a class=\"toolbutton emailicon etacLink\" href=\"#\" title=\"Email This Topic\">",
"      Email",
"     </a>",
"    </div>",
"    <div id=\"disclaimer\">",
"     The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions.",
"The use of UpToDate content is governed by the",
"     <a class=\"legal legal_termsofuse\" href=\"/home/terms-use\" target=\"_blank\">",
"      UpToDate Terms of Use",
"     </a>",
"     . &copy;2013 UpToDate, Inc. All rights reserved.",
"    </div>",
"    <div id=\"topicVersionRevision\">",
"     Topic 15809 Version 3.0",
"    </div>",
"   </div>",
"   <!--  basicsTopicLeft -->",
"  </div>",
"  <!-- basicsTopicMinWidth -->",
" </div>",
" <!-- topicContent -->",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-203.80.222.8-EE4A41C0CF-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f28_50_29474=[""].join("\n");
var outline_f28_50_29474=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1717207\">",
"      What is knee replacement?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1717214\">",
"      When are knee problems treated with knee replacement?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1717221\">",
"      What happens during knee replacement surgery?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1717228\">",
"      What happens after surgery?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1717235\">",
"      What problems can people have from knee replacement?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1717242\">",
"      Where do I go after I leave the hospital?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1717249\">",
"      When will I be able to do my usual activities again?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1717256\">",
"      How do I know if knee replacement is right for me?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1717263\">",
"      More on this topic",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PI/15809\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li>",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?17/11/17584\">",
"      Right knee",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?12/44/12998?source=related_link\">",
"      Patient information: Deep vein thrombosis (DVT) (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?1/3/1075?source=related_link\">",
"      Patient information: Deep vein thrombosis (blood clots in the legs) (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?18/21/18769?source=related_link\">",
"      Patient information: Joint infection (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?24/4/24642?source=related_link\">",
"      Patient information: Knee pain (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?42/3/43058?source=related_link\">",
"      Patient information: Osteoarthritis (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?16/31/16883?source=related_link\">",
"      Patient information: Rheumatoid arthritis (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?21/13/21717?source=related_link\">",
"      Patient information: Total knee replacement (arthroplasty) (Beyond the Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f28_50_29475="Zinc chloride: Pediatric drug information";
var content_f28_50_29475=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Zinc chloride: Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"UTD.htm?31/25/32146?source=see_link\">",
"    see \"Zinc chloride: Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?33/0/33795?source=see_link\">",
"    see \"Zinc chloride: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F1043014\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Trace Element",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block don drugH1Div\" id=\"F16229145\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Neonatal",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Parenteral nutrition, maintenance requirement:",
"     </b>",
"     I.V.:",
"     <b>",
"      Note:",
"     </b>",
"     Dosage expressed in terms of",
"     <b>",
"      elemental",
"     </b>",
"     zinc:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ASPEN recommendations:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Premature neonates &lt;3 kg: 400 mcg/kg/day (Mirtallo, 2004); higher doses have been suggested in premature neonates: 450-500 mcg/kg/day (Vanek, 2012)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Term neonates &ge;3 kg: 50-250 mcg/kg/day (Mirtallo, 2004; Vanek, 2012)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Manufacturer's labeling:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Premature neonates &lt;3 kg: 300 mcg/kg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Term neonates &ge;3 kg: 100 mcg/kg/day",
"    </p>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F1043021\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"UTD.htm?31/25/32146?source=see_link\">",
"      see \"Zinc chloride: Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Note:",
"     </b>",
"     Dosages may be presented in units of mcg or mg, use caution to ensure correct units. Clinical response may not occur for up to 6-8 weeks:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Infants, Children, and Adolescents:",
"     <b>",
"      Parenteral nutrition, maintenance requirement:",
"     </b>",
"     I.V.:",
"     <b>",
"      Note:",
"     </b>",
"     Dosage expressed in terms of",
"     <b>",
"      elemental",
"     </b>",
"     zinc; higher doses may be needed if impaired intestinal absorption or an excessive loss of zinc (eg, excessive, prolonged diarrhea, high-output intestinal fistula, burns)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     ASPEN recommendations:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Age-directed dosing (Vanek, 2012):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     Infants &lt;3 months: 250 mcg/kg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     Infants &ge;3 months: 50 mcg/kg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     Children: 50 mcg/kg/day; maximum daily dose: 5000 mcg/",
"     <b>",
"      day",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Weight-directed dosing (Mirtallo, 2004):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     Infants &lt;10 kg: 50-250 mcg/kg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     Children 10-40 kg: 50-125 mcg/kg/day; maximum daily dose: 5000 mcg/",
"     <b>",
"      day",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     Adolescents &gt;40 kg: 2-5 mg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Manufacturer labeling: Infants &gt;3 kg and Children &le;5 years: 100 mcg/kg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Adults:",
"     <b>",
"      Parenteral nutrition, maintenance requirement:",
"     </b>",
"     I.V.:",
"     <b>",
"      Note:",
"     </b>",
"     Dosage expressed in terms of",
"     <b>",
"      elemental",
"     </b>",
"     zinc:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Acute metabolic states: 4.5-6 mg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Metabolically stable: 2.5-4 mg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Replacement for small bowel fluid loss (metabolically stable): An additional 12.2 mg zinc/L of fluid lost or an additional 17.1 mg zinc per kg of stool or ileostomy output",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F235718\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, solution [preservative free]: 1 mg/mL (10 mL)",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F235709\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F16229146\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Dilute as component of daily parenteral nutrition or maintenance fluids; must be diluted in &ge;100 mL; do not give undiluted by direct injection into a peripheral vein due to potential for phlebitis and tissue irritation and potential to increase renal losses of minerals from a bolus injection",
"    </p>",
"   </div>",
"   <div class=\"block sta drugH1Div\" id=\"F16229141\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Stability",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Store intact vial at 20&deg;C to 25&deg;C (68&deg;F to 77&deg;F).",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F1043015\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Prevention of zinc deficiency as an additive to parenteral nutrition (FDA approved in all ages)",
"    </p>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F235730\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Rare but important or life-threatening: Hypotension, indigestion, jaundice, leukopenia, nausea, neutropenia, pulmonary edema, vomiting",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F16229138\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to zinc salts or any component; peripheral undiluted administration",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F16229140\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Administration of zinc in absence of copper may decrease plasma copper levels. The parenteral product contains aluminum; toxic aluminum concentrations may be seen with high doses, prolonged use, or renal dysfunction. Premature neonates are at higher risk due to immature renal function and aluminum intake from other parenteral sources. Parenteral aluminum exposure of  &gt;4-5 mcg/kg/day is associated with CNS and bone toxicity and tissue loading may occur at lower doses.",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F16229139\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Do not administer undiluted by direct injection into a peripheral vein due to potential for phlebitis, tissue irritation, and potential increased renal loss of minerals from a bolus injection.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13300236\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F6223728\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Eltrombopag: Zinc Salts may decrease the serum concentration of Eltrombopag.  Management: Separate administration of eltrombopag and any polyvalent cation (e.g., zinc-containing products) by at least 4 hours.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Trientine: Zinc Salts may decrease the serum concentration of Trientine. Trientine may decrease the serum concentration of Zinc Salts.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F235715\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F13880759\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Zinc crosses the placenta and can be measured in the cord blood and placenta. Fetal concentrations are regulated by the placenta (de Moraes, 2011).",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F16229147\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Patients on parenteral nutrition should have periodic serum copper and serum zinc levels; alkaline phosphatase, taste acuity, mental depression",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F16229142\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     A cofactor for more than 70 enzymes which are important to carbohydrate and protein metabolism, zinc helps to maintain normal growth and tissue repair, normal skin hydration, and senses of taste and smell",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F16229143\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacokinetics (Adult data unless noted)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Distribution: Storage sites are liver and skeletal muscle; serum levels do not adequately reflect whole-body zinc status",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Protein binding: 55% bound to albumin; 40% bound to alpha 1-macroglobulin",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Elimination: Primarily in feces (Anderson, 1998)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      American Academy of Pediatrics Committee on Nutrition, \"Zinc,\"",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 1978, 62(3):408-12.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?28/50/29475/abstract-text/704215/pubmed\" id=\"704215\" target=\"_blank\">",
"        704215",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Anderson LA, Hakojarvi SL, and Boudreaux SK, &ldquo;Zinc Acetate Treatment in Wilson's Disease,&rdquo;",
"      <i>",
"       Ann Pharmacother",
"      </i>",
"      , 1998, 32(1):78-87.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?28/50/29475/abstract-text/9475826/pubmed\" id=\"9475826\" target=\"_blank\">",
"        9475826",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Department Health &amp; Human Services, Food Drug Administration, \"Aluminum in Large and Small Volume Parenterals Used in Total Parenteral Nutrition,\"",
"      <i>",
"       Federal Register",
"      </i>",
"      , 2000, 65(17):4103-11.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Mirtallo J, Canada T, Johnson D, et al, \"Safe Practices for Parenteral Nutrition,\"",
"      <i>",
"       JPEN J Parenter Enteral Nutr",
"      </i>",
"      , 2004, 28(6):S39-70.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?28/50/29475/abstract-text/15568296/pubmed\" id=\"15568296\" target=\"_blank\">",
"        15568296",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Vanek VW, Borum P, Buchman A, et al, \"A.S.P.E.N. Position Paper: Recommendations for Changes in Commercially Available Parenteral Multivitamin and Multi-trace Element Products,\"",
"      <i>",
"       Nutr Clin Pract",
"      </i>",
"      , 2012, 27(4):440-91.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?28/50/29475/abstract-text/22730042/pubmed\" id=\"22730042\" target=\"_blank\">",
"        22730042",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 88580 Version 1.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-122.72.76.133-C1C910ED83-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f28_50_29475=[""].join("\n");
var outline_f28_50_29475=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1043014\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16229145\">",
"      Dosing: Neonatal",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1043021\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F235718\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F235709\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16229146\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16229141\">",
"      Stability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1043015\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F235730\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16229138\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16229140\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16229139\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13300236\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6223728\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F235715\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13880759\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16229147\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16229142\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16229143\">",
"      Pharmacokinetics (Adult data unless noted)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/88580\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/88580|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?31/25/32146?source=related_link\">",
"      Zinc chloride: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?33/0/33795?source=related_link\">",
"      Zinc chloride: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f28_50_29476="Tinnitus handicap inventory";
var content_f28_50_29476=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F64655&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F64655&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 562px\">",
"   <div class=\"ttl\">",
"    Tinnitus handicap inventory questionnaire",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 542px; height: 582px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from Clinical Health Services, Inc. (file://www.clinicalhealthservices.com).",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f28_50_29476=[""].join("\n");
var outline_f28_50_29476=null;
var title_f28_50_29477="Etiology of epididymitis";
var content_f28_50_29477=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F73122&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F73122&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 575px\">",
"   <div class=\"ttl\">",
"    Etiology of epididymitis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 555px; height: 366px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Multiple etiologies of epididymitis.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Sheldon, CA. The pediatric genitourinary examination. Inguinal, urethral, and genital diseases. Pediatr Clin North Am 2001; 48:1339. Copyright &copy; 2001 Elsevier.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f28_50_29477=[""].join("\n");
var outline_f28_50_29477=null;
var title_f28_50_29478="Orthodromic AVRT tutorial";
var content_f28_50_29478=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F54720&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F54720&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic2\" style=\"width: 1046px;\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Electrocardiogram (ECG) showing orthodromic atrioventricular reentrant tachycardia (AVRT)",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 343px; height: 92px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Atrioventricular reentrant tachycardia (AVRT)&nbsp;is a supraventricular tachycardia associated with an accessory pathway connection between the atria and ventricles. The pathway may conduct antegrade only, retrograde only, or bith antegrade and retrograde.&nbsp;AVRT is usually initiated by an atrial premature beat (arrow). The most common type of AVRT, termed orthodromic AVRT,&nbsp;uses the AV node and His Purkinje system (which has a relatively short refractory period) for antegrade conduction to the ventricles and the accessory AV pathway (which in these patients has a relatively long antegrade refractory period when compared to the node) for retrograde conduction. During orthodromic AVRT, QRS complexes are narrow. During sinus rhythm, however, wide and bizarre QRS complexes (indicative of the WPW pattern) are caused by conduction over both the accessory and normal pathways, resulting in a fusion beat. Since there is 1:1 retrograde activation of the atrium, a negative P wave may be present following the QRS complex.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
"  <div class=\"figure\" style=\"width: 456px\">",
"   <div class=\"ttl\">",
"    Sinus rhythm",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 456px; height: 103px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The normal P wave in sinus rhythm is slightly notched since activation of the right atrium precedes that of the left atrium. The P wave is upright in a positive direction in leads I and II. A P wave with a uniform morphology precedes each QRS complex. The rate is between 60 and 100 beats per minute and the cycle length is uniform between sequential P waves and QRS complexes. In addition, the P wave morphology and PR intervals are identical from beat to beat.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f28_50_29478=[""].join("\n");
var outline_f28_50_29478=null;
var title_f28_50_29479="Quantitative coronary angiography: Clinical applications";
var content_f28_50_29479=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Quantitative coronary angiography: Clinical applications",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?28/50/29479/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?28/50/29479/contributors\">",
"     Morton J Kern, MD, FSCAI, FAHA, FACC",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?28/50/29479/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?28/50/29479/contributors\">",
"     Donald Cutlip, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?28/50/29479/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?28/50/29479/contributors\">",
"     Gordon M Saperia, MD, FACC",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?28/50/29479/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jul 30, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;A reduction in the coronary artery luminal cross-sectional diameter, estimated by visual inspection of the radiocontrast lumenogram during angiography, has been utilized to formulate predictions about clinical presentations and stress-induced reductions in coronary blood flow. Anatomic and physiologic approaches to coronary artery disease are complementary and at times will yield contradictory results. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/22/13672?source=see_link\">",
"     \"Clinical use of coronary artery pressure and Doppler flow measurements\"",
"    </a>",
"    .) As a result, quantitative approaches to the angiographic evaluation of coronary anatomy are occasionally employed in some laboratories.",
"   </p>",
"   <p>",
"    There are a number of clinical applications for quantitative coronary arteriography (QCA) including predicting restenosis after angioplasty, comparing the results of different interventional techniques, and evaluating the natural history of coronary artery disease. These issues will be reviewed here, beginning with the limitations of visual and quantitative coronary arteriography, while the technical aspects of QCA are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/38/24165?source=see_link\">",
"     \"Quantitative coronary angiography: Technical issues\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     LIMITATIONS OF VISUAL CORONARY ARTERIOGRAPHY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The rationale for performing QCA is based upon the limitations of visual coronary arteriography. The greatest advantage of QCA is its theoretical freedom from observer influences and bias, minimizing significant potential intraobserver and interobserver variability [",
"    <a class=\"abstract\" href=\"UTD.htm?28/50/29479/abstract/1-3\">",
"     1-3",
"    </a>",
"    ]. In prospective studies, the potential for observer error with visual analysis from a coronary angiogram has been estimated to exceed 35 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?28/50/29479/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The extent of the variability is related in part to the severity of the lesion under scrutiny; lesser degrees of variation are reported for stenoses which represent either less than 20 percent or more than 80 percent of the vessel diameter [",
"    <a class=\"abstract\" href=\"UTD.htm?28/50/29479/abstract/4\">",
"     4",
"    </a>",
"    ]. Visual analysis generally leads to overestimation of severe stenoses, and to underestimation of more modest degrees of luminal narrowing [",
"    <a class=\"abstract\" href=\"UTD.htm?28/50/29479/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There is also significant discordance between visual estimates of luminal narrowing and the functional significance of stenosis [",
"    <a class=\"abstract\" href=\"UTD.htm?28/50/29479/abstract/6\">",
"     6",
"    </a>",
"    ]. The functional significance of coronary stenotic lesions is governed not only be degree of stenosis, but also by such features as the shape, length, and eccentricity of the lesion, collateral routes of perfusion, and vasomotor tone among others [",
"    <a class=\"abstract\" href=\"UTD.htm?28/50/29479/abstract/7-10\">",
"     7-10",
"    </a>",
"    ]. These physical constraints and resultant flow characteristics contribute to the disparity between the angiographic and corresponding physiologic assessment of disease severity [",
"    <a class=\"abstract\" href=\"UTD.htm?28/50/29479/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In standard cineangiography, the two-dimensional projection of the vessel onto the radiographic film poses an additional problem. Because of image foreshortening, certain segments of the coronary vessel, particularly those which deviate from a plane which is parallel to the image intensifier, will be recorded in a distorted and qualitatively inaccurate manner. This phenomenon, as well as the potential for both lesional eccentricity and overlap of vascular segments within the image, necessitates the recording of multiple angiographic projections, particularly for the more complex left coronary artery [",
"    <a class=\"abstract\" href=\"UTD.htm?28/50/29479/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Further difficulty is posed by compensatory vasodilatation of the normal vessel surrounding a coronary stenosis [",
"    <a class=\"abstract\" href=\"UTD.htm?28/50/29479/abstract/12\">",
"     12",
"    </a>",
"    ]. As a result, quantitation of the reference, normal diameter is always problematic [",
"    <a class=\"abstract\" href=\"UTD.htm?28/50/29479/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     LIMITATIONS OF QUANTITATIVE CORONARY ANGIOGRAPHY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Methods of angiographic assessment which rely upon computer-based quantitation minimize the observer variability [",
"    <a class=\"abstract\" href=\"UTD.htm?28/50/29479/abstract/14-16\">",
"     14-16",
"    </a>",
"    ] and permit the theoretical prediction of pathophysiologic variables, such as pressure gradients and lesional flow resistances [",
"    <a class=\"abstract\" href=\"UTD.htm?28/50/29479/abstract/17-20\">",
"     17-20",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    However, QCA shares a number of significant limitations with the standard angiographic technique since it indirectly defines the anatomy of the vascular wall through inferences about the lumen. Coronary atherosclerosis is a variable and diffuse process which may elude detection by angiography [",
"    <a class=\"abstract\" href=\"UTD.htm?28/50/29479/abstract/12,21\">",
"     12,21",
"    </a>",
"    ], a finding confirmed by postmortem studies [",
"    <a class=\"abstract\" href=\"UTD.htm?28/50/29479/abstract/22,23\">",
"     22,23",
"    </a>",
"    ] and intravascular ultrasound imaging techniques [",
"    <a class=\"abstract\" href=\"UTD.htm?28/50/29479/abstract/24\">",
"     24",
"    </a>",
"    ]. In addition, the vascular features which accompany unstable ischemic syndromes and unfavorable angioplasty outcomes, such as ulceration or complex plaque morphology, are better evaluated by endovascular techniques such as intracoronary ultrasound imaging, optical coherence tomography (OCT), and angioscopy than by quantitative angiography [",
"    <a class=\"abstract\" href=\"UTD.htm?28/50/29479/abstract/25,26\">",
"     25,26",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/27/34234?source=see_link\">",
"     \"Intravascular ultrasound, optical coherence tomography, and angioscopy of coronary circulation\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Vasomotion and side branches",
"    </span>",
"    &nbsp;&mdash;&nbsp;In quantitative studies, the use of serially quantitated angiographic data may be limited by several physiologic and procedural constraints. These include variability of coronary vasomotor tone, which can influence both the lesional and the reference diameters [",
"    <a class=\"abstract\" href=\"UTD.htm?28/50/29479/abstract/27\">",
"     27",
"    </a>",
"    ]; variability in radiographic angle and x-ray tube height; and inhomogeneity in the distribution of radiocontrast within the target vessel.",
"   </p>",
"   <p>",
"    Arterial side branches that overlap the regions of interest are an additional source of difficulty, producing quantitative inaccuracies. Despite the theoretical independence of the videodensitometric technique from some of these limitations, there has not been uniform support for the comparability of pre- and post-angioplasty measurements [",
"    <a class=\"abstract\" href=\"UTD.htm?28/50/29479/abstract/28,29\">",
"     28,29",
"    </a>",
"    ]. In one study, for example, changes in radiographic angulation appeared to influence the reliability of the quantitations, even with densitometry [",
"    <a class=\"abstract\" href=\"UTD.htm?28/50/29479/abstract/30\">",
"     30",
"    </a>",
"    ]. Furthermore, the phantom-imaging studies used to validate the techniques of QCA often rely on an unrealistic idealization of imaging conditions. In one study using plexiglass phantoms, imaged both inside and outside a human thorax, the more realistic radiographic backgrounds were associated with a 38 percent increase in the variability of outcome, and a systematic overestimation of the diameter of the smallest phantom within the study series [",
"    <a class=\"abstract\" href=\"UTD.htm?28/50/29479/abstract/31\">",
"     31",
"    </a>",
"    ]. A low concentration of radiocontrast also significantly increased the tendency for error.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Correlations with functional results",
"    </span>",
"    &nbsp;&mdash;&nbsp;Perhaps the single greatest drawback of QCA is the lack of correlation between the functional predictions of angiographic disease severity and directly measured physiologic variables, as they relate to coronary flow reserve, fraction flow reserve (FFR), or the translesional gradient. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/22/13672?source=see_link\">",
"     \"Clinical use of coronary artery pressure and Doppler flow measurements\"",
"    </a>",
"    .) Although the absolute value for minimal luminal diameter in coronary stenosis is one of the most important determinants of physiologic impact [",
"    <a class=\"abstract\" href=\"UTD.htm?28/50/29479/abstract/20,32-34\">",
"     20,32-34",
"    </a>",
"    ], because of the numerous other factors contributing to resistance to blood flow, it should be expected that there will be differences between the anatomic and physiologic data, most often in the assessment of disease severity, especially in the intermediate ranges of angiographic stenoses.",
"   </p>",
"   <p>",
"    The hemodynamic predictions derived from QCA are well-supported in animal studies [",
"    <a class=\"abstract\" href=\"UTD.htm?28/50/29479/abstract/18,35\">",
"     18,35",
"    </a>",
"    ]. In human coronary artery disease, it has been suggested that there is a similar useful relationship between QCA findings, ie, percent diameter stenosis and minimal luminal cross-sectional area, and other predictors of altered coronary flow physiology such as coronary flow reserve and the transstenotic pressure gradient [",
"    <a class=\"abstract\" href=\"UTD.htm?28/50/29479/abstract/19,20,34,36,37\">",
"     19,20,34,36,37",
"    </a>",
"    ]. However, some investigators have been unable to demonstrate a correlation between percent diameter stenosis and coronary flow reserve in patients with multivessel coronary disease. In one study that used Doppler flow wire techniques, the angiographically-predicted translesional pressure gradient and the intracoronary flow velocity were simultaneously measured in 25 patients [",
"    <a class=\"abstract\" href=\"UTD.htm?28/50/29479/abstract/38\">",
"     38",
"    </a>",
"    ]. There was a lack of correlation between baseline pressure gradients, hyperemic gradients, and predicted coronary flow reserve, as measured by the two techniques. Furthermore, stenotic flow reserve was poorly correlated with measured pressure gradients and the physiologic measurements correlated poorly with the angiographically predicted minimal cross- sectional area.",
"   </p>",
"   <p>",
"    In another report, the angiographic measurements of lesion severity, when verified with pressure-derived indices, were imprecise in individual patients [",
"    <a class=\"abstract\" href=\"UTD.htm?28/50/29479/abstract/39\">",
"     39",
"    </a>",
"    ]. Nevertheless, a threshold value of less than 1.5 mm for the minimal luminal diameter was predictive of reduced fractional flow reserve in the myocardium.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     RESTENOSIS AFTER ANGIOPLASTY",
"    </span>",
"    &nbsp;&mdash;&nbsp;QCA as applied in angiographic core laboratories has become the standard technique for the study of restenosis after percutaneous transluminal coronary angioplasty (PTCA) [",
"    <a class=\"abstract\" href=\"UTD.htm?28/50/29479/abstract/40,41\">",
"     40,41",
"    </a>",
"    ], directional coronary atherectomy [",
"    <a class=\"abstract\" href=\"UTD.htm?28/50/29479/abstract/13\">",
"     13",
"    </a>",
"    ], endovascular stent placement [",
"    <a class=\"abstract\" href=\"UTD.htm?28/50/29479/abstract/42,43\">",
"     42,43",
"    </a>",
"    ], and laser-assisted angioplasty [",
"    <a class=\"abstract\" href=\"UTD.htm?28/50/29479/abstract/44,45\">",
"     44,45",
"    </a>",
"    ]. A study comparing QCA with intracoronary ultrasound, a very precise method for assessment of the coronary lumen, found that QCA was equally accurate for poststent assessment except when very mild restenosis occurred within a highly opaque stent [",
"    <a class=\"abstract\" href=\"UTD.htm?28/50/29479/abstract/46\">",
"     46",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Automated serial measurements permit quantitation of the reduction in minimal luminal diameter between the postprocedural angiogram and the follow-up study. In addition, the degree of balloon stretch and elastic recoil after the procedure can be determined [",
"    <a class=\"abstract\" href=\"UTD.htm?28/50/29479/abstract/45\">",
"     45",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/30/27108?source=see_link\">",
"     \"Coronary complications of atheroablative devices\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/48/38666?source=see_link\">",
"     \"Periprocedural complications of percutaneous coronary intervention\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    QCA has been used to investigate some of the mechanisms of restenosis, such as elastic recoil [",
"    <a class=\"abstract\" href=\"UTD.htm?28/50/29479/abstract/47\">",
"     47",
"    </a>",
"    ], angiographic risk factors for restenosis [",
"    <a class=\"abstract\" href=\"UTD.htm?28/50/29479/abstract/48\">",
"     48",
"    </a>",
"    ] and the temporal relationships of the late loss of luminal diameter [",
"    <a class=\"abstract\" href=\"UTD.htm?28/50/29479/abstract/49\">",
"     49",
"    </a>",
"    ]. QCA has also been used to evaluate the role of pharmacologic lipid-lowering for minimizing restenosis after percutaneous balloon angioplasty [",
"    <a class=\"abstract\" href=\"UTD.htm?28/50/29479/abstract/41\">",
"     41",
"    </a>",
"    ]. QCA is not as sensitive as angioscopy or intracoronary ultrasound or OCT for the detection of intraluminal irregularities, such as dissection or new thrombus formation [",
"    <a class=\"abstract\" href=\"UTD.htm?28/50/29479/abstract/50\">",
"     50",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Comparison of angioplasty techniques",
"    </span>",
"    &nbsp;&mdash;&nbsp;Quantitative angiography has been used in the studies designed to evaluate both the long-term merits and therapeutic efficacy of various endovascular techniques and devices. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/11/41142?source=see_link\">",
"     \"Specialized revascularization devices in the management of coronary heart disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The CAVEAT-I trial, for example, was designed to compare the therapeutic benefits of directional atherectomy and standard balloon angioplasty [",
"    <a class=\"abstract\" href=\"UTD.htm?28/50/29479/abstract/51\">",
"     51",
"    </a>",
"    ]. A similar study, CAVEAT-II, compared these two approaches in saphenous vein graft lesions [",
"    <a class=\"abstract\" href=\"UTD.htm?28/50/29479/abstract/52\">",
"     52",
"    </a>",
"    ]. A core laboratory performed serial quantitative angiography over a six-month observation period in both studies. Despite a greater initial luminal gain and procedural success after atherectomy, there was no difference in six-month restenosis rates. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/11/41142?source=see_link\">",
"     \"Specialized revascularization devices in the management of coronary heart disease\"",
"    </a>",
"    .) QCA has also been used to compare PTCA alone with stenting or excimer laser angioplasty [",
"    <a class=\"abstract\" href=\"UTD.htm?28/50/29479/abstract/44,53\">",
"     44,53",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    It has been postulated that the long-term angiographic outcome after intervention is determined by the immediate postprocedural angiographic result, and is independent of the device employed [",
"    <a class=\"abstract\" href=\"UTD.htm?28/50/29479/abstract/53\">",
"     53",
"    </a>",
"    ]. To validate this hypothesis, multicenter randomized trials, utilizing core laboratory assessment of quantitative angiography, have been proposed; when completed, such studies will refine the outcome analysis of current interventional devices.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     NATURAL HISTORY OF CORONARY HEART DISEASE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Another broad area of application for QCA has been within studies designed to establish the natural history of coronary artery disease. In one report, for example, serial QCA performed over three years revealed a tendency toward mild but significant disease progression [",
"    <a class=\"abstract\" href=\"UTD.htm?28/50/29479/abstract/54\">",
"     54",
"    </a>",
"    ]. The angiographic severity of disease at the onset of the study was the single greatest determinant for disease progression, which occurred more rapidly in those vessels with a larger initial minimal diameter which were presumably associated with milder disease at outset. Other risk factors for rapid progression, such as an elevated serum lipoprotein (a) level, have been investigated in a similar manner [",
"    <a class=\"abstract\" href=\"UTD.htm?28/50/29479/abstract/55\">",
"     55",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    All QCA measures of disease progression obtained from serial studies, especially measurements of lesion change (percent diameter stenosis and minimum lumen diameter), are related to cardiac events, including myocardial infarction, death, and revascularization [",
"    <a class=\"abstract\" href=\"UTD.htm?28/50/29479/abstract/56\">",
"     56",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    QCA has also contributed to current and evolving concepts of atherosclerotic pathogenesis and disease progression. As an example, endothelial vasodilator dysfunction, which is known to accompany atherosclerosis in native and allograft vessels, can be investigated with QCA [",
"    <a class=\"abstract\" href=\"UTD.htm?28/50/29479/abstract/57\">",
"     57",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/39/23162?source=see_link\">",
"     \"Endothelial dysfunction\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A growing body of evidence derived from quantitative analysis of serial angiograms strongly supports the hypothesis that progression of established atheromatous disease can be significantly retarded, if not reversed, by aggressive lifestyle and pharmacologic interventions [",
"    <a class=\"abstract\" href=\"UTD.htm?28/50/29479/abstract/58-61\">",
"     58-61",
"    </a>",
"    ]; endothelial function can also be improved [",
"    <a class=\"abstract\" href=\"UTD.htm?28/50/29479/abstract/57\">",
"     57",
"    </a>",
"    ]. These changes are associated with better patient outcomes [",
"    <a class=\"abstract\" href=\"UTD.htm?28/50/29479/abstract/62\">",
"     62",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/38/43626?source=see_link&amp;anchor=H5#H5\">",
"     \"Clinical trials of cholesterol lowering in patients with coronary heart disease or coronary risk equivalents\", section on 'Improvement in atherosclerosis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Quantitative coronary arteriography (QCA) attempts to overcome some of the limitations of the visual estimate of the severity of coronary stenoses, particularly observer bias. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Limitations of visual coronary arteriography'",
"      </a>",
"      above.)",
"      <br/>",
"      <br/>",
"      While QCA poses many actual and theoretical advantages over routine angiography, there are counterbalancing considerations that limit the applicability of the method. Foremost among these potential limitations is the propensity of angiographic predictions of clinical importance to deviate from physiologic measurements. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Limitations of quantitative coronary angiography'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Since QCA can over or under predict the functional significance of coronary stenoses, evaluation using diagnostic modalities that obtain physiologic information is sometimes justified. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Correlations with functional results'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      QCA assists in predicting restenosis after angioplasty, comparing the results of different interventional techniques, and evaluating the natural history of coronary artery disease. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Restenosis after angioplasty'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      QCA is inferior to techniques such as intravascular ultrasound (IVUS) or optical coherence tomography (OCT) for detecting the extent of coronary or the vascular features that accompany unstable ischemic syndromes and unfavorable angioplasty outcomes, such as ulceration or complex plaque morphology. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Natural history of coronary heart disease'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/50/29479/abstract/1\">",
"      DeRouen TA, Murray JA, Owen W. Variability in the analysis of coronary arteriograms. Circulation 1977; 55:324.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/50/29479/abstract/2\">",
"      Goldberg RK, Kleiman NS, Minor ST, et al. Comparison of quantitative coronary angiography to visual estimates of lesion severity pre and post PTCA. Am Heart J 1990; 119:178.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/50/29479/abstract/3\">",
"      Zir LM. Observer variability in coronary angiography. Int J Cardiol 1983; 3:171.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/50/29479/abstract/4\">",
"      Shub C, Vlietstra RE, Smith HC, et al. The unpredictable progression of symptomatic coronary artery disease: a serial clinical-angiographic analysis. Mayo Clin Proc 1981; 56:155.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/50/29479/abstract/5\">",
"      Fleming RM, Kirkeeide RL, Smalling RW, Gould KL. Patterns in visual interpretation of coronary arteriograms as detected by quantitative coronary arteriography. J Am Coll Cardiol 1991; 18:945.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/50/29479/abstract/6\">",
"      White CW, Wright CB, Doty DB, et al. Does visual interpretation of the coronary arteriogram predict the physiologic importance of a coronary stenosis? N Engl J Med 1984; 310:819.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/50/29479/abstract/7\">",
"      Vlodaver Z, Neufeld HN, Edwards JE. Pathology of coronary disease. Semin Roentgenol 1972; 7:376.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/50/29479/abstract/8\">",
"      Epstein SE, Cannon RO 3rd, Watson RM, et al. Dynamic coronary obstruction as a cause of angina pectoris: implications regarding therapy. Am J Cardiol 1985; 55:61B.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/50/29479/abstract/9\">",
"      Feldman RL, Nichols WW, Pepine CJ, Conti CR. Hemodynamic significance of the length of a coronary arterial narrowing. Am J Cardiol 1978; 41:865.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/50/29479/abstract/10\">",
"      Feldman RL, Nichols WW, Pepine CJ, et al. The coronary hemodynamics of left main and branch coronary stenoses. The effects of reduction in stenosis diameter, stenosis length, and number of stenoses. J Thorac Cardiovasc Surg 1979; 77:377.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/50/29479/abstract/11\">",
"      Gould KL. Percent coronary stenosis: battered gold standard, pernicious relic or clinical practicality? J Am Coll Cardiol 1988; 11:886.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/50/29479/abstract/12\">",
"      Stiel GM, Stiel LS, Schofer J, et al. Impact of compensatory enlargement of atherosclerotic coronary arteries on angiographic assessment of coronary artery disease. Circulation 1989; 80:1603.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/50/29479/abstract/13\">",
"      Umans VA, Robert A, Foley D, et al. Clinical, histologic and quantitative angiographic predictors of restenosis after directional coronary atherectomy: a multivariate analysis of the renarrowing process and late outcome. J Am Coll Cardiol 1994; 23:49.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/50/29479/abstract/14\">",
"      Reiber JH, Serruys PW, Kooijman CJ, et al. Assessment of short-, medium-, and long-term variations in arterial dimensions from computer-assisted quantitation of coronary cineangiograms. Circulation 1985; 71:280.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/50/29479/abstract/15\">",
"      Vas R, Eigler N, Miyazono C, et al. Digital quantification eliminates intraobserver and interobserver variability in the evaluation of coronary artery stenosis. Am J Cardiol 1985; 56:718.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/50/29479/abstract/16\">",
"      Zir LM, Miller SW, Dinsmore RE, et al. Interobserver variability in coronary angiography. Circulation 1976; 53:627.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/50/29479/abstract/17\">",
"      Gould KL, Kelley KO. Physiological significance of coronary flow velocity and changing stenosis geometry during coronary vasodilation in awake dogs. Circ Res 1982; 50:695.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/50/29479/abstract/18\">",
"      Gould KL, Kelley KO, Bolson EL. Experimental validation of quantitative coronary arteriography for determining pressure-flow characteristics of coronary stenosis. Circulation 1982; 66:930.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/50/29479/abstract/19\">",
"      Wilson RF, Marcus ML, White CW. Prediction of the physiologic significance of coronary arterial lesions by quantitative lesion geometry in patients with limited coronary artery disease. Circulation 1987; 75:723.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/50/29479/abstract/20\">",
"      Zijlstra F, van Ommeren J, Reiber JH, Serruys PW. Does the quantitative assessment of coronary artery dimensions predict the physiologic significance of a coronary stenosis? Circulation 1987; 75:1154.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/50/29479/abstract/21\">",
"      McPherson DD, Hiratzka LF, Lamberth WC, et al. Delineation of the extent of coronary atherosclerosis by high-frequency epicardial echocardiography. N Engl J Med 1987; 316:304.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/50/29479/abstract/22\">",
"      Arnett EN, Isner JM, Redwood DR, et al. Coronary artery narrowing in coronary heart disease: comparison of cineangiographic and necropsy findings. Ann Intern Med 1979; 91:350.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/50/29479/abstract/23\">",
"      Dietz WA, Tobis JM, Isner JM. Failure of angiography to accurately depict the extent of coronary artery narrowing in three fatal cases of percutaneous transluminal coronary angioplasty. J Am Coll Cardiol 1992; 19:1261.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/50/29479/abstract/24\">",
"      Nissen SE, Gurley JC, Grines CL, et al. Intravascular ultrasound assessment of lumen size and wall morphology in normal subjects and patients with coronary artery disease. Circulation 1991; 84:1087.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/50/29479/abstract/25\">",
"      Ambrose JA. Prognostic implications of lesion irregularity on coronary angiography. J Am Coll Cardiol 1991; 18:675.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/50/29479/abstract/26\">",
"      Haase J, Ozaki Y, Di Mario C, et al. Can intracoronary ultrasound correctly assess the luminal dimensions of coronary artery lesions? A comparison with quantitative angiography. Eur Heart J 1995; 16:112.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/50/29479/abstract/27\">",
"      Lesperance J, Hudon G, White CW, et al. Comparison by quantitative angiographic assessment of coronary stenoses of one view showing the severest narrowing to two orthogonal views. Am J Cardiol 1989; 64:462.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/50/29479/abstract/28\">",
"      Sanz ML, Mancini J, LeFree MT, et al. Variability of quantitative digital subtraction coronary angiography before and after percutaneous transluminal coronary angioplasty. Am J Cardiol 1987; 60:55.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/50/29479/abstract/29\">",
"      Tobis J, Nalcioglu O, Johnston WD, et al. Videodensitometric determination of minimum coronary artery luminal diameter before and after angioplasty. Am J Cardiol 1987; 59:38.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/50/29479/abstract/30\">",
"      Katritsis D, Lythall DA, Cooper IC, et al. Assessment of coronary angioplasty: comparison of visual assessment, hand-held caliper measurement and automated digital quantitation. Cathet Cardiovasc Diagn 1988; 15:237.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/50/29479/abstract/31\">",
"      Herrington DM, Siebes M, Walford GD. Sources of error in quantitative coronary angiography. Cathet Cardiovasc Diagn 1993; 29:314.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/50/29479/abstract/32\">",
"      Kirkeeide RL, Gould KL, Parsel L. Assessment of coronary stenoses by myocardial perfusion imaging during pharmacologic coronary vasodilation. VII. Validation of coronary flow reserve as a single integrated functional measure of stenosis severity reflecting all its geometric dimensions. J Am Coll Cardiol 1986; 7:103.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/50/29479/abstract/33\">",
"      Klocke FJ. Measurements of coronary blood flow and degree of stenosis: current clinical implications and continuing uncertainties. J Am Coll Cardiol 1983; 1:31.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/50/29479/abstract/34\">",
"      Zijlstra F, Fioretti P, Reiber JH, Serruys PW. Which cineangiographically assessed anatomic variable correlates best with functional measurements of stenosis severity? A comparison of quantitative analysis of the coronary cineangiogram with measured coronary flow reserve and exercise/redistribution thallium-201 scintigraphy. J Am Coll Cardiol 1988; 12:686.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/50/29479/abstract/35\">",
"      Gould KL, Kirkeeide RL, Buchi M. Coronary flow reserve as a physiologic measure of stenosis severity. J Am Coll Cardiol 1990; 15:459.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/50/29479/abstract/36\">",
"      Wijns W, Serruys PW, Reiber JH, et al. Quantitative angiography of the left anterior descending coronary artery: correlations with pressure gradient and results of exercise thallium scintigraphy. Circulation 1985; 71:273.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/50/29479/abstract/37\">",
"      Harrison DG, White CW, Hiratzka LF, et al. The value of lesion cross-sectional area determined by quantitative coronary angiography in assessing the physiologic significance of proximal left anterior descending coronary arterial stenoses. Circulation 1984; 69:1111.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/50/29479/abstract/38\">",
"      Tron C, Kern MJ, Donohue TJ, et al. Comparison of quantitative angiographically derived and measured translesion pressure and flow velocity in coronary artery disease. Am J Cardiol 1995; 75:111.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/50/29479/abstract/39\">",
"      Bart&uacute;nek J, Sys SU, Heyndrickx GR, et al. Quantitative coronary angiography in predicting functional significance of stenoses in an unselected patient cohort. J Am Coll Cardiol 1995; 26:328.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/50/29479/abstract/40\">",
"      Serruys PW, Foley DP, Kirkeeide RL, King SB 3rd. Restenosis revisited: insights provided by quantitative coronary angiography. Am Heart J 1993; 126:1243.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/50/29479/abstract/41\">",
"      Foley DP, Bonnier H, Jackson G, et al. Prevention of restenosis after coronary balloon angioplasty: rationale and design of the Fluvastatin Angioplasty Restenosis (FLARE) Trial. The FLARE Study Group. Am J Cardiol 1994; 73:50D.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/50/29479/abstract/42\">",
"      Foley JB, Penn IM, Brown RI, et al. Safety, success, and restenosis after elective coronary implantation of the Palmaz-Schatz stent in 100 patients at a single center. Am Heart J 1993; 125:686.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/50/29479/abstract/43\">",
"      Ellis SG, Savage M, Fischman D, et al. Restenosis after placement of Palmaz-Schatz stents in native coronary arteries. Initial results of a multicenter experience. Circulation 1992; 86:1836.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/50/29479/abstract/44\">",
"      Strikwerda S, Montauban van Swijndregt E, Foley DP, et al. Immediate and late outcome of excimer laser and balloon coronary angioplasty: a quantitative angiographic comparison based on matched lesions. J Am Coll Cardiol 1995; 26:939.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/50/29479/abstract/45\">",
"      Strikwerda S, van Swijndregt EM, Melkert R, Serruys PW. Quantitative angiographic comparison of elastic recoil after coronary excimer laser-assisted balloon angioplasty and balloon angioplasty alone. J Am Coll Cardiol 1995; 25:378.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/50/29479/abstract/46\">",
"      Pomerantsev EV, Kobayashi Y, Fitzgerald PJ, et al. Coronary stents: In vitro aspects of an angiographic and ultrasound quantification with in vivo correlation. Circulation 1998; 98:1495.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/50/29479/abstract/47\">",
"      Rensing BJ, Hermans WR, Strauss BH, Serruys PW. Regional differences in elastic recoil after percutaneous transluminal coronary angioplasty: a quantitative angiographic study. J Am Coll Cardiol 1991; 17:34B.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/50/29479/abstract/48\">",
"      Rensing BJ, Hermans WR, Vos J, et al. Luminal narrowing after percutaneous transluminal coronary angioplasty. A study of clinical, procedural, and lesional factors related to long-term angiographic outcome. Coronary Artery Restenosis Prevention on Repeated Thromboxane Antagonism (CARPORT) Study Group. Circulation 1993; 88:975.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/50/29479/abstract/49\">",
"      Serruys PW, Luijten HE, Beatt KJ, et al. Incidence of restenosis after successful coronary angioplasty: a time-related phenomenon. A quantitative angiographic study in 342 consecutive patients at 1, 2, 3, and 4 months. Circulation 1988; 77:361.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/50/29479/abstract/50\">",
"      Kalbfleisch SJ, McGillem MJ, Simon SB, et al. Automated quantitation of indexes of coronary lesion complexity. Comparison between patients with stable and unstable angina. Circulation 1990; 82:439.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/50/29479/abstract/51\">",
"      Topol EJ, Leya F, Pinkerton CA, et al. A comparison of directional atherectomy with coronary angioplasty in patients with coronary artery disease. The CAVEAT Study Group. N Engl J Med 1993; 329:221.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/50/29479/abstract/52\">",
"      Holmes DR Jr, Topol EJ, Califf RM, et al. A multicenter, randomized trial of coronary angioplasty versus directional atherectomy for patients with saphenous vein bypass graft lesions. CAVEAT-II Investigators. Circulation 1995; 91:1966.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/50/29479/abstract/53\">",
"      Kuntz RE, Gibson CM, Nobuyoshi M, Baim DS. Generalized model of restenosis after conventional balloon angioplasty, stenting and directional atherectomy. J Am Coll Cardiol 1993; 21:15.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/50/29479/abstract/54\">",
"      Sandor T, Als AV, Paulin S. Cine-densitometric measurement of coronary arterial stenoses. Cathet Cardiovasc Diagn 1979; 5:229.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/50/29479/abstract/55\">",
"      Terres W, Tatsis E, Pfalzer B, et al. Rapid angiographic progression of coronary artery disease in patients with elevated lipoprotein(a). Circulation 1995; 91:948.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/50/29479/abstract/56\">",
"      Mack WJ, Xiang M, Selzer RH, Hodis HN. Serial quantitative coronary angiography and coronary events. Am Heart J 2000; 139:993.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/50/29479/abstract/57\">",
"      Treasure CB, Klein JL, Weintraub WS, et al. Beneficial effects of cholesterol-lowering therapy on the coronary endothelium in patients with coronary artery disease. N Engl J Med 1995; 332:481.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/50/29479/abstract/58\">",
"      Quinn TG, Alderman EL, McMillan A, Haskell W. Development of new coronary atherosclerotic lesions during a 4-year multifactor risk reduction program: the Stanford Coronary Risk Intervention Project (SCRIP). J Am Coll Cardiol 1994; 24:900.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/50/29479/abstract/59\">",
"      Stone PH, Gibson CM, Pasternak RC, et al. Natural history of coronary atherosclerosis using quantitative angiography in men, and implications for clinical trials of coronary regression. The Harvard Atherosclerosis Reversibility Project Study Group. Am J Cardiol 1993; 71:766.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/50/29479/abstract/60\">",
"      Hodis HN, Mack WJ, LaBree L, et al. Serial coronary angiographic evidence that antioxidant vitamin intake reduces progression of coronary artery atherosclerosis. JAMA 1995; 273:1849.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/50/29479/abstract/61\">",
"      Effect of simvastatin on coronary atheroma: the Multicentre Anti-Atheroma Study (MAAS). Lancet 1994; 344:633.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/50/29479/abstract/62\">",
"      Superko HR, Krauss RM. Coronary artery disease regression. Convincing evidence for the benefit of aggressive lipoprotein management. Circulation 1994; 90:1056.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 1526 Version 5.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-221.179.173.170-7B5B02C4AA-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f28_50_29479=[""].join("\n");
var outline_f28_50_29479=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H9\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      LIMITATIONS OF VISUAL CORONARY ARTERIOGRAPHY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      LIMITATIONS OF QUANTITATIVE CORONARY ANGIOGRAPHY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Vasomotion and side branches",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Correlations with functional results",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      RESTENOSIS AFTER ANGIOPLASTY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Comparison of angioplasty techniques",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      NATURAL HISTORY OF CORONARY HEART DISEASE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/38/43626?source=related_link\">",
"      Clinical trials of cholesterol lowering in patients with coronary heart disease or coronary risk equivalents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/22/13672?source=related_link\">",
"      Clinical use of coronary artery pressure and Doppler flow measurements",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/30/27108?source=related_link\">",
"      Coronary complications of atheroablative devices",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/39/23162?source=related_link\">",
"      Endothelial dysfunction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/27/34234?source=related_link\">",
"      Intravascular ultrasound, optical coherence tomography, and angioscopy of coronary circulation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/48/38666?source=related_link\">",
"      Periprocedural complications of percutaneous coronary intervention",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/38/24165?source=related_link\">",
"      Quantitative coronary angiography: Technical issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/11/41142?source=related_link\">",
"      Specialized revascularization devices in the management of coronary heart disease",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f28_50_29480="Position of subcarinal nodes";
var content_f28_50_29480=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F54056%7EPULM%2F73983%7EPULM%2F65244&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F54056%7EPULM%2F73983%7EPULM%2F65244&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Schematic representation of the anatomic relationships of the subcarinal lymph nodes",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 368px; height: 245px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from Kavuru, MS, Mehta, AC. Applied anatomy of the airways. In: Wang, KP, Mehta, AC (Eds), Flexible Bronchoscopy, Blackwell Science Inc, Cambridge, MA 1995.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Position of the right paratracheal lymph node",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 325px; height: 329px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from Kavuru, MS, Mehta, AC. Applied anatomy of the airways. In: Wang, KP, Mehta, AC (Eds), Flexible Bronchoscopy Blackwell Science Inc, Cambridge, MA 1995.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Position of the left paratracheal lymph node",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 310px; height: 355px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from Kavuru, MS, Mehta, AC. Applied anatomy of the airways. In: Wang, KP, Mehta, AC (Eds), Flexible Bronchoscopy, Blackwell Science Inc, Cambridge, MA 1995.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f28_50_29480=[""].join("\n");
var outline_f28_50_29480=null;
var title_f28_50_29481="Fluvoxamine: Drug information";
var content_f28_50_29481=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Fluvoxamine: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?6/13/6358?source=see_link\">",
"    see \"Fluvoxamine: Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"UTD.htm?40/22/41320?source=see_link\">",
"    see \"Fluvoxamine: Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block black-box-warn drugH1Div\" id=\"F5708808\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     ALERT: U.S. Boxed Warning",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The FDA-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information.  For verbatim wording of the boxed warning, consult the product labeling or",
"     <a href=\"file://www.fda.gov\" target=\"_blank\">",
"      www.fda.gov",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F6195103\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Luvox&reg; CR",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F173600\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Alti-Fluvoxamine;",
"     </li>",
"     <li>",
"      Apo-Fluvoxamine&reg;;",
"     </li>",
"     <li>",
"      Luvox&reg;;",
"     </li>",
"     <li>",
"      Novo-Fluvoxamine;",
"     </li>",
"     <li>",
"      Nu-Fluvoxamine;",
"     </li>",
"     <li>",
"      PMS-Fluvoxamine;",
"     </li>",
"     <li>",
"      Rhoxal-fluvoxamine;",
"     </li>",
"     <li>",
"      Riva-Fluvox;",
"     </li>",
"     <li>",
"      Sandoz-Fluvoxamine",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F173640\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Antidepressant, Selective Serotonin Reuptake Inhibitor",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F173604\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Obsessive-compulsive disorder:",
"     </b>",
"     Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Immediate release: Initial: 50 mg once daily at bedtime; may be increased in 50 mg increments at 4- to 7-day intervals, as tolerated; usual dose range: 100-300 mg/day; maximum dose: 300 mg/day.",
"     <b>",
"      Note:",
"     </b>",
"     When total daily dose exceeds 100 mg, the dose should be given in 2 divided doses with larger portion administered at bedtime.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Extended release: Initial: 100 mg once daily at bedtime; may be increased in 50 mg increments at intervals of at least 1 week; usual dosage range: 100-300 mg/day; maximum dose: 300 mg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Social anxiety disorder (unlabeled use):",
"     </b>",
"     Oral:  Extended release: Initial: 100 mg once daily at bedtime; may be increased in 50 mg increments at intervals of at least 1 week; usual dosage range: 100-300 mg/day; maximum dose: 300 mg/day (Davidson, 2004; Stein, 2003; Westenberg, 2004)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Post-traumatic stress disorder (PTSD) (unlabeled use):",
"     </b>",
"     Immediate release: Oral: 75 mg twice daily (Spivak, 2006)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     <b>",
"      MAO inhibitor recommendations:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <i>",
"      Switching to or from an MAO inhibitor intended to treat psychiatric disorders:",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Allow 14 days to elapse between discontinuing an MAO inhibitor intended to treat psychiatric disorders and initiation of fluvoxamine.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Allow 14 days to elapse between discontinuing fluvoxamine and initiation of an MAO inhibitor intended to treat psychiatric disorders.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <i>",
"      Use with other MAO inhibitors (linezolid or I.V. methylene blue):",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Do not initiate fluvoxamine in patients receiving linezolid or I.V. methylene blue; consider other interventions for psychiatric condition.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     If urgent treatment with linezolid or I.V. methylene blue is required in a patient already receiving fluvoxamine and potential benefits outweigh potential risks, discontinue fluvoxamine promptly and administer linezolid or I.V. methylene blue. Monitor for serotonin syndrome for 2 weeks or until 24 hours after the last dose of linezolid or I.V. methylene blue, whichever comes first. May resume fluvoxamine 24 hours after the last dose of linezolid or I.V. methylene blue.",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F173619\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?40/22/41320?source=see_link\">",
"      see \"Fluvoxamine: Pediatric drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Obsessive-compulsive disorder:",
"     </b>",
"     Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Children 8-17 years: Immediate release: Initial: 25 mg once daily at bedtime; may be increased in 25 mg increments at 4- to 7-day intervals, as tolerated, to maximum therapeutic benefit; usual dose range: 50-200 mg/day.",
"     <b>",
"      Note:",
"     </b>",
"     When total daily dose of immediate release exceeds 50 mg, the dose should be given in 2 divided doses with larger portion administered at bedtime.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Maximum dose:",
"     </i>",
"     Children: 8-11 years: 200 mg/day; Adolescents: 300 mg/day; lower doses may be effective in female versus male patients",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     <b>",
"      MAO inhibitor recommendations:",
"     </b>",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F173605\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing. Reduce dose; titrate slowly.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F15896268\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment provided in manufacturer&rsquo;s labeling. Limited data suggest fluvoxamine does not accumulate in patients with renal impairment.",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F173606\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment provided in manufacturer&rsquo;s labeling. Limited data suggest fluvoxamine clearance is reduced in patients with hepatic impairment. Reduced initial dose and slow titration may be required.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F173577\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Capsule, extended release, oral, as maleate: 100 mg, 150 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Luvox&reg; CR: 100 mg, 150 mg [gluten free]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral, as maleate: 25 mg, 50 mg, 100 mg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F173561\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block meg drugH1Div\" id=\"F7874605\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Guide",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     An FDA-approved patient medication guide, which is available with the product information and as follows, must be dispensed with this medication:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">",
"     Luvox&reg; CR capsule:",
"     <a href=\"file://www.fda.gov/downloads/Drugs/DrugSafety/ucm088625.pdf\" target=\"_blank\">",
"      file://www.fda.gov/downloads/Drugs/DrugSafety/ucm088625.pdf",
"     </a>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">",
"     Fluvoxamine tablet:",
"     <a href=\"file://www.fda.gov/downloads/Drugs/DrugSafety/UCM249169.pdf\" target=\"_blank\">",
"      file://www.fda.gov/downloads/Drugs/DrugSafety/UCM249169.pdf",
"     </a>",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F6195124\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     May be administered with or without food. Do not crush, open, or chew extended release capsules.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F173580\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of obsessive-compulsive disorder (OCD)",
"    </p>",
"   </div>",
"   <div class=\"block usu drugH1Div\" id=\"F173636\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use - Unlabeled",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of major depression; panic disorder; anxiety disorders in children; treatment of mild dementia-associated agitation in nonpsychotic patients; post-traumatic stress disorder (PTSD); social anxiety disorder (SAD); patients; treatment of paraphilia/hypersexuality",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F173650\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       FluvoxaMINE may be confused with flavoxATE, FLUoxetine, fluPHENAZine",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Luvox may be confused with Lasix&reg;, Levoxyl&reg;, Lovenox&reg;",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      BEERS Criteria medication:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       This drug may be potentially inappropriate for use in geriatric patients (Quality of evidence - moderate; Strength of recommendation - strong).",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F173638\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Frequency varies by dosage form and indication. Adverse reactions reported as a composite of all indications.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &gt;10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Headache (22% to 35%), insomnia (21% to 35%), somnolence (22% to 27%), dizziness (11% to 15%), nervousness (10% to 12%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Nausea (34% to 40%), diarrhea (11% to 18%), xerostomia (10% to 14%), anorexia (6% to 14%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Genitourinary: Ejaculation abnormal (8% to 11%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Weakness (14% to 26%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cardiovascular: Chest pain (3%), palpitation (3%), vasodilation (2% to 3%), hypertension (1% to 2%), edema (&le;1%), hypotension (&le;1%), syncope (&le;1%), tachycardia (&le;1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Pain (10%), anxiety (5% to 8%), abnormal dreams (3%), abnormal thinking (3%), agitation (2% to 3%), apathy (&ge;1% to 3%), chills (2%), CNS stimulation (2%), depression (2%), neurosis (2%), amnesia, malaise, manic reaction, psychotic reaction",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Dermatologic: Bruising (4%), acne (2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Libido decreased (2% to 10%; incidence higher in males), anorgasmia (2% to 5%), sexual function abnormal (2% to 4%), menorrhagia (3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Dyspepsia (8% to 10%), constipation (4% to 10%), vomiting (4% to 6%), abdominal pain (5%), flatulence (4%), taste perversion (2% to 3%), toothache and dental caries (2% to 3%), dysphagia (2%), gingivitis (2%), weight loss (&le;1% to 2%), weight gain",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Genitourinary: Polyuria (2% to 3%), impotence (2%), urinary tract infection (2%), urinary retention (1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hepatic: Liver function tests abnormal (&ge;1% to 2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Tremor (5% to 8%), myalgia (5%), paresthesia (3%), hypertonia (2%), twitching (2%), hyper-/hypokinesia, myoclonus",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Ocular: Amblyopia (2% to 3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Respiratory: Upper respiratory infection (9%), pharyngitis (6%), yawn (2% to 5%), laryngitis (3%), bronchitis (2%), dyspnea (2%), epistaxis (2%), cough increased, sinusitis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Miscellaneous: Diaphoresis (6% to 7%), flu-like syndrome (3%), viral infection (2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &lt;1% (Limited to important or life-threatening):  Acute renal failure, agranulocytosis, akinesia, allergic reaction, anaphylactic reaction, anemia, angina, angioedema, anuria, aplastic anemia, apnea, asthma, ataxia, AV block, bradycardia, bullous eruption, cardiomyopathy, cardiorespiratory arrest, cerebrovascular accident, cholecystitis, cholelithiasis, colitis, conduction delay, coronary artery disease, diplopia, dyskinesia, dystonia, extrapyramidal syndrome, embolus, GI bleeding, goiter, hallucinations, heart failure, hematemesis, hematuria, Henoch-Sch&ouml;nlein purpura, hepatitis, hemoptysis, homicidal ideation, hypercholesterolemia, hyper-/hypoglycemia, hypokalemia, hyponatremia, hypothyroidism, ileus, interstitial lung disease, intestinal obstruction, jaundice, leukopenia, leukocytosis, loss of consciousness, lymphadenopathy, MI, myasthenia, myopathy, neuralgia, neuroleptic malignant syndrome, neuropathy, pancreatitis, paralysis, pericarditis, porphyria, purpura, QT prolongation, retinal detachment, rhabdomyolysis, serotonin syndrome, ST segment changes, seizure, Stevens-Johnson syndrome, suicidal tendencies, supraventricular extrasystoles, tardive dyskinesia, thrombocytopenia, toxic epidermal necrolysis, vasculitis, ventricular arrhythmia, ventricular tachycardia (including torsade de pointes), white blood cells decreased",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F173583\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Concurrent use with alosetron, pimozide, ramelteon, thioridazine, or tizanidine; use of MAO inhibitors intended to treat psychiatric disorders (concurrently or within 14 days of discontinuing either fluvoxamine or the MAO inhibitor); initiation of fluvoxamine in a patient receiving linezolid or intravenous methylene blue",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F173565\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Major psychiatric warnings:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Suicidal thinking/behavior:",
"     <b>",
"      [U.S. Boxed Warning]: Antidepressants increase the risk of suicidal thinking and behavior in children, adolescents, and young adults (18-24 years of age) with major depressive disorder (MDD) and other psychiatric disorders;",
"     </b>",
"     consider risk prior to prescribing. Short-term studies did not show an increased risk in patients &gt;24 years of age and showed a decreased risk in patients &ge;65 years. Closely monitor patients for clinical worsening, suicidality, or unusual changes in behavior, particularly during the initial 1-2 months of therapy or during periods of dosage adjustments (increases or decreases); the patient&rsquo;s family or caregiver should be instructed to closely observe the patient and communicate condition with healthcare provider. A medication guide concerning the use of antidepressants should be dispensed with each prescription.",
"     <b>",
"      Fluvoxamine is FDA approved for the treatment of OCD in children &ge;8 years of age; extended release capsules are not FDA approved for use in children.",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; The possibility of a suicide attempt is inherent in major depression and may persist until remission occurs. Patients treated with antidepressants should be observed for clinical worsening and suicidality, especially during the initial few months of a course of drug therapy, or at times of dose changes, either increases or decreases. Worsening depression and severe abrupt suicidality that are not part of the presenting symptoms may require discontinuation or modification of drug therapy. Use caution in high-risk patients during initiation of therapy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Prescriptions should be written for the smallest quantity consistent with good patient care. The patient's family or caregiver should be alerted to monitor patients for the emergence of suicidality and associated behaviors such as anxiety, agitation, panic attacks, insomnia, irritability, hostility, impulsivity, akathisia, hypomania, and mania; patients should be instructed to notify their healthcare provider if any of these symptoms or worsening depression or psychosis occur.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Anticholinergic effects: Relatively devoid of these side effects.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Bleeding risk: May impair platelet aggregation resulting in increased risk of bleeding events, particularly if used concomitantly with aspirin, NSAIDs, warfarin or other anticoagulants. Bleeding related to SSRI use has been reported to range from relatively minor bruising and epistaxis to life-threatening hemorrhage.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; CNS depression: Has a low potential to impair cognitive or motor performance; caution operating hazardous machinery or driving.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Serotonin syndrome: Potentially life-threatening serotonin syndrome (SS) has occurred with serotonergic agents (eg, SSRIs, SNRIs), particularly when used in combination with other serotonergic agents (eg, triptans, TCAs, fentanyl, lithium, tramadol, buspirone, St John&rsquo;s wort, tryptophan) or agents that impair metabolism of serotonin (eg, MOA inhibitors intended to treat psychiatric disorders, other MAO inhibitors [ie, linezolid and intravenous methylene blue]). Monitor patients closely for signs of SS such as mental status changes (eg, agitation, hallucinations, delirium, coma); autonomic instability (eg, tachycardia, labile blood pressure, diaphoresis); neuromuscular changes (eg, tremor, rigidity, myoclonus); GI symptoms (eg, nausea, vomiting, diarrhea); and/or seizures. Discontinue treatment (and any concomitant serotonergic agent) immediately if signs/symptoms arise.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Sexual dysfunction: May cause or exacerbate sexual dysfunction.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; SIADH and hyponatremia: SSRIs and SNRIs have been associated with the development of SIADH; hyponatremia has been reported rarely (including severe cases with serum sodium &lt;110 mmol/L), predominately in the elderly. Volume depletion and/or concurrent use of diuretics likely increases risk.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Cardiovascular disease: Use with caution in patients with cardiovascular disease; fluvoxamine has not been systemically evaluated in patients with a recent history of MI or unstable heart disease.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatic impairment: Use with caution in patients with hepatic impairment; clearance is decreased and plasma concentrations are increased; a lower dosage may be needed.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Mania/hypomania: May worsen psychosis in some patients or precipitate a shift to mania or hypomania in patients with bipolar disorder. Monotherapy in patients with bipolar disorder should be avoided. Patients presenting with depressive symptoms should be screened for bipolar disorder.",
"     <b>",
"      Fluvoxamine is not FDA approved for the treatment of bipolar depression.",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Seizure disorder: Use with caution in patients with a previous seizure disorder or condition predisposing to seizures such as brain damage or alcoholism.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concurrent drug therapy issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Agents which lower seizure threshold: Use caution with concurrent use of drugs which lower the seizure threshold.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Elderly: Use caution in elderly patients; may cause or exacerbate syndrome of inappropriate antidiuretic hormone secretion or hyponatremia; monitor sodium closely with initiation or dosage adjustments in older adults (Beers Criteria).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Smokers: Fluvoxamine levels may be lower in patients who smoke.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Electroconvulsive therapy: May increase the risks associated with electroconvulsive therapy; consider discontinuing, when possible, prior to ECT treatment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Withdrawal syndrome: May cause dysphoric mood, irritability, agitation, dizziness, sensory disturbances (eg, electric shock-like sensations), anxiety, confusion, headache, lethargy, emotional lability, insomnia, hypomania, tinnitus, and seizures. Upon discontinuation of fluvoxamine therapy, gradually taper dose. If intolerable symptoms occur following a decrease in dosage or upon discontinuation of therapy, then resuming the previous dose with a more gradual taper should be considered.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F173633\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Substrate",
"     </b>",
"     of CYP1A2 (major), CYP2D6 (major);",
"     <b>",
"      Note:",
"     </b>",
"     Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential;",
"     <b>",
"      Inhibits",
"     </b>",
"     CYP1A2 (strong), CYP2B6 (weak), CYP2C19 (strong), CYP2C9 (weak), CYP2D6 (weak), CYP3A4 (weak)",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F173570\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Abiraterone Acetate: May increase the serum concentration of CYP2D6 Substrates. Management: Avoid concurrent use of abiraterone with CYP2D6 substrates that have a narrow therapeutic index whenever possible.  When concurrent use is not avoidable, monitor patients closely for signs/symptoms of toxicity.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Abiraterone Acetate: May increase the serum concentration of CYP1A2 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Agents with Antiplatelet Properties (e.g., P2Y12 inhibitors, NSAIDs, SSRIs, etc.): May enhance the anticoagulant effect of other Agents with Antiplatelet Properties.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alcohol (Ethyl): May enhance the adverse/toxic effect of Selective Serotonin Reuptake Inhibitors. Specifically, the risk of psychomotor impairment may be enhanced. Management: Patients receiving selective serotonin reuptake inhibitors should be advised to avoid alcohol.  Monitor for increased psychomotor impairment in patients who consume alcohol during treatment with selective serotonin reuptake inhibitors.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alosetron: FluvoxaMINE may decrease the metabolism of Alosetron.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Analgesics (Opioid): May enhance the serotonergic effect of Selective Serotonin Reuptake Inhibitors. This may cause serotonin syndrome.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Anticoagulants: Agents with Antiplatelet Properties may enhance the anticoagulant effect of Anticoagulants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antidepressants (Serotonin Reuptake Inhibitor/Antagonist): Selective Serotonin Reuptake Inhibitors may enhance the serotonergic effect of Antidepressants (Serotonin Reuptake Inhibitor/Antagonist). This may cause serotonin syndrome.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antipsychotics: May enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Asenapine: FluvoxaMINE may increase the serum concentration of Asenapine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aspirin: Selective Serotonin Reuptake Inhibitors may enhance the antiplatelet effect of Aspirin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bendamustine: CYP1A2 Inhibitors (Strong) may increase the serum concentration of Bendamustine. Concentrations of the active metabolites of bendamustine may be decreased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Benzodiazepines (metabolized by oxidation): Selective Serotonin Reuptake Inhibitors may decrease the metabolism of Benzodiazepines (metabolized by oxidation).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bromazepam: FluvoxaMINE may increase the serum concentration of Bromazepam.  Management: With concomitant fluvoxamine, consider use of a benzodiazepine that does not undergo oxidative metabolism (e.g., lorazepam). If bromazepam is initiated in patients receiving fluvoxamine, monitor closely for increased bromazepam levels/adverse effects.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     BusPIRone: May enhance the serotonergic effect of Selective Serotonin Reuptake Inhibitors. This may cause serotonin syndrome. Selective Serotonin Reuptake Inhibitors may decrease the metabolism of BusPIRone.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CarBAMazepine: May increase the metabolism of Selective Serotonin Reuptake Inhibitors. Specifically those agents metabolized via CYP1A2, 2C, and/or 3A4 isoenzymes. Selective Serotonin Reuptake Inhibitors may decrease the metabolism of CarBAMazepine. Specifically those SSRIs that inhibit CYP3A4 isoenzymes.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cimetidine: May decrease the metabolism of Selective Serotonin Reuptake Inhibitors.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Clopidogrel: CYP2C19 Inhibitors (Strong) may decrease serum concentrations of the active metabolite(s) of Clopidogrel.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CloZAPine: Selective Serotonin Reuptake Inhibitors may decrease the metabolism of CloZAPine.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CNS Depressants: May enhance the adverse/toxic effect of Selective Serotonin Reuptake Inhibitors. Specifically, the risk of psychomotor impairment may be enhanced.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cobicistat: May increase the serum concentration of Selective Serotonin Reuptake Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Collagenase (Systemic): Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Collagenase (Systemic). Specifically, the risk of injection site bruising and/or bleeding may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP1A2 Inducers (Strong): May increase the metabolism of CYP1A2 Substrates. Management: Consider an alternative for one of the interacting drugs. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP1A2 Inhibitors (Moderate): May decrease the metabolism of CYP1A2 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP1A2 Inhibitors (Strong): May decrease the metabolism of CYP1A2 Substrates.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP1A2 Substrates: CYP1A2 Inhibitors (Strong) may decrease the metabolism of CYP1A2 Substrates.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2C19 Substrates: CYP2C19 Inhibitors (Strong) may decrease the metabolism of CYP2C19 Substrates.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2D6 Inhibitors (Moderate): May decrease the metabolism of CYP2D6 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2D6 Inhibitors (Strong): May decrease the metabolism of CYP2D6 Substrates.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cyproheptadine: May diminish the therapeutic effect of Selective Serotonin Reuptake Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cyproterone: May decrease the serum concentration of CYP1A2 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dabigatran Etexilate: Agents with Antiplatelet Properties may enhance the anticoagulant effect of Dabigatran Etexilate. Agents with Antiplatelet Properties may increase the serum concentration of Dabigatran Etexilate. This mechanism applies specifically to clopidogrel.  Management: Increase monitoring for signs/symptoms of bleeding. The Canadian product monograph for dabigatran specifically recommends avoiding concomitant use with GIIb/IIIa inhibitors or ticlopidine, or with aspirin used for stroke prevention in atrial fibrillation.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Darunavir: May increase the serum concentration of CYP2D6 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dasatinib: May enhance the anticoagulant effect of Agents with Antiplatelet Properties.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Deferasirox: May increase the serum concentration of CYP1A2 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Desmopressin: Selective Serotonin Reuptake Inhibitors may enhance the adverse/toxic effect of Desmopressin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Drotrecogin Alfa (Activated): Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Drotrecogin Alfa (Activated). Bleeding may occur.  Management: When possible, avoid use of drotrecogin within 7 days of use of any IIb/IIIa antagonists, higher dose aspirin (more than 650 mg/day), or use of other antiplatelet agents.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     DULoxetine: May enhance the serotonergic effect of FluvoxaMINE. This could result in serotonin syndrome. FluvoxaMINE may increase the serum concentration of DULoxetine. Management: Coadminister these agents with great caution.  If duloxetine and fluvoxamine are used in combination, monitor for signs and symptoms of serotonin toxicity/serotonin syndrome, as well as other toxic effects of duloxetine.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Erlotinib: FluvoxaMINE may increase the serum concentration of Erlotinib.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fosphenytoin: FluvoxaMINE may increase the serum concentration of Fosphenytoin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Glucosamine: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Grapefruit Juice: May increase the serum concentration of FluvoxaMINE.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Haloperidol: FluvoxaMINE may increase the serum concentration of Haloperidol.  Management: Monitor for increased haloperidol concentrations/effects when patients are receiving fluvoxamine, particularly when fluvoxamine dose is 150 mg/day or greater.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (Anticoagulant/Antiplatelet Properties) (eg, Alfalfa, Anise, Bilberry): May enhance the adverse/toxic effect of Agents with Antiplatelet Properties. Bleeding may occur.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Hypoglycemic Agents: Selective Serotonin Reuptake Inhibitors may enhance the hypoglycemic effect of Hypoglycemic Agents. Selective Serotonin Reuptake Inhibitors may increase the serum concentration of Hypoglycemic Agents.  Management: Consider increased monitoring of glycemic control with concomitant use of a hypoglycemic agent and an SSRI. Dosage adjustments of the hypoglycemic agent may be necessary upon SSRI initiation or discontinuation.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ibritumomab: Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Ibritumomab. Both agents may contribute to impaired platelet function and an increased risk of bleeding.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Iobenguane I 123: Selective Serotonin Reuptake Inhibitors may diminish the therapeutic effect of Iobenguane I 123.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ioflupane I 123: Selective Serotonin Reuptake Inhibitors may diminish the diagnostic effect of Ioflupane I 123.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Linezolid: May enhance the serotonergic effect of Selective Serotonin Reuptake Inhibitors. This could result in serotonin syndrome.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lithium: May enhance the serotonergic effect of Selective Serotonin Reuptake Inhibitors. This could increase the risk of serotonin toxicity/serotonin syndrome.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lomitapide: CYP3A4 Inhibitors (Weak) may increase the serum concentration of Lomitapide.  Management: Limit the maximum adult dose of lomitapide to 30 mg daily when used in combination with any weak CYP3A4 inhibitor.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     MAO Inhibitors: May enhance the serotonergic effect of Selective Serotonin Reuptake Inhibitors. This may cause serotonin syndrome.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methadone: Selective Serotonin Reuptake Inhibitors may decrease the metabolism of Methadone. Fluvoxamine appears to be the only interacting SSRI.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methylene Blue: Selective Serotonin Reuptake Inhibitors may enhance the serotonergic effect of Methylene Blue. This could result in serotonin syndrome.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metoclopramide: May enhance the adverse/toxic effect of Selective Serotonin Reuptake Inhibitors. Management: Seek alternatives to this combination when possible. Monitor patients receiving metoclopramide with selective serotonin reuptake inhibitors for signs of extrapyramidal symptoms, neuroleptic malignant syndrome, and serotonin syndrome.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metoclopramide: Serotonin Modulators may enhance the adverse/toxic effect of Metoclopramide. This may be manifest as symptoms consistent with serotonin syndrome or neuroleptic malignant syndrome.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metyrosine: May enhance the adverse/toxic effect of Selective Serotonin Reuptake Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mexiletine: Selective Serotonin Reuptake Inhibitors may decrease the metabolism of Mexiletine.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Multivitamins/Minerals (with ADEK, Folate, Iron): May enhance the antiplatelet effect of Agents with Antiplatelet Properties.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     NSAID (COX-2 Inhibitor): Selective Serotonin Reuptake Inhibitors may enhance the antiplatelet effect of NSAID (COX-2 Inhibitor). NSAID (COX-2 Inhibitor) may diminish the therapeutic effect of Selective Serotonin Reuptake Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     NSAID (Nonselective): Selective Serotonin Reuptake Inhibitors may enhance the antiplatelet effect of NSAID (Nonselective). NSAID (Nonselective) may diminish the therapeutic effect of Selective Serotonin Reuptake Inhibitors.  Management: Consider using alternative analgesics, when appropriate, and/or addition of an gastroprotective agent.  Monitor patients closely for signs/symptoms of bleeding, and for evidence of diminished SSRI effectiveness with concurrent use.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     OLANZapine: FluvoxaMINE may decrease the metabolism of OLANZapine.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Omega-3 Fatty Acids: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Peginterferon Alfa-2b: May decrease the serum concentration of CYP2D6 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pentosan Polysulfate Sodium: May enhance the adverse/toxic effect of Agents with Antiplatelet Properties. Specifically, the risk of bleeding may be increased by concurrent use of these agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pentoxifylline: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Phenytoin: FluvoxaMINE may increase the serum concentration of Phenytoin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pimozide: Selective Serotonin Reuptake Inhibitors may enhance the adverse/toxic effect of Pimozide.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pirfenidone: CYP1A2 Inhibitors (Strong) may increase the serum concentration of Pirfenidone.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pomalidomide: CYP1A2 Inhibitors (Strong) may increase the serum concentration of Pomalidomide.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Propafenone: FluvoxaMINE may increase the serum concentration of Propafenone.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Propranolol: FluvoxaMINE may increase the serum concentration of Propranolol.  Management: Use a lower initial propranolol dose and be cautious with propranolol dose titration.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Prostacyclin Analogues: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     QuiNIDine: Selective Serotonin Reuptake Inhibitors may decrease the metabolism of QuiNIDine. Fluvoxamine appears to be the only SSRI of concern.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ramelteon: FluvoxaMINE may decrease the metabolism of Ramelteon.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rivaroxaban: Agents with Antiplatelet Properties may enhance the anticoagulant effect of Rivaroxaban.  Management: Avoid concurrent use of clopidogrel with rivaroxaban unless the anticipated benefits outweigh the risks of bleeding.  Avoid concurrent use of rivaroxaban with other antiplatelet agents whenever possible.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Roflumilast: FluvoxaMINE may increase serum concentrations of the active metabolite(s) of Roflumilast. FluvoxaMINE may increase the serum concentration of Roflumilast.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ropivacaine: FluvoxaMINE may decrease the metabolism of Ropivacaine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Salicylates: Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Salicylates. Increased risk of bleeding may result.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Serotonin Modulators: May enhance the adverse/toxic effect of other Serotonin Modulators. The development of serotonin syndrome may occur.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Theophylline Derivatives: FluvoxaMINE may decrease the metabolism of Theophylline Derivatives.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Dyphylline.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Thioridazine: FluvoxaMINE may increase the serum concentration of Thioridazine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Thrombolytic Agents: Agents with Antiplatelet Properties may enhance the anticoagulant effect of Thrombolytic Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tipranavir: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     TiZANidine: FluvoxaMINE may decrease the metabolism of TiZANidine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tositumomab and Iodine I 131 Tositumomab: Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Tositumomab and Iodine I 131 Tositumomab. Specifically, the risk of bleeding-related adverse events may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     TraMADol: Selective Serotonin Reuptake Inhibitors may enhance the neuroexcitatory and/or seizure-potentiating effect of TraMADol. TraMADol may enhance the serotonergic effect of Selective Serotonin Reuptake Inhibitors. This may cause serotonin syndrome.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tricyclic Antidepressants: Selective Serotonin Reuptake Inhibitors may decrease the metabolism of Tricyclic Antidepressants.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tryptophan: May enhance the serotonergic effect of Selective Serotonin Reuptake Inhibitors. This may cause serotonin syndrome.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vitamin E: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vitamin K Antagonists (eg, warfarin): Selective Serotonin Reuptake Inhibitors may enhance the anticoagulant effect of Vitamin K Antagonists.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Zolpidem: FluvoxaMINE may enhance the CNS depressant effect of Zolpidem. FluvoxaMINE may increase the serum concentration of Zolpidem.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F173596\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ethanol: May increase CNS depression; monitor for increased effects with coadministration. Caution patients about effects.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Herb/Nutraceutical: Avoid valerian, St John's wort, tryptophan, SAMe, kava kava (may increase risk of serotonin syndrome and/or excessive sedation). Avoid alfalfa, anise, bilberry, bladderwrack, bromelain, cat's claw, celery, chamomile, coleus, cordyceps, dong quai, evening primrose, fenugreek, feverfew, garlic, ginger, ginkgo biloba, ginseng (American), ginseng (Panax), ginseng (Siberian), grape seed, green tea, guggul, horse chestnuts, horseradish, licorice, prickly ash, red clover, reishi, SAMe (S-adenosylmethionine), sweet clover, turmeric, white willow (all have additional antiplatelet activity). Bioavailability of melatonin may be increased by fluvoxamine.",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F173572\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F173585\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adverse events have been observed in animal reproduction studies. Fluvoxamine crosses the human placenta. An increased risk of teratogenic effects, including cardiovascular defects, may be associated with maternal use of fluvoxamine or other SSRIs; however, available information is conflicting. Nonteratogenic effects in the newborn following SSRI/SNRI exposure late in the third trimester include respiratory distress, cyanosis, apnea, seizures, temperature instability, feeding difficulty, vomiting, hypoglycemia, hypo- or hypertonia, hyper-reflexia, jitteriness, irritability, constant crying, and tremor. Symptoms may be due to the toxicity of the SSRIs/SNRIs or a discontinuation syndrome and may be consistent with serotonin syndrome associated with SSRI treatment. Persistent pulmonary hypertension of the newborn (PPHN) has also been reported with SSRI exposure. The long-term effects of",
"     <i>",
"      in utero",
"     </i>",
"     SSRI exposure on infant development and behavior are not known.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     The ACOG recommends that therapy with SSRIs or SNRIs during pregnancy be individualized; treatment of depression during pregnancy should incorporate the clinical expertise of the mental health clinician, obstetrician, primary healthcare provider, and pediatrician. According to the American Psychiatric Association (APA), the risks of medication treatment should be weighed against other treatment options and untreated depression. For women who discontinue antidepressant medications during pregnancy and who may be at high risk for postpartum depression, the medications can be restarted following delivery. Treatment algorithms have been developed by the ACOG and the APA for the management of depression in women prior to conception and during pregnancy.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F173609\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Enters breast milk/consider risk:benefit (AAP rates &ldquo;of concern&rdquo;; AAP 2001 update pending)",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F4028911\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Fluvoxamine is excreted in breast milk. Based on case reports, the dose the infant receives is relatively small and adverse events have not been observed. Adverse events have been reported in nursing infants exposed to some SSRIs. According to the manufacturer, the decision to continue or discontinue breast-feeding during therapy should take into account the risk of exposure to the infant and the benefits of treatment to the mother.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     The long-term effects on development and behavior have not been studied; therefore, fluvoxamine should be prescribed to a mother who is breast-feeding only when the benefits outweigh the potential risks. Maternal use of an SSRI during pregnancy may cause delayed milk secretion.",
"    </p>",
"   </div>",
"   <div class=\"block dic drugH1Div\" id=\"F6195123\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dietary Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     May be taken with or without food.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F2524580\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Capsule, 24-hour",
"     </b>",
"     (FluvoxaMINE Maleate ER Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     100 mg (30): $305.51",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     150 mg (30): $327.87",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Capsule, 24-hour",
"     </b>",
"     (Luvox CR Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     100 mg (30): $339.48",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     150 mg (30): $364.32",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (FluvoxaMINE Maleate Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     25 mg (100): $230.30",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     50 mg (100): $257.35",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     100 mg (100): $263.95",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F173574\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Mental status for depression, suicide ideation (especially at the beginning of therapy or when doses are increased or decreased), anxiety, social functioning, mania, panic attacks; signs/symptoms of serotonin syndrome; akathisia; weight gain or loss, nutritional intake, sleep; liver function assessment prior to beginning drug therapy",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F173586\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Anwu (MY, TW);",
"     </li>",
"     <li>",
"      Avoxin (HR);",
"     </li>",
"     <li>",
"      Dumirox (ES, KP, UY);",
"     </li>",
"     <li>",
"      Dumyrox (GR, PT);",
"     </li>",
"     <li>",
"      Faverin (AE, AU, BH, CY, EG, GB, HK, IE, IQ, IR, JO, KW, LB, LY, OM, PK, QA, SA, SG, SY, TH, TR, YE);",
"     </li>",
"     <li>",
"      Favoxil (IL);",
"     </li>",
"     <li>",
"      Fevalax (PY);",
"     </li>",
"     <li>",
"      Fevarin (BG, CZ, DK, EE, FI, HN, HR, HU, IT, NL, NO, PL, RU, SE);",
"     </li>",
"     <li>",
"      Floxyfral (AT, BE, CH, FR, LU);",
"     </li>",
"     <li>",
"      Fluvohexal (DE);",
"     </li>",
"     <li>",
"      Fluvoxim (PE);",
"     </li>",
"     <li>",
"      Fluvoxin (IN, TH);",
"     </li>",
"     <li>",
"      Luvox (AR, AU, BR, CL, CN, EC, ID, MX, MY, NZ, PE, TW, VE, ZA);",
"     </li>",
"     <li>",
"      Movox (AU);",
"     </li>",
"     <li>",
"      Voxam (AU);",
"     </li>",
"     <li>",
"      Voxamin (CO);",
"     </li>",
"     <li>",
"      Voxamine (PH);",
"     </li>",
"     <li>",
"      Vuminix (MX)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F173564\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Inhibits CNS neuron serotonin uptake; minimal or no effect on reuptake of norepinephrine or dopamine; does not significantly bind to alpha-adrenergic, histamine or cholinergic receptors",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F173582\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Onset of action: Depression: The onset of action is within a week; however, individual response varies greatly and full response may not be seen until 8-12 weeks after initiation of treatment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: Steady-state plasma concentrations have been noted to be 2-3 times higher in children than those in adolescents; female children demonstrated a significantly higher AUC than males",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: V",
"     <sub>",
"      d",
"     </sub>",
"     : ~25 L/kg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: ~80%, primarily to albumin",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Extensively hepatic via oxidative demethylation and deamination",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Bioavailability: Immediate release: 53%; not significantly affected by food",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination: 15-16 hours; 17-26 hours in the elderly",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak, plasma: 3-8 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Urine (~85% as metabolites; ~2% as unchanged drug)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      American Academy of Pediatrics Committee on Drugs, &ldquo;Transfer of Drugs and Other Chemicals Into Human Milk,&rdquo;",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 2001, 108(3):776-89.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?28/50/29481/abstract-text/11533352/pubmed\" id=\"11533352\" target=\"_blank\">",
"        11533352",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      American College of Obstetricians and Gynecologists, ACOG Practice Bulletin: Clinical Management Guidelines for Obstetricians-Gynecologists No. 92 April 2008 (Replaces Practice Bulletin Number 87, November 2007), &ldquo;Use of Psychiatric Medications During Pregnancy and Lactation,&rdquo;",
"      <i>",
"       Obstet Gynecol",
"      </i>",
"      , 2008, 111(4):1001-20.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?28/50/29481/abstract-text/18378767/pubmed\" id=\"18378767\" target=\"_blank\">",
"        18378767",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      American Geriatrics Society 2012 Beers Criteria Update Expert Panel, \"American Geriatrics Society Updated Beers Criteria for Potentially Inappropriate Medication Use in Older Adults,\"",
"      <i>",
"       J Am Geriatr Soc",
"      </i>",
"      , 2012, 60(4):616-31.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?28/50/29481/abstract-text/22376048/pubmed\" id=\"22376048\" target=\"_blank\">",
"        22376048",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Bandelow B, Zohar J, Hollander E, et al, &ldquo;World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for the Pharmacological Treatment of Anxiety, Obsessive-Compulsive and Post-Traumatic Stress Disorders -- First Revision,&rdquo;",
"      <i>",
"       World J Biol Psychiatry",
"      </i>",
"      , 2008, 9(4): 248-312. Available at file://www.wfsbp.org/fileadmin/pdf/guides/Guidelines_Anxiety_revision.pdf",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?28/50/29481/abstract-text/18949648/pubmed\" id=\"18949648\" target=\"_blank\">",
"        18949648",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Benedek DM, Friedman MJ, Zatzick D, et al, &ldquo;Guideline Watch (March 2009): Practice Guideline for the Treatment of Patients With Acute Stress Disorder and Posttraumatic Stress Disorder.&rdquo; Available at  file://www.psychiatryonline.com/pracGuide/loadGuidelinePdf.aspx?file=AcuteStressDisorder-PTSD_GuidelineWatch",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Boyer EW and Shannon M, &ldquo;The Serotonin Syndrome,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 2005, 352:1112-20.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?28/50/29481/abstract-text/15784664/pubmed\" id=\"15784664\" target=\"_blank\">",
"        15784664",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Chambers CD, Hernandez-Diaz S, Van Marter LJ, et al, &ldquo;Selective Serotonin-Reuptake Inhibitors and Risk of Persistent Pulmonary Hypertension of the Newborn,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 2006, 354(6):579-87.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?28/50/29481/abstract-text/16467545/pubmed\" id=\"16467545\" target=\"_blank\">",
"        16467545",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Davidson J, Yaryura-Tobias J, DuPont R, et al, \"Fluvoxamine-Controlled Release Formulation for the Treatment of Generalized Social Anxiety Disorder,\"",
"      <i>",
"       J Clin Psychopharmacol",
"      </i>",
"      , 2004, 24(2):118-25.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?28/50/29481/abstract-text/15206657/pubmed\" id=\"15206657\" target=\"_blank\">",
"        15206657",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      De Vries MH, Raghoebar M, Mathlener IS, et al, &ldquo;Single and Multiple Oral Dose Fluvoxamine Kinetics in Young and Elderly Subjects,&rdquo;",
"      <i>",
"       Ther Drug Monit",
"      </i>",
"      , 1992, 14(6):493-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?28/50/29481/abstract-text/1485372/pubmed\" id=\"1485372\" target=\"_blank\">",
"        1485372",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Dunkley EJ, Isbister GK, Sibbritt D, et al, &ldquo;The Hunter Serotonin Toxicity Criteria: Simple and Accurate Diagnostic Decision Rules for Serotonin Toxicity,&rdquo;",
"      <i>",
"       QJM",
"      </i>",
"      , 2003, 96(9):635-42.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?28/50/29481/abstract-text/12925718/pubmed\" id=\"12925718\" target=\"_blank\">",
"        12925718",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      &ldquo;Fluvoxamine for the Treatment of Anxiety Disorders in Children and Adolescents. The Research Unit on Pediatric Psychopharmacology Anxiety Study Group,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 2001, 344(17):1279-85.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?28/50/29481/abstract-text/11323729/pubmed\" id=\"11323729\" target=\"_blank\">",
"        11323729",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Grimsley SR and Jann MW, &ldquo;Paroxetine, Sertraline, and Fluvoxamine: New Selective Serotonin Reuptake Inhibitors,&rdquo;",
"      <i>",
"       Clin Pharm",
"      </i>",
"      , 1992, 11(11):930-57.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?28/50/29481/abstract-text/1464219/pubmed\" id=\"1464219\" target=\"_blank\">",
"        1464219",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      H&auml;rtter S, Gr&ouml;zinger M, Weigmann H, et al, \"Increased Bioavailability of Oral Melatonin After Fluvoxamine Coadministration,\"",
"      <i>",
"       Clin Pharmacol Ther",
"      </i>",
"      , 2000, 67(1):1-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?28/50/29481/abstract-text/10668847/pubmed\" id=\"10668847\" target=\"_blank\">",
"        10668847",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Mokhlesi B, Leikin JB, Murray P, et al, &ldquo;Adult Toxicology in Critical Care: Part II: Specific Poisonings,&rdquo;",
"      <i>",
"       Chest",
"      </i>",
"      , 2003, 123(3):897-922.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?28/50/29481/abstract-text/12628894/pubmed\" id=\"12628894\" target=\"_blank\">",
"        12628894",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Nelson JC and Devanand DP, \"A Systematic Review and Meta-Analysis of Placebo-Controlled Antidepressant Studies in People With Depression and Dementia,\"",
"      <i>",
"       J Am Geriatr Soc",
"      </i>",
"      , 2011, 59(4):577-85.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?28/50/29481/abstract-text/21453380/pubmed\" id=\"21453380\" target=\"_blank\">",
"        21453380",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Pass SE and Simpson RW, &ldquo;Discontinuation and Reinstitution of Medications During the Perioperative Period,&rdquo;",
"      <i>",
"       Am J Health Syst Pharm",
"      </i>",
"      , 2004, 61(9):899-912.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?28/50/29481/abstract-text/15156966/pubmed\" id=\"15156966\" target=\"_blank\">",
"        15156966",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Rabins PV, Blacker D, Rovner BW, et al, &ldquo;American Psychiatric Association Practice Guideline for the Treatment of Patients With Alzheimer's Disease and Other Dementias. Second Edition,&rdquo;",
"      <i>",
"       Am J Psychiatry",
"      </i>",
"      , 2007, 164(12 Suppl):5-56.  Available at file://psychiatryonline.org/guidelines.aspx",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?28/50/29481/abstract-text/18340692/pubmed\" id=\"18340692\" target=\"_blank\">",
"        18340692",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Riddle MA, Reeve EA, Yaryura-Tobias JA, et al, &ldquo;Fluvoxamine for Children and Adolescents With Obsessive-Compulsive Disorder: A Randomized, Controlled, Multicenter Trial,&rdquo;",
"      <i>",
"       J Am Acad Child Adolesc Psychiatry",
"      </i>",
"      , 2001, 40(2):222-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?28/50/29481/abstract-text/11211371/pubmed\" id=\"11211371\" target=\"_blank\">",
"        11211371",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Roose SP, Glassman AH, Attia E, et al, &ldquo;Comparative Efficacy of Selective Serotonin Reuptake Inhibitors and Tricyclics in the Treatment of Melancholia,&rdquo;",
"      <i>",
"       Am J Psychiatry",
"      </i>",
"      , 1994, 151(12):1735-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?28/50/29481/abstract-text/7977878/pubmed\" id=\"7977878\" target=\"_blank\">",
"        7977878",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Spivak B, Strous RD, Shaked G, et al., &ldquo;Reboxetine Versus Fluvoxamine in the Treatment of Motor Vehicle Accident-Related Posttraumatic Stress Disorder: A Double-blind, Fixed-Dosage, Controlled Trial,&rdquo;",
"      <i>",
"       J Clin Psychopharmacol",
"      </i>",
"      , 2006,  26(2):153-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?28/50/29481/abstract-text/16633143/pubmed\" id=\"16633143\" target=\"_blank\">",
"        16633143",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Stein DJ, Westenberg HG, Yang H, et al, \"Fluvoxamine CR in the Long-Term Treatment of Social Anxiety Disorder: The 12- to 24-Week Extension Phase of a Multicentre, Randomized, Placebo-Controlled Trial,\"",
"      <i>",
"       Int J Neuropsychopharmacol",
"      </i>",
"      , 2003, 6(4):317-23.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?28/50/29481/abstract-text/14604447/pubmed\" id=\"14604447\" target=\"_blank\">",
"        14604447",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Stevens DL, &ldquo;Association Between Selective Serotonin-Reuptake Inhibitors, Second-Generation Antipsychotics, and Neuroleptic Malignant Syndrome,&rdquo;",
"      <i>",
"       Ann Pharmacother",
"      </i>",
"      , 2008, 42(9):1290-7.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Thibaut F, De La Barra F, Gordon H, et al, &ldquo;The World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for the Biological Treatment of Paraphilias,&rdquo;",
"      <i>",
"       World J Biol Psychiatry",
"      </i>",
"      , 2010, 11(4):604-55.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?28/50/29481/abstract-text/20459370/pubmed\" id=\"20459370\" target=\"_blank\">",
"        20459370",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Yonkers KA, Wisner KL, Stewart DE, et al, &ldquo;The Management of Depression During Pregnancy: A Report From the American Psychiatric Association and the American College of Obstetricians and Gynecologists,&rdquo;",
"      <i>",
"       Obstet Gynecol",
"      </i>",
"      , 2009, 114(3):703-13.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?28/50/29481/abstract-text/19701065/pubmed\" id=\"19701065\" target=\"_blank\">",
"        19701065",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Westenberg HG, Stein DJ, Yang H, et al, \"A Double-Blind Placebo-Controlled Study of Controlled Release Fluvoxamine for the Treatment of Generalized Social Anxiety Disorder,\"",
"      <i>",
"       J Clin Psychopharmacol",
"      </i>",
"      , 2004, 24(1):49-55.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?28/50/29481/abstract-text/14709947/pubmed\" id=\"14709947\" target=\"_blank\">",
"        14709947",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Wynn RL, &ldquo;New Antidepressant Medications,&rdquo;",
"      <i>",
"       Gen Dent",
"      </i>",
"      , 1997, 45(1):24-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?28/50/29481/abstract-text/9171475/pubmed\" id=\"9171475\" target=\"_blank\">",
"        9171475",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 8474 Version 51.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1005-122.72.76.133-E2305D93BD-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f28_50_29481=[""].join("\n");
var outline_f28_50_29481=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5708808\">",
"      ALERT: U.S. Boxed Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6195103\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F173600\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F173640\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F173604\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F173619\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F173605\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15896268\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F173606\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F173577\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F173561\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7874605\">",
"      Medication Guide",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6195124\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F173580\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F173636\">",
"      Use - Unlabeled",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F173650\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F173638\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F173583\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F173565\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F173633\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F173570\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F173596\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F173572\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F173585\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F173609\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4028911\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6195123\">",
"      Dietary Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2524580\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F173574\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F173586\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F173564\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F173582\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8474\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8474|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?6/13/6358?source=related_link\">",
"      Fluvoxamine: Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?40/22/41320?source=related_link\">",
"      Fluvoxamine: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f28_50_29482="Hepatorenal syndrome";
var content_f28_50_29482=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Hepatorenal syndrome",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?28/50/29482/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?28/50/29482/contributors\">",
"     Bruce A Runyon, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?28/50/29482/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?28/50/29482/contributors\">",
"     Richard H Sterns, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?28/50/29482/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?28/50/29482/contributors\">",
"     John P Forman, MD, MSc",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?28/50/29482/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 26, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The hepatorenal syndrome is one of many potential causes of acute kidney injury in patients with acute or chronic liver disease. Affected patients usually have portal hypertension due to cirrhosis, severe alcoholic hepatitis, or (less often) metastatic tumors, but can also have fulminant hepatic failure from any cause [",
"    <a class=\"abstract\" href=\"UTD.htm?28/50/29482/abstract/1-3\">",
"     1-3",
"    </a>",
"    ]. The hepatorenal syndrome represents the end-stage of a sequence of reductions in renal perfusion induced by increasingly severe hepatic injury. The hepatorenal syndrome is a diagnosis of exclusion and is associated with a poor prognosis.",
"   </p>",
"   <p>",
"    This topic will review the hepatorenal syndrome in detail. Overviews of the complications of fulminant hepatic failure and cirrhosis are provided elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/40/38538?source=see_link\">",
"     \"Acute liver failure in adults: Management and prognosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/59/17337?source=see_link\">",
"     \"Overview of the complications, prognosis, and management of cirrhosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     PATHOGENESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Arterial vasodilatation in the splanchnic circulation, which is triggered by portal hypertension, appears to play a central role in the hemodynamic changes and the decline in renal function in cirrhosis [",
"    <a class=\"abstract\" href=\"UTD.htm?28/50/29482/abstract/1-3\">",
"     1-3",
"    </a>",
"    ]. The presumed mechanism is increased production or activity of vasodilators, mainly in the splanchnic circulation, with nitric oxide thought to be most important [",
"    <a class=\"abstract\" href=\"UTD.htm?28/50/29482/abstract/1,4,5\">",
"     1,4,5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    As the hepatic disease becomes more severe, there is a progressive rise in cardiac output and fall in systemic vascular resistance; the latter change occurs despite local increases in renal and femoral vascular resistance that result in part from hypotension-induced activation of the renin-angiotensin and sympathetic nervous systems (",
"    <a class=\"graphic graphic_figure graphicRef74244 \" href=\"UTD.htm?36/51/37693\">",
"     figure 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?28/50/29482/abstract/1-3,6\">",
"     1-3,6",
"    </a>",
"    ]. Thus, the reduction in total vascular resistance results from decreased vascular resistance in the splanchnic circulation [",
"    <a class=\"abstract\" href=\"UTD.htm?28/50/29482/abstract/6\">",
"     6",
"    </a>",
"    ], perhaps in part under the influence of nitric oxide derived from the endothelium. Bacterial translocation from the intestine into the mesenteric lymph nodes may play an important role in this process [",
"    <a class=\"abstract\" href=\"UTD.htm?28/50/29482/abstract/1,7,8\">",
"     1,7,8",
"    </a>",
"    ]. A review of the hemodynamic changes seen with progressive cirrhosis can be found in a separate topic review. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/1/21527?source=see_link\">",
"     \"Pathogenesis of ascites in patients with cirrhosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The decline in renal perfusion in this setting is associated with reductions in glomerular filtration rate (GFR) and sodium excretion (often to less than 10",
"    <span class=\"nowrap\">",
"     meq/day",
"    </span>",
"    in advanced cirrhosis) [",
"    <a class=\"abstract\" href=\"UTD.htm?28/50/29482/abstract/9,10\">",
"     9,10",
"    </a>",
"    ] and a fall in mean arterial pressure, despite the intense renal vasoconstriction [",
"    <a class=\"abstract\" href=\"UTD.htm?28/50/29482/abstract/10\">",
"     10",
"    </a>",
"    ]. The importance of splanchnic vasodilatation in these changes can be indirectly illustrated by the response to ornipressin, an analog of antidiuretic hormone (arginine vasopressin) that is a preferential splanchnic vasoconstrictor [",
"    <a class=\"abstract\" href=\"UTD.htm?28/50/29482/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In patients with advanced cirrhosis, the administration of ornipressin",
"    <strong>",
"     or",
"    </strong>",
"    other vasopressin analogues partially corrects many of the systemic and renal hemodynamic abnormalities that are present (",
"    <a class=\"graphic graphic_figure graphicRef68506 \" href=\"UTD.htm?38/9/39069\">",
"     figure 2",
"    </a>",
"    ); these include an elevation in mean arterial pressure, reductions in plasma renin activity and norepinephrine concentration, and increases in renal blood flow, GFR (from 18 to 29",
"    <span class=\"nowrap\">",
"     mL/min),",
"    </span>",
"    and urinary sodium excretion and volume.",
"   </p>",
"   <p>",
"    In addition, acutely lowering renal sympathetic tone and renal vascular resistance in the early stages of hepatorenal syndrome by the intravenous administration of the sympatholytic agent,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/53/19289?source=see_link\">",
"     clonidine",
"    </a>",
"    , can raise the GFR by as much as 25 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?28/50/29482/abstract/12\">",
"     12",
"    </a>",
"    ]. However, this benefit does not appear to be sustained with chronic oral therapy, despite a persistent reduction in sympathetic activity [",
"    <a class=\"abstract\" href=\"UTD.htm?28/50/29482/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The response to creation of a portasystemic shunt also supports the importance of splanchnic hemodynamics in the genesis of the hepatorenal syndrome. Portasystemic shunting has improved renal function in a limited number of patients with the hepatorenal syndrome [",
"    <a class=\"abstract\" href=\"UTD.htm?28/50/29482/abstract/14\">",
"     14",
"    </a>",
"    ], but it is infrequently used as treatment for this disorder [",
"    <a class=\"abstract\" href=\"UTD.htm?28/50/29482/abstract/15\">",
"     15",
"    </a>",
"    ]. One report, however, suggested that the reduction in intrahepatic pressure induced by this modality may",
"    <strong>",
"     prevent",
"    </strong>",
"    the development of the hepatorenal syndrome. This retrospective study evaluated 204 patients with variceal bleeding who were treated with either a portasystemic shunt or sclerotherapy (or other non-shunt modalities) [",
"    <a class=\"abstract\" href=\"UTD.htm?28/50/29482/abstract/16\">",
"     16",
"    </a>",
"    ]. Portasystemic shunting was associated with a lower incidence of ascites (15 versus 73 percent) and hepatorenal syndrome (4 versus 21 percent), a higher incidence of encephalopathy, and no difference in overall patient survival.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9884469\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients who develop the hepatorenal syndrome usually have portal hypertension due to cirrhosis, severe alcoholic hepatitis, or, less often, metastatic tumors [",
"    <a class=\"abstract\" href=\"UTD.htm?28/50/29482/abstract/1-3\">",
"     1-3",
"    </a>",
"    ]. However, patients with fulminant hepatic failure from any cause may develop hepatorenal syndrome.",
"   </p>",
"   <p>",
"    The incidence of hepatorenal syndrome was evaluated in a prospective study of 229 nonazotemic patients with cirrhosis and ascites: the hepatorenal syndrome developed in 18 and 39 percent at one and five years, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?28/50/29482/abstract/10\">",
"     10",
"    </a>",
"    ]. Patients with hyponatremia and a high plasma renin activity were at highest risk. These signs of neurohumoral activation presumably reflected a more severe decline in effective perfusion [",
"    <a class=\"abstract\" href=\"UTD.htm?28/50/29482/abstract/1,6\">",
"     1,6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Hepatorenal syndrome also occurs frequently in patients with acute liver disease. In a study of patients with alcoholic hepatitis, for example, hepatorenal syndrome occurred in 28 of 101 patients [",
"    <a class=\"abstract\" href=\"UTD.htm?28/50/29482/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although hepatorenal syndrome can be seen in most forms of severe hepatic disease, patients with primary biliary cirrhosis appear relatively protected [",
"    <a class=\"abstract\" href=\"UTD.htm?28/50/29482/abstract/18\">",
"     18",
"    </a>",
"    ]. Sodium retention, ascites formation, and the hepatorenal syndrome all tend to occur less often in primary biliary cirrhosis, possibly due in part to the natriuretic and renal vasodilator actions of retained bile salts.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     CLINICAL PRESENTATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The hepatorenal syndrome is characterized by the following features in a patient who has established or clinically evident acute or chronic liver disease [",
"    <a class=\"abstract\" href=\"UTD.htm?28/50/29482/abstract/1-3,10,19\">",
"     1-3,10,19",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      A progressive rise in serum creatinine",
"     </li>",
"     <li>",
"      An often normal urine sediment",
"     </li>",
"     <li>",
"      No or minimal proteinuria (less than 500 mg per day)",
"     </li>",
"     <li>",
"      A very low rate of sodium excretion (ie, urine sodium concentration less than 10",
"      <span class=\"nowrap\">",
"       meq/L)",
"      </span>",
"     </li>",
"     <li>",
"      Oliguria",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    However, not all patients with hepatorenal syndrome have oliguria (especially early in its course), a progressive rise in serum creatinine, and a benign urine sediment. Urine volumes may be higher than previously appreciated. Some studies, for example, have found that the urine volume may exceed 400 mL per day, with markedly lower output being observed only within a few days from death [",
"    <a class=\"abstract\" href=\"UTD.htm?28/50/29482/abstract/20,21\">",
"     20,21",
"    </a>",
"    ]. In addition, the serum creatinine may increase by as little as 0.1",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (9",
"    <span class=\"nowrap\">",
"     micromol/L)",
"    </span>",
"    per day, with intermittent periods of stabilization or even slight improvement. Lastly, the urine sediment may show a variety of abnormalities, such as hematuria due to bladder instrumentation and underlying coagulopathy, and granular casts due to hyperbilirubinemia.",
"   </p>",
"   <p>",
"    Based upon the rapidity of the decline in kidney function, two forms of hepatorenal syndrome have been described [",
"    <a class=\"abstract\" href=\"UTD.htm?28/50/29482/abstract/1,19,22\">",
"     1,19,22",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Type 1 hepatorenal syndrome",
"      </strong>",
"      &ndash; Type 1 hepatorenal syndrome is the more serious type; it is defined as at least a twofold increase in serum creatinine (reflecting a 50 percent reduction in creatinine clearance) to a level greater than 2.5",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (221",
"      <span class=\"nowrap\">",
"       micromol/L)",
"      </span>",
"      during a period of less than two weeks. At the time of diagnosis, some patients with type 1 hepatorenal syndrome have a urine output less than 400 to 500 mL per day [",
"      <a class=\"abstract\" href=\"UTD.htm?28/50/29482/abstract/19,21\">",
"       19,21",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <strong>",
"       Type 2 hepatorenal syndrome",
"      </strong>",
"      &ndash; Type 2 hepatorenal syndrome is defined as renal impairment that is less severe than that observed with type 1 disease. The major clinical feature in patients with type 2 hepatorenal syndrome is ascites that is resistant to diuretics.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5670964\">",
"    <span class=\"h2\">",
"     Precipitants",
"    </span>",
"    &nbsp;&mdash;&nbsp;The onset of renal failure is typically insidious but can be precipitated by an acute insult, such as bacterial infection or gastrointestinal bleeding [",
"    <a class=\"abstract\" href=\"UTD.htm?28/50/29482/abstract/10,19,23\">",
"     10,19,23",
"    </a>",
"    ]. Spontaneous bacterial peritonitis, for example, can trigger progressive hepatorenal syndrome, although it is more likely to occur in patients who already have some degree of renal insufficiency [",
"    <a class=\"abstract\" href=\"UTD.htm?28/50/29482/abstract/24,25\">",
"     24,25",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/1/4121?source=see_link&amp;anchor=H7#H7\">",
"     \"Treatment and prophylaxis of spontaneous bacterial peritonitis\", section on 'Renal failure'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Although overly rapid diuresis has often been mentioned as a precipitant of hepatorenal syndrome, perhaps because most patients are taking diuretics when the syndrome is diagnosed, diuretics do",
"    <strong>",
"     not",
"    </strong>",
"    cause hepatorenal syndrome. Diuretics can, however, cause azotemia, particularly if fluid is removed too rapidly in patients without peripheral edema. Diuretic-induced azotemia improves with the cessation of therapy and fluid repletion. In comparison, the hepatorenal syndrome typically worsens inexorably, even after diuretics are stopped. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/44/19145?source=see_link&amp;anchor=H9#H9\">",
"     \"Initial therapy of ascites in patients with cirrhosis\", section on 'Concerns'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17253448\">",
"    <span class=\"h2\">",
"     Problems with estimating kidney function",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with hepatorenal syndrome may have renal dysfunction that is substantially more severe than is suggested by the serum creatinine. Both urea and creatinine production may be substantially reduced in this setting, due to the liver disease and to decreased muscle mass and decreased protein and meat intake. The net effect is that a serum creatinine that appears to be within the normal range (eg, 1 to 1.3",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    [88.4 to 115",
"    <span class=\"nowrap\">",
"     micromol/L])",
"    </span>",
"    may be associated with a glomerular filtration rate (GFR) that ranges from as low as 20 to 60",
"    <span class=\"nowrap\">",
"     mL/min",
"    </span>",
"    to a clearly normal value above 100",
"    <span class=\"nowrap\">",
"     mL/min,",
"    </span>",
"    depending primarily upon muscle mass. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/45/36570?source=see_link&amp;anchor=H20664189#H20664189\">",
"     \"Assessment of kidney function\", section on 'Using creatinine to estimate GFR'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The blood urea nitrogen (BUN) is variable in these patients. For a given GFR, it may be lower or higher than expected. If protein intake is very low, reduced urea production may result in a low BUN and a low BUN to creatinine ratio. In contrast, if protein intake is adequate, increased passive reabsorption of urea in the proximal tubule, driven by enhanced proximal tubular reabsorption of sodium and water, can result in a high BUN and a high BUN to creatinine ratio. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/54/12138?source=see_link\">",
"     \"Etiology and diagnosis of prerenal disease and acute tubular necrosis in acute kidney injury (acute renal failure)\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hepatorenal syndrome is diagnosed based upon clinical criteria. There is no one specific test that can establish the diagnosis. Investigational urinary biomarkers such as neutrophil gelatinase-associated lipocalin (NGAL) tend to be lower in prerenal azotemia and hepatorenal syndrome than in acute tubular necrosis (ATN), but there is considerable overlap between these conditions [",
"    <a class=\"abstract\" href=\"UTD.htm?28/50/29482/abstract/26,27\">",
"     26,27",
"    </a>",
"    ]. In addition, hepatorenal syndrome is a diagnosis of exclusion, meaning that other potential etiologies of acute or subacute kidney injury in patients with liver disease should be considered unlikely before a diagnosis of hepatorenal syndrome is made.",
"   </p>",
"   <p>",
"    The following definition and diagnostic criteria have been proposed for the hepatorenal syndrome [",
"    <a class=\"abstract\" href=\"UTD.htm?28/50/29482/abstract/1,19,22\">",
"     1,19,22",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Chronic or acute hepatic disease with advanced hepatic failure and portal hypertension.",
"     </li>",
"     <li>",
"      A serum creatinine above 1.5",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (133",
"      <span class=\"nowrap\">",
"       micromol/L)",
"      </span>",
"      that progresses over days to weeks (ie, acute or subacute kidney injury). As noted above, the rise in serum creatinine with reductions in glomerular filtration rate (GFR) may be minimal due to the marked reduction in creatinine production among such patients. (See",
"      <a class=\"local\" href=\"#H17253448\">",
"       'Problems with estimating kidney function'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The absence of any other apparent cause for the acute kidney injury, including shock, current or recent treatment with nephrotoxic drugs, and the absence of ultrasonographic evidence of obstruction or parenchymal renal disease. Spontaneous bacterial peritonitis is complicated by acute kidney injury that may be reversible in 30 to 40 percent of patients. It can be associated with ATN, but it is also a major precipitant of the hepatorenal syndrome. Thus, ongoing infection with spontaneous bacterial peritonitis should not exclude the possibility of hepatorenal syndrome. This means that therapy for hepatorenal syndrome can commence while the bacterial infection is still being treated. In addition, hepatorenal syndrome can occur in patients with preexisting chronic kidney disease [",
"      <a class=\"abstract\" href=\"UTD.htm?28/50/29482/abstract/28\">",
"       28",
"      </a>",
"      ]. Thus, the presence of another renal diagnosis (eg, diabetic nephropathy) does not necessarily exclude hepatorenal syndrome. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?4/1/4121?source=see_link&amp;anchor=H7#H7\">",
"       \"Treatment and prophylaxis of spontaneous bacterial peritonitis\", section on 'Renal failure'",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      In conjunction with excluding other apparent causes of renal disease, the following criteria also apply:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Urine red cell excretion of less than 50 cells per high power field (when no urinary catheter is in place) and protein excretion less than 500",
"      <span class=\"nowrap\">",
"       mg/day.",
"      </span>",
"     </li>",
"     <li>",
"      Lack of improvement in renal function after volume expansion with intravenous albumin (1",
"      <span class=\"nowrap\">",
"       g/kg",
"      </span>",
"      of body weight per day up to 100",
"      <span class=\"nowrap\">",
"       g/day)",
"      </span>",
"      for at least two days and withdrawal of diuretics.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    As noted above, patients diagnosed with hepatorenal syndrome are classified as type 1 hepatorenal syndrome (more severe) or type 2 hepatorenal syndrome (less severe) based upon the rapidity of the acute kidney injury and the degree of renal impairment. Type 1 hepatorenal syndrome is present if the serum creatinine increases by at least twofold to a value greater than 2.5",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (221",
"    <span class=\"nowrap\">",
"     micromol/L)",
"    </span>",
"    during a period of less than two weeks. Less rapidly progressive disease is classified as type 2.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     DIFFERENTIAL DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of the hepatorenal syndrome is one of",
"    <strong>",
"     exclusion",
"    </strong>",
"    , entertained only after other potential causes of acute or subacute kidney injury have been ruled out [",
"    <a class=\"abstract\" href=\"UTD.htm?28/50/29482/abstract/29\">",
"     29",
"    </a>",
"    ]. As examples:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Both glomerulonephritis and vasculitis can occur in patients with liver disease and should be suspected in patients with an active urine sediment containing red cells and red cell and other casts. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?1/19/1337?source=see_link\">",
"       \"Clinical presentation and diagnosis of IgA nephropathy\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?36/30/37353?source=see_link\">",
"       \"Renal disease associated with hepatitis C virus infection\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?43/28/44488?source=see_link\">",
"       \"Renal disease associated with hepatitis B virus infection\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Obesity with fatty liver is a relatively common cause of cirrhosis. Many of these patients have diabetes and can develop diabetic nephropathy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/13/38105?source=see_link\">",
"     \"Epidemiology, clinical features, and diagnosis of nonalcoholic fatty liver disease in adults\"",
"    </a>",
"    .) A prospective study from 2011 that analyzed 562 patients with cirrhosis and renal function impairment at a single center found that hepatorenal syndrome was less common than prerenal or infection-associated kidney injury [",
"    <a class=\"abstract\" href=\"UTD.htm?28/50/29482/abstract/29\">",
"     29",
"    </a>",
"    ]. Of the 463 patients in this study in whom a diagnosis could be made, the following frequencies were noted:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Kidney injury associated with infection (such as sepsis or spontaneous bacterial peritonitis) &ndash; 46 percent",
"     </li>",
"     <li>",
"      Prerenal acute kidney injury &ndash; 32 percent",
"     </li>",
"     <li>",
"      Hepatorenal syndrome &ndash; 13 percent",
"     </li>",
"     <li>",
"      Parenchymal renal disease (such as glomerulonephritis) &ndash; 9 percent",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The frequency of acute tubular necrosis (ATN) in this study was not defined, although older case series report that 10 to 20 percent of patients with acute kidney injury in the setting of cirrhosis have ATN [",
"    <a class=\"abstract\" href=\"UTD.htm?28/50/29482/abstract/29\">",
"     29",
"    </a>",
"    ]. It is possible that ATN is less common now, due to avoidance of nephrotoxins such as nonsteroidal anti-inflammatory drugs and aminoglycosides in these patients. In addition, some experts believe that some patients with ongoing infection (principally spontaneous bacterial peritonitis in the absence of septic shock) can have hepatorenal syndrome since a substantial proportion of such patients (18 percent in one report) have persistent or progressive kidney injury despite successful antibiotic therapy for peritonitis [",
"    <a class=\"abstract\" href=\"UTD.htm?28/50/29482/abstract/22\">",
"     22",
"    </a>",
"    ]. Thus, as mentioned above, the presence of spontaneous bacterial peritonitis should not exclude the diagnosis of hepatorenal syndrome.",
"   </p>",
"   <p>",
"    Kidney biopsy is not commonly performed in patients with cirrhosis and acute kidney injury, particularly when there is minimal hematuria and proteinuria. As an example, in a series of 65 patients with cirrhosis and renal disease who underwent transjugular kidney biopsy, only 18 patients had no proteinuria and no hematuria [",
"    <a class=\"abstract\" href=\"UTD.htm?28/50/29482/abstract/30\">",
"     30",
"    </a>",
"    ]. Of these 18 patients, glomerular lesions were identified in ten (such as IgA nephropathy, membranoproliferative glomerulonephritis, or diabetic nephropathy), and ATN was identified in seven. Transjugular kidney biopsy, performed by an interventional radiologist, can be considered if the result may have an impact on treatment and if such treatment could outweigh the potential harms associated with the interventional procedure. Although there is a common misconception that the kidneys are histologically normal, a relatively specific but subtle and reversible renal lesion has been described&mdash;glomerular tubular reflux [",
"    <a class=\"abstract\" href=\"UTD.htm?28/50/29482/abstract/31\">",
"     31",
"    </a>",
"    ]. The author has seen this lesion many times at autopsy.",
"   </p>",
"   <p>",
"    Distinguishing the hepatorenal syndrome from these other disorders is clinically important because of the marked difference in prognosis. ATN and most causes of prerenal disease are generally reversible. In contrast, the prognosis is poor in the hepatorenal syndrome (especially type 1), with most patients dying within weeks of the onset of renal injury unless liver transplantation is performed or effective treatment is given [",
"    <a class=\"abstract\" href=\"UTD.htm?28/50/29482/abstract/10,32\">",
"     10,32",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Acute tubular necrosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with cirrhosis may develop ATN after a course of aminoglycoside therapy, the administration of a radiocontrast agent, or an episode of sepsis or bleeding with a decrease in blood pressure [",
"    <a class=\"abstract\" href=\"UTD.htm?28/50/29482/abstract/1\">",
"     1",
"    </a>",
"    ]. The presence of ATN is usually suspected from the history and from the often rapid rise in the serum creatinine, which contrasts to the usually gradual rise in hepatorenal syndrome. An unresolved issue is whether the prolonged renal ischemia in the hepatorenal syndrome can, in some cases, lead to ATN [",
"    <a class=\"abstract\" href=\"UTD.htm?28/50/29482/abstract/1,19\">",
"     1,19",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Some of the traditional laboratory methods used to distinguish prerenal disease from ATN may not be helpful in patients with hepatic disease. As an example, ATN is usually associated with a fractional excretion of sodium above 2 percent and granular and epithelial cell casts in the urine sediment. Calculators are available to compute the fractional excretion of sodium: (",
"    <a class=\"calc calc_professional\" href=\"UTD.htm?25/13/25809?source=see_link\">",
"     calculator 1",
"    </a>",
"    ) and (",
"    <a class=\"calc calc_professional\" href=\"UTD.htm?24/28/25025?source=see_link\">",
"     calculator 2",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    However, the fractional excretion of sodium may remain below 1 percent in patients with cirrhosis who develop ATN due to the persistent renal ischemia induced by the hepatic disease [",
"    <a class=\"abstract\" href=\"UTD.htm?28/50/29482/abstract/33\">",
"     33",
"    </a>",
"    ]. The urinalysis also may be misleading. Granular and epithelial cell casts may be seen with marked hyperbilirubinemia alone and are therefore not diagnostic of ATN; how this occurs is not understood. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/54/12138?source=see_link\">",
"     \"Etiology and diagnosis of prerenal disease and acute tubular necrosis in acute kidney injury (acute renal failure)\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/17/8472?source=see_link\">",
"     \"Fractional excretion of sodium, urea, and other molecules in acute kidney injury (acute renal failure)\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Prerenal disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;The hepatorenal syndrome has been difficult to distinguish from prerenal azotemia. Prerenal disease in patients with cirrhosis can be induced by gastrointestinal fluid losses, bleeding, or therapy with a diuretic or a nonsteroidal anti-inflammatory drug (since renal vasodilator prostaglandins in part maintain renal perfusion in this setting) [",
"    <a class=\"abstract\" href=\"UTD.htm?28/50/29482/abstract/1,34\">",
"     1,34",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/0/24582?source=see_link\">",
"     \"NSAIDs: Acute kidney injury (acute renal failure) and nephrotic syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Thus, the diagnosis of the hepatorenal syndrome requires that there be no improvement in renal function following discontinuation of potential nephrotoxins and a trial of fluid repletion. In addition, emerging kidney biomarkers may prove helpful in distinguishing prerenal disease, hepatorenal syndrome, and ATN in patients with cirrhosis [",
"    <a class=\"abstract\" href=\"UTD.htm?28/50/29482/abstract/26\">",
"     26",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H97745174\">",
"    <span class=\"h2\">",
"     Approach to therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The ideal therapy for hepatorenal syndrome is improvement of liver function from recovery of alcoholic hepatitis, treatment of decompensated hepatitis B with effective antiviral therapy, recovery from acute hepatic failure, or liver transplantation [",
"    <a class=\"abstract\" href=\"UTD.htm?28/50/29482/abstract/35,36\">",
"     35,36",
"    </a>",
"    ]. The ability of liver function to improve with abstinence from alcohol and effective antiviral therapy of hepatitis B is remarkable. (See",
"    <a class=\"local\" href=\"#H97745161\">",
"     'Improving hepatic function'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    However, when improvement of liver function is not possible in the short term, we recommend that medical therapy be instituted in an attempt to reverse the acute kidney injury associated with hepatorenal syndrome. Our suggestions regarding the choice of medical therapy depend upon several factors, including: whether the patient is admitted to the intensive care unit; the availability of certain drugs, for which there is national and regional variability; and whether the patient is a candidate for liver transplantation:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In patients with hepatorenal syndrome who are",
"      <strong>",
"       admitted to the intensive care unit",
"      </strong>",
"      , we suggest initial treatment with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?16/28/16838?source=see_link\">",
"       norepinephrine",
"      </a>",
"      in combination with albumin. Norepinephrine is given intravenously as a continuous infusion (0.5 to 3",
"      <span class=\"nowrap\">",
"       mg/hr)",
"      </span>",
"      with the goal of raising the mean arterial pressure by 10 mmHg, and albumin is given for at least two days as an intravenous bolus (1",
"      <span class=\"nowrap\">",
"       g/kg",
"      </span>",
"      per day [100 g maximum]). Intravenous vasopressin may also be effective, starting at 0.01",
"      <span class=\"nowrap\">",
"       units/min",
"      </span>",
"      and titrating upward as needed to raise the mean arterial pressure as noted below. (See",
"      <a class=\"local\" href=\"#H5671866\">",
"       'Norepinephrine for patients in the intensive care unit'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      In patients with hepatorenal syndrome who are",
"      <strong>",
"       not admitted to the intensive care unit",
"      </strong>",
"      , our suggestions depend upon the availability of certain drugs:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Where terlipressin therapy is available, we suggest initial treatment with terlipressin in combination with albumin. Terlipressin is given as an intravenous bolus (1 to 2 mg every four to six hours), and albumin is given for two days as an intravenous bolus (1",
"      <span class=\"nowrap\">",
"       g/kg",
"      </span>",
"      per day [100 g maximum]), followed by 25 to 50 grams per day until terlipressin therapy is discontinued. (See",
"      <a class=\"local\" href=\"#H5672085\">",
"       'Terlipressin plus albumin where available'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      Where terlipressin therapy is not available (principally the United States), we suggest initial treatment with a combination of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?2/35/2613?source=see_link\">",
"       midodrine",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?42/7/43128?source=see_link\">",
"       octreotide",
"      </a>",
"      , and albumin. Midodrine is given orally (starting at 7.5 and increasing the dose at eight-hour intervals up to a maximum of 15 mg by mouth three times daily), octreotide is either given as a continuous intravenous infusion (50",
"      <span class=\"nowrap\">",
"       mcg/hr)",
"      </span>",
"      or subcutaneously (100 to 200 mcg three times daily), and albumin is given for two days as an intravenous bolus (1",
"      <span class=\"nowrap\">",
"       g/kg",
"      </span>",
"      per day [100 g maximum]), followed by 25 to 50 grams per day until midodrine and octreotide therapy is discontinued. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Midodrine, octreotide, and albumin where terlipressin is not available'",
"      </a>",
"      below.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In highly selected",
"      <strong>",
"       patients who fail to respond to medical therapy",
"      </strong>",
"      with the above regimens and who are considered well enough to undergo the procedure, transjugular intrahepatic portosystemic shunt (TIPS) is sometimes successful. However, this procedure is associated with numerous complications and, because of the need for intravenous contrast, it may cause acute kidney injury. For this reason, some experts prefer dialysis as a first option (continuous renal replacement therapy) in most cases, particularly for patients whose serum creatinine remains above 1.5",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      despite medical therapy. (See",
"      <a class=\"local\" href=\"#H5672740\">",
"       'Transjugular intrahepatic portosystemic shunt'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      In patients who fail to respond to the above therapies, develop severely impaired renal function, and either are candidates for liver transplantation or have a reversible form of liver injury and are expected to survive, we recommend dialysis as a bridge to liver transplantation or liver recovery. (See",
"      <a class=\"local\" href=\"#H18565503\">",
"       'Dialysis'",
"      </a>",
"      below.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The goal of medical therapy or TIPS in patients with hepatorenal syndrome is reversal of the acute kidney injury. In addition, when patients are treated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/28/16838?source=see_link\">",
"     norepinephrine",
"    </a>",
"    , terlipressin, or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/35/2613?source=see_link\">",
"     midodrine",
"    </a>",
"    plus",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/7/43128?source=see_link\">",
"     octreotide",
"    </a>",
"    , an immediate goal of therapy is to raise the mean arterial pressure by approximately 10 to 15 mmHg. In a systematic review of 501 patients with hepatorenal syndrome from 21 studies, the magnitude of the increase in mean arterial pressure induced by these vasoconstrictors was significantly associated with the magnitude of the decrease in serum creatinine [",
"    <a class=\"abstract\" href=\"UTD.htm?28/50/29482/abstract/37\">",
"     37",
"    </a>",
"    ]. As an example, a 9 mmHg increase in mean arterial pressure predicted a 1",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (88.4",
"    <span class=\"nowrap\">",
"     micromol/L)",
"    </span>",
"    decrease in serum creatinine. The authors also predicted that an increase in mean arterial pressure of 9 to 13 mmHg would be necessary to achieve resolution in most patients with type 1 hepatorenal syndrome.",
"   </p>",
"   <p>",
"    In patients treated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/28/16838?source=see_link\">",
"     norepinephrine",
"    </a>",
"    , terlipressin, or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/7/43128?source=see_link\">",
"     octreotide",
"    </a>",
"    , we usually treat for a total of",
"    <strong>",
"     two weeks",
"    </strong>",
"    . However, we and others occasionally treat for longer durations (up to one month or more) if there is some but not complete improvement in renal function after two weeks of therapy. In patients who respond to therapy, we occasionally treat indefinitely with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/35/2613?source=see_link\">",
"     midodrine",
"    </a>",
"    to maintain a higher mean arterial pressure (or until liver transplantation or resolution of liver injury). Many patients who recover from type 1 hepatorenal syndrome continue to have refractory ascites, and midodrine may be effective in such patients [",
"    <a class=\"abstract\" href=\"UTD.htm?28/50/29482/abstract/38\">",
"     38",
"    </a>",
"    ]. In contrast, if a patient has no improvement in renal function after two weeks, therapy with these drugs can be considered futile.",
"   </p>",
"   <p>",
"    The following sections will review the different therapies that have been evaluated in the treatment of hepatorenal syndrome. Issues related to the treatment of ascites in patients with cirrhosis (eg, fluid and sodium intake, diuretic therapy) are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/44/19145?source=see_link\">",
"     \"Initial therapy of ascites in patients with cirrhosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/40/35465?source=see_link\">",
"     \"Treatment of diuretic-resistant ascites in patients with cirrhosis\"",
"    </a>",
"    and",
"    <a class=\"local\" href=\"#H5670964\">",
"     'Precipitants'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H97745161\">",
"    <span class=\"h2\">",
"     Improving hepatic function",
"    </span>",
"    &nbsp;&mdash;&nbsp;The best hope for reversal of the renal failure is an improvement in hepatic function due to partial resolution of the primary disease or to successful liver transplantation [",
"    <a class=\"abstract\" href=\"UTD.htm?28/50/29482/abstract/39-41\">",
"     39-41",
"    </a>",
"    ]. Improvement in the underlying liver disease is most impressive in patients with alcoholic liver disease (particularly severe alcoholic hepatitis) with abstinence or with decompensated cirrhosis due to hepatitis B virus infection treated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/7/38007?source=see_link\">",
"     lamivudine",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?28/50/29482/abstract/42,43\">",
"     42,43",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5671866\">",
"    <span class=\"h2\">",
"     Norepinephrine for patients in the intensive care unit",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although not usually available on the general medical ward,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/28/16838?source=see_link\">",
"     norepinephrine",
"    </a>",
"    can be administered in the intensive care unit and has been used successfully in patients with hepatorenal syndrome [",
"    <a class=\"abstract\" href=\"UTD.htm?28/50/29482/abstract/44\">",
"     44",
"    </a>",
"    ]. Vasopressin, also available in the intensive care unit, may be effective in patients with hepatorenal syndrome [",
"    <a class=\"abstract\" href=\"UTD.htm?28/50/29482/abstract/45\">",
"     45",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In an open-label trial, 46 patients with type 1 hepatorenal syndrome (mean serum creatinine, 3.2",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    [283",
"    <span class=\"nowrap\">",
"     micromol/L])",
"    </span>",
"    were randomly assigned to receive combination therapy with terlipressin plus albumin or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/28/16838?source=see_link\">",
"     norepinephrine",
"    </a>",
"    plus albumin (using the doses described above) [",
"    <a class=\"abstract\" href=\"UTD.htm?28/50/29482/abstract/46\">",
"     46",
"    </a>",
"    ]. Treatment was administered for 15 days, and all patients were followed for a month. The following results were obtained, neither of which were statistically significant:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Resolution of hepatorenal syndrome (defined as a fall in the serum creatinine to below 1.5",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      [133",
"      <span class=\"nowrap\">",
"       micromol/L])",
"      </span>",
"      occurred in 39 percent of patients receiving terlipressin and 43 percent of patients receiving",
"      <a class=\"drug drug_general\" href=\"UTD.htm?16/28/16838?source=see_link\">",
"       norepinephrine",
"      </a>",
"      .",
"     </li>",
"     <li>",
"      The 30 day survival rate was 30 percent with terlipressin and 35 percent with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?16/28/16838?source=see_link\">",
"       norepinephrine",
"      </a>",
"      .",
"     </li>",
"     <li>",
"      Treatment-related adverse events occurred in six patients in the terlipressin group and two patients in the",
"      <a class=\"drug drug_general\" href=\"UTD.htm?16/28/16838?source=see_link\">",
"       norepinephrine",
"      </a>",
"      group.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Although the efficacy and safety of terlipressin and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/28/16838?source=see_link\">",
"     norepinephrine",
"    </a>",
"    appeared similar, the cost of terlipressin therapy was more than three times the cost of norepinephrine therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?28/50/29482/abstract/46\">",
"     46",
"    </a>",
"    ]. A second, smaller trial reached a similar conclusion [",
"    <a class=\"abstract\" href=\"UTD.htm?28/50/29482/abstract/47\">",
"     47",
"    </a>",
"    ]: after 14 days of therapy, reversal of hepatorenal syndrome occurred in ten of twelve patients treated with terlipressin and seven of ten patients treated with norepinephrine; the adverse event rate was also similar between the groups; and the cost of therapy was 14 times greater with terlipressin.",
"   </p>",
"   <p>",
"    Thus, we suggest",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/28/16838?source=see_link\">",
"     norepinephrine",
"    </a>",
"    rather than terlipressin or other therapies for treatment of hepatorenal syndrome who are admitted to the intensive care unit.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5672465\">",
"    <span class=\"h2\">",
"     Patients not in the intensive care unit",
"    </span>",
"    &nbsp;&mdash;&nbsp;Optimal medical therapy for patients with hepatorenal syndrome who are not admitted to the intensive care unit varies according to whether terlipressin is available.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5672085\">",
"    <span class=\"h3\">",
"     Terlipressin plus albumin where available",
"    </span>",
"    &nbsp;&mdash;&nbsp;Vasopressin and its analogs (ornipressin and terlipressin) should theoretically reduce splanchnic vasodilation. As an example, when ornipressin was administered in combination with either infusion of albumin or a peritoneovenous shunt (to expand the effective arterial blood volume and reduce the release of vasoconstrictors such as angiotensin II and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/28/16838?source=see_link\">",
"     norepinephrine",
"    </a>",
"    ), there was an increase in glomerular filtration rate (GFR) (",
"    <a class=\"graphic graphic_figure graphicRef68506 \" href=\"UTD.htm?38/9/39069\">",
"     figure 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?28/50/29482/abstract/11,48,49\">",
"     11,48,49",
"    </a>",
"    ]. However, this regimen may also induce significant renal ischemia [",
"    <a class=\"abstract\" href=\"UTD.htm?28/50/29482/abstract/48\">",
"     48",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Another vasopressin analog, terlipressin, has also been examined as a treatment for hepatorenal syndrome in several randomized trials [",
"    <a class=\"abstract\" href=\"UTD.htm?28/50/29482/abstract/50-55\">",
"     50-55",
"    </a>",
"    ]. A 2012 Cochrane meta-analysis synthesized the results from these trials [",
"    <a class=\"abstract\" href=\"UTD.htm?28/50/29482/abstract/56\">",
"     56",
"    </a>",
"    ]; of the six trials included, three compared terlipressin plus albumin with albumin alone, one compared terlipressin alone with albumin alone, and two compared terlipressin alone with either placebo or no therapy. Only one of the trials was double blind; the dose and duration of terlipressin therapy varied across studies. The following findings were reported:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Terlipressin therapy significantly reduced mortality compared with albumin alone or no therapy (54 versus 73 percent).",
"     </li>",
"     <li>",
"      In addition, terlipressin therapy significantly increased the proportion of patients who achieved reversal of hepatorenal syndrome (54 versus 11 percent). Reversal of hepatorenal syndrome was variably defined, but in most trials meant achieving a serum creatinine less than 1.5",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (133",
"      <span class=\"nowrap\">",
"       micromol/L).",
"      </span>",
"     </li>",
"     <li>",
"      Although terlipressin did not significantly increase the risk of gastrointestinal side effects or infection, it did increase the rate of cardiovascular adverse events (11 versus 0 percent).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These data suggest that terlipressin therapy may improve renal function and reduce mortality. Thus, for patients with hepatorenal syndrome who are not admitted to the intensive care unit, we suggest combination therapy with terlipressin plus albumin rather than other therapies. However, terlipressin is not available in the United States. When terlipressin is not available, combination therapy with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/35/2613?source=see_link\">",
"     midodrine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/7/43128?source=see_link\">",
"     octreotide",
"    </a>",
"    , and albumin is used for patients not in the intensive care unit. (See",
"    <a class=\"local\" href=\"#H12\">",
"     'Midodrine, octreotide, and albumin where terlipressin is not available'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Midodrine, octreotide, and albumin where terlipressin is not available",
"    </span>",
"    &nbsp;&mdash;&nbsp;Therapy with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/35/2613?source=see_link\">",
"     midodrine",
"    </a>",
"    (a selective alpha-1 adrenergic agonist),",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/7/43128?source=see_link\">",
"     octreotide",
"    </a>",
"    (a somatostatin analog), and albumin may be highly effective and safe in patients with hepatorenal syndrome. Midodrine is a systemic vasoconstrictor, and octreotide is an inhibitor of endogenous vasodilator release (which produces splanchnic vasoconstriction); combined therapy theoretically improves renal and systemic hemodynamics [",
"    <a class=\"abstract\" href=\"UTD.htm?28/50/29482/abstract/57\">",
"     57",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In a nonrandomized study of 13 consecutive patients with type 1 hepatorenal syndrome, the first eight were treated with intravenous dopamine (2 to 4",
"    <span class=\"nowrap\">",
"     mcg/kg",
"    </span>",
"    per min) and the last five patients were treated with oral",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/35/2613?source=see_link\">",
"     midodrine",
"    </a>",
"    (7.5 to 12.5 mg three times daily) plus",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/7/43128?source=see_link\">",
"     octreotide",
"    </a>",
"    (100 to 200 mcg subcutaneously three times daily) [",
"    <a class=\"abstract\" href=\"UTD.htm?28/50/29482/abstract/58\">",
"     58",
"    </a>",
"    ]. Both groups also received intravenous albumin daily during treatment. The goal of therapy was to raise the mean arterial pressure by 15 mmHg. The following results were reported:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Among the five patients who received",
"      <a class=\"drug drug_general\" href=\"UTD.htm?2/35/2613?source=see_link\">",
"       midodrine",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?42/7/43128?source=see_link\">",
"       octreotide",
"      </a>",
"      , mean arterial pressure, renal plasma flow, GFR, and urine volume all increased. Among those who received dopamine, there was no change in these parameters.",
"     </li>",
"     <li>",
"      Three of the five patients treated with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?2/35/2613?source=see_link\">",
"       midodrine",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?42/7/43128?source=see_link\">",
"       octreotide",
"      </a>",
"      survived to hospital discharge. Of these, one successfully underwent liver transplantation, another was alive at 472 days, and the third ultimately died after discontinuing therapy. Among the two who were not discharged, one discontinued therapy after two months and was successfully transplanted, while the other died at 29 days of pneumonia despite total recovery of renal function. Minimal side effects, including tingling, goose bumps, and diarrhea, were observed. In contrast, seven of the eight patients who received dopamine died during the first twelve days. One patient recovered renal function and survived to be transplanted.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Additional data substantiate the potential efficacy and safety of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/7/43128?source=see_link\">",
"     octreotide",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/35/2613?source=see_link\">",
"     midodrine",
"    </a>",
"    . In a retrospective study, 60 patients with hepatorenal syndrome were treated with midodrine (up to 15 mg three times daily), octreotide (200 mcg subcutaneously three times daily), and albumin, and 21 concurrent patients only received albumin [",
"    <a class=\"abstract\" href=\"UTD.htm?28/50/29482/abstract/21\">",
"     21",
"    </a>",
"    ]. Therapy with midodrine and octreotide was associated with significantly lower mortality (43 versus 71 percent) and a significantly higher proportion of patients who had resolution of hepatorenal syndrome (40 versus 10 percent).",
"   </p>",
"   <p>",
"    In our experience, the speed with which effective treatment is achieved appears to be important. Thus, we prefer continuous infusion of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/7/43128?source=see_link\">",
"     octreotide",
"    </a>",
"    at 50",
"    <span class=\"nowrap\">",
"     mcg/hr",
"    </span>",
"    rather than subcutaneous injection. This can be delivered on a general medical ward. The",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/35/2613?source=see_link\">",
"     midodrine",
"    </a>",
"    dose should be increased with each consecutive dose in order to achieve an increase in blood pressure rapidly. It is our experience that 15 mg three times per day may be more effective than 12.5 mg three times per day. Changing the dose after 24 hours on the prior dose raises the blood pressure too slowly and may lead to failure of therapy.",
"   </p>",
"   <p>",
"    In contrast to combination therapy with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/35/2613?source=see_link\">",
"     midodrine",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/7/43128?source=see_link\">",
"     octreotide",
"    </a>",
"    , octreotide monotherapy does not appear to be beneficial. In a randomized crossover study, 14 patients with hepatorenal syndrome were treated with four days of octreotide plus albumin and four days of albumin alone in random order [",
"    <a class=\"abstract\" href=\"UTD.htm?28/50/29482/abstract/59\">",
"     59",
"    </a>",
"    ]. Response to therapy was identical with both treatments. Midodrine alone or in combination with albumin (but without octreotide) has not been evaluated in patients with type 1 hepatorenal syndrome.",
"   </p>",
"   <p>",
"    Thus, for patients with hepatorenal syndrome who are not admitted to the intensive care unit and for whom terlipressin is unavailable, we suggest combination therapy with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/7/43128?source=see_link\">",
"     octreotide",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/35/2613?source=see_link\">",
"     midodrine",
"    </a>",
"    , and albumin rather than other therapies.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5672923\">",
"    <span class=\"h2\">",
"     Patients who do not respond to initial medical therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Treatment options for patients who do not respond to one of the medical therapies listed above include TIPS and dialysis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5672740\">",
"    <span class=\"h3\">",
"     Transjugular intrahepatic portosystemic shunt",
"    </span>",
"    &nbsp;&mdash;&nbsp;The transjugular intrahepatic portosystemic shunt (TIPS) has been used in the treatment of refractory ascites. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/35/34359?source=see_link\">",
"     \"Indications for the use of transjugular intrahepatic portosystemic shunts\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    When used in this setting, there may also be a delayed improvement in renal function [",
"    <a class=\"abstract\" href=\"UTD.htm?28/50/29482/abstract/60-64\">",
"     60-64",
"    </a>",
"    ]. In one study, for example, the average plasma creatinine concentration was 1.5",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (132",
"    <span class=\"nowrap\">",
"     micromol/L)",
"    </span>",
"    at baseline, was unchanged at one week, and fell to 0.9",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (80",
"    <span class=\"nowrap\">",
"     micromol/L)",
"    </span>",
"    by six months [",
"    <a class=\"abstract\" href=\"UTD.htm?28/50/29482/abstract/60\">",
"     60",
"    </a>",
"    ]. In another series, there was a nonsignificant trend toward an increase in GFR (65",
"    <span class=\"nowrap\">",
"     mL/min",
"    </span>",
"    at baseline to 76",
"    <span class=\"nowrap\">",
"     mL/min",
"    </span>",
"    at four weeks) [",
"    <a class=\"abstract\" href=\"UTD.htm?28/50/29482/abstract/62\">",
"     62",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There is much less information on the use of TIPS in patients who fulfill criteria for the hepatorenal syndrome [",
"    <a class=\"abstract\" href=\"UTD.htm?28/50/29482/abstract/15\">",
"     15",
"    </a>",
"    ]. One report described 16 such patients, six of whom had severe hepatorenal syndrome (defined as a serum creatinine of 2.5",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    [220",
"    <span class=\"nowrap\">",
"     micromol/L]",
"    </span>",
"    or higher, or a creatinine clearance below 20",
"    <span class=\"nowrap\">",
"     mL/min)",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?28/50/29482/abstract/63\">",
"     63",
"    </a>",
"    ]. Within two weeks, there was an approximate doubling of the creatinine clearance with a proportionate reduction in the serum creatinine and an increase in urinary sodium excretion. Additional improvements in renal function occurred over the ensuing six to eight weeks. Only three patients failed to respond, all of whom died within six weeks after TIPS.",
"   </p>",
"   <p>",
"    Another series evaluated seven patients with cirrhosis and hepatorenal syndrome, defined as a doubling of the serum creatinine to more than 2.5",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (221",
"    <span class=\"nowrap\">",
"     micromol/L)",
"    </span>",
"    or a 50 percent reduction in creatinine clearance to below 20",
"    <span class=\"nowrap\">",
"     mL/min",
"    </span>",
"    in less than two weeks, despite volume expansion [",
"    <a class=\"abstract\" href=\"UTD.htm?28/50/29482/abstract/64\">",
"     64",
"    </a>",
"    ]. Insertion of a TIPS was associated with a gradual improvement in GFR (9 to 27",
"    <span class=\"nowrap\">",
"     mL/min),",
"    </span>",
"    reductions in the blood urea nitrogen (BUN) and serum creatinine, and, in most patients, a reduction in the activity of the renin-angiotensin and sympathetic nervous systems suggesting an improvement in systemic hemodynamics. The average survival following TIPS placement was approximately five months, which is longer than the expected survival of such patients.",
"   </p>",
"   <p>",
"    Unfortunately, many patients with hepatorenal syndrome are too ill to undergo TIPS. In a study that devised a prediction model to determine survival following elective TIPS, those patients with type 1 hepatorenal syndrome have a predicted 90 day mortality following TIPS of at least 25 percent if cirrhosis is due to alcoholic or cholestatic liver disease and at least 80 percent if cirrhosis is due to other causes [",
"    <a class=\"abstract\" href=\"UTD.htm?28/50/29482/abstract/65\">",
"     65",
"    </a>",
"    ]. A prediction model scoring system based upon the survival of 231 patients who underwent elective TIPS was devised to predict survival after the procedure.",
"   </p>",
"   <p>",
"    In addition, TIPS is associated with various complications [",
"    <a class=\"abstract\" href=\"UTD.htm?28/50/29482/abstract/15\">",
"     15",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      An increase in the rate of hepatic encephalopathy",
"     </li>",
"     <li>",
"      A worsening of liver function (marked by a rise in serum bilirubin)",
"     </li>",
"     <li>",
"      A bleeding complication due to the procedure",
"     </li>",
"     <li>",
"      A risk of renal injury associated with intravenous contrast, which is often necessary, even if carbon dioxide is used as the main contrast agent",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Overall, these results suggest that, in selected patients with hepatorenal syndrome, TIPS may provide short-term benefit. Given the risks associated with this procedure (particularly the high incidence of encephalopathy), it should be considered only as a last resort in selected patients.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18565503\">",
"    <span class=\"h3\">",
"     Dialysis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with hepatorenal syndrome who progress to renal failure can be treated with dialysis, which is most commonly done when patients are awaiting a liver transplant or when there is the possibility of improvement in liver function. In addition, dialysis improves the priority score for the transplant in the United States. In one retrospective, single-center study, 30 percent of patients who required dialysis survived to liver transplantation [",
"    <a class=\"abstract\" href=\"UTD.htm?28/50/29482/abstract/66\">",
"     66",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Survival on dialysis is generally limited by the severity of the hepatic failure [",
"    <a class=\"abstract\" href=\"UTD.htm?28/50/29482/abstract/67\">",
"     67",
"    </a>",
"    ], as well as concurrent respiratory failure [",
"    <a class=\"abstract\" href=\"UTD.htm?28/50/29482/abstract/68\">",
"     68",
"    </a>",
"    ]. Patients with an acute and potentially reversible hepatic insult may particularly benefit from dialysis since renal function will recover in parallel with improving hepatic function [",
"    <a class=\"abstract\" href=\"UTD.htm?28/50/29482/abstract/40\">",
"     40",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Hemodialysis is frequently difficult to perform in patients with hepatorenal syndrome since decompensated hepatic function is associated with hemodynamic instability. Some success has been realized with continuous renal replacement modalities [",
"    <a class=\"abstract\" href=\"UTD.htm?28/50/29482/abstract/69\">",
"     69",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/40/28295?source=see_link\">",
"     \"Continuous renal replacement therapy in acute kidney injury (acute renal failure)\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Other therapies",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of other drugs have been tried for the treatment of hepatorenal syndrome, such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/41/662?source=see_link\">",
"     misoprostol",
"    </a>",
"    , N-acetylcysteine, and angiotensin-converting enzyme inhibitors. None of these approaches are consistently associated with benefit, and therefore none are recommended. In rare patients, a peritoneovenous shunt is used.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h3\">",
"     Peritoneovenous shunt",
"    </span>",
"    &nbsp;&mdash;&nbsp;A peritoneovenous shunt, which drains peritoneal fluid from the peritoneum into the internal jugular vein, reinfuses ascites into the vascular space. This modality has been used in patients with refractory ascites and renal failure due to the hepatorenal syndrome [",
"    <a class=\"abstract\" href=\"UTD.htm?28/50/29482/abstract/32,70-74\">",
"     32,70-74",
"    </a>",
"    ]. In these settings, the increase in fluid return to the cardiopulmonary circulation can lead sequentially to decreased activity of sodium-retaining and vasoconstrictive mechanisms (such as the renin-angiotensin-aldosterone system), a marked rise in urinary sodium excretion, and a modest elevation in GFR [",
"    <a class=\"abstract\" href=\"UTD.htm?28/50/29482/abstract/32,70,73\">",
"     32,70,73",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    However, it is now rarely used because of an appreciable rate of complications and the lack of evidence that peritoneovenous shunting prolongs patient survival, which may be several years in patients with normal or near-normal hepatic and renal function tests but less than six weeks in patients with the hepatorenal syndrome [",
"    <a class=\"abstract\" href=\"UTD.htm?28/50/29482/abstract/32,71,72,75,76\">",
"     32,71,72,75,76",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The major problem with the peritoneovenous shunt is the relatively high rate of complications, including disseminated intravascular coagulation (due to entry into the blood stream of endotoxin or other procoagulant material in the ascitic fluid), infection of the shunt, which can lead to bacteremia, variceal bleeding resulting from volume expansion and a concurrent rise in portal venous pressure, and small bowel obstruction [",
"    <a class=\"abstract\" href=\"UTD.htm?28/50/29482/abstract/70,77,78\">",
"     70,77,78",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The net effect is that the perioperative mortality can reach 25 percent in patients with advanced disease [",
"    <a class=\"abstract\" href=\"UTD.htm?28/50/29482/abstract/77,78\">",
"     77,78",
"    </a>",
"    ]. In comparison, peritoneovenous shunting is relatively well-tolerated in patients with ascites but relatively normal renal function [",
"    <a class=\"abstract\" href=\"UTD.htm?28/50/29482/abstract/71,72\">",
"     71,72",
"    </a>",
"    ]. Furthermore, the perioperative morbidity can be diminished if, prior to insertion of the shunt, there is intraoperative drainage of the ascites, which is then replaced by 5 liters of isotonic saline [",
"    <a class=\"abstract\" href=\"UTD.htm?28/50/29482/abstract/71,78\">",
"     71,78",
"    </a>",
"    ]. This regimen can minimize those complications related to massive ascites infusion: disseminated intravascular coagulation and increased portal pressure.",
"   </p>",
"   <p>",
"    The only remaining indications for peritoneovenous shunt are:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Unusual forms of ascites such as chylous ascites.",
"     </li>",
"     <li>",
"      Post-liver transplant patient with refractory ascites.",
"     </li>",
"     <li>",
"      Patients with cirrhosis and diuretic-resistant ascites who are not candidates for transplantation or TIPS and who are too obese or have too many abdominal surgical scars to permit safe, successful paracentesis. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?34/40/35465?source=see_link\">",
"       \"Treatment of diuretic-resistant ascites in patients with cirrhosis\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h1\">",
"     PREVENTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hepatorenal syndrome regularly develops in patients with systemic bacterial infection (eg, spontaneous bacterial peritonitis [SBP])",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    severe alcoholic hepatitis. The following therapies may prevent the development of hepatorenal syndrome in these patients:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Intravenous albumin &ndash; In patients with SBP, the administration of intravenous albumin (1.5",
"      <span class=\"nowrap\">",
"       g/kg)",
"      </span>",
"      at the time of diagnosis of infection and another dose of albumin (1",
"      <span class=\"nowrap\">",
"       g/kg)",
"      </span>",
"      on day 3 of antibiotic treatment reduces the incidence of both renal impairment and mortality. A meta-analysis of four controlled trials (with a total of 288 patients) evaluated the impact of albumin infusion (in addition to antibiotics) on renal impairment and mortality in patients with SBP [",
"      <a class=\"abstract\" href=\"UTD.htm?28/50/29482/abstract/79\">",
"       79",
"      </a>",
"      ]. Albumin infusion was associated with a significant decrease in the incidence of renal impairment (8 versus 31 percent) and a significant reduction in mortality (16 versus 35 percent). These data support the use of albumin infusion in patients with SBP. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?4/1/4121?source=see_link&amp;anchor=H8#H8\">",
"       \"Treatment and prophylaxis of spontaneous bacterial peritonitis\", section on 'Intravenous albumin'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?16/9/16536?source=see_link\">",
"       Norfloxacin",
"      </a>",
"      &ndash; A randomized trial reported significant benefits with the oral administration of norfloxacin at 400",
"      <span class=\"nowrap\">",
"       mg/day",
"      </span>",
"      to 68 patients with cirrhosis and ascitic fluid total protein &lt;1.5",
"      <span class=\"nowrap\">",
"       g/dL",
"      </span>",
"      who fulfilled either of the following two criteria: a Child-Pugh score &gt;9 points and serum bilirubin &gt;3",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (51.3",
"      <span class=\"nowrap\">",
"       micromol/L);",
"      </span>",
"      or a serum creatinine &gt;1.2",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      [106",
"      <span class=\"nowrap\">",
"       micromol/L]",
"      </span>",
"      or blood urea nitrogen (BUN) &gt;20",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      or serum sodium &lt;130",
"      <span class=\"nowrap\">",
"       meq/L",
"      </span>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?28/50/29482/abstract/80\">",
"       80",
"      </a>",
"      ]. Norfloxacin was associated with the following significant benefits: decreased one-year probability of SBP (7 versus 61 percent) and hepatorenal syndrome (28 versus 41 percent), and improved survival at three months (94 versus 62 percent) and one year (60 percent versus 48 percent). Based upon these and other findings, we recommend the use of norfloxacin in selected patients with cirrhosis and ascites; specific recommendations are discussed elsewhere. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?4/1/4121?source=see_link&amp;anchor=H13#H13\">",
"       \"Treatment and prophylaxis of spontaneous bacterial peritonitis\", section on 'Efficacy of prophylaxis'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?13/28/13765?source=see_link\">",
"       Pentoxifylline",
"      </a>",
"      &ndash; An initial trial of 61 patients with cirrhosis, ascites, and a baseline creatinine clearance of 41 to 80",
"      <span class=\"nowrap\">",
"       mL/min",
"      </span>",
"      per 1.73 m",
"      <sup>",
"       2",
"      </sup>",
"      showed significant benefit with pentoxifylline (1200",
"      <span class=\"nowrap\">",
"       mg/day)",
"      </span>",
"      for six months as compared with placebo [",
"      <a class=\"abstract\" href=\"UTD.htm?28/50/29482/abstract/81\">",
"       81",
"      </a>",
"      ]. However, a subsequent meta-analysis demonstrated no benefit on hepatorenal syndrome or mortality [",
"      <a class=\"abstract\" href=\"UTD.htm?28/50/29482/abstract/82\">",
"       82",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?0/43/698?source=see_link&amp;anchor=H234081702#H234081702\">",
"       \"Alcoholic hepatitis: Natural history and management\", section on 'Pentoxifylline'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h1\">",
"     PROGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Overall, the mortality of patients with liver failure is substantially worse if they develop hepatorenal syndrome [",
"    <a class=\"abstract\" href=\"UTD.htm?28/50/29482/abstract/83\">",
"     83",
"    </a>",
"    ]. Without therapy, most patients die within weeks of the onset of the renal impairment. In turn, the outcome of patients with hepatorenal syndrome, as well as recovery of kidney function, is strongly dependent upon reversal of the hepatic failure, whether spontaneous, following medical therapy, or following successful liver transplantation [",
"    <a class=\"abstract\" href=\"UTD.htm?28/50/29482/abstract/84\">",
"     84",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The rate of recovery of kidney function following recovery of liver failure is uncertain; reported rates are affected by varying pretransplant kidney function and differences over time in indications for dialysis and in eligibility for liver transplantation. However, a substantial proportion of patients who have progressed to dialysis and survive to receive a liver transplant do recover kidney function [",
"    <a class=\"abstract\" href=\"UTD.htm?28/50/29482/abstract/85\">",
"     85",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/28/34250?source=see_link\">",
"     \"Renal function and nonrenal solid organ transplantation\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H97742010\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The hepatorenal syndrome is one of many potential causes of acute kidney injury in patients with acute or chronic liver disease. Affected patients usually have portal hypertension due to cirrhosis, severe alcoholic hepatitis, or (less often) metastatic tumors, but can also have fulminant hepatic failure from any cause. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Arterial vasodilatation in the splanchnic circulation, which is triggered by portal hypertension, appears to play a central role in the hemodynamic changes and the decline in renal function in the hepatorenal syndrome. The presumed mechanism is increased production or activity of vasodilators, mainly in the splanchnic circulation, with nitric oxide thought to be most important. As the hepatic disease becomes more severe, there is a progressive rise in cardiac output and fall in systemic vascular resistance; the latter change occurs despite local increases in renal and femoral vascular resistance that result in part from hypotension-induced activation of the renin-angiotensin and sympathetic nervous systems (",
"      <a class=\"graphic graphic_figure graphicRef74244 \" href=\"UTD.htm?36/51/37693\">",
"       figure 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Pathogenesis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients who develop the hepatorenal syndrome usually have portal hypertension due to cirrhosis, severe alcoholic hepatitis, and, less often, metastatic tumors. However, patients with fulminant hepatic failure from any cause may develop hepatorenal syndrome. In patients with cirrhosis and ascites, the hepatorenal syndrome occurs in approximately 20 and 40 percent at one and five years, respectively. In patients with acute liver disease, the hepatorenal syndrome occurs in approximately 25 to 30 percent. (See",
"      <a class=\"local\" href=\"#H9884469\">",
"       'Epidemiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The hepatorenal syndrome is usually characterized by the following features in a patient who has established or clinically evident acute or chronic liver disease (see",
"      <a class=\"local\" href=\"#H4\">",
"       'Clinical presentation'",
"      </a>",
"      above):",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      A progressive rise in serum creatinine",
"     </li>",
"     <li>",
"      A benign urine sediment",
"     </li>",
"     <li>",
"      No or minimal proteinuria (less than 500 mg per day)",
"     </li>",
"     <li>",
"      A very low rate of sodium excretion (ie, urine sodium concentration less than 10",
"      <span class=\"nowrap\">",
"       meq/L)",
"      </span>",
"     </li>",
"     <li>",
"      Oliguria",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Based upon the rapidity of the decline in kidney function, two forms of hepatorenal syndrome have been described (see",
"      <a class=\"local\" href=\"#H4\">",
"       'Clinical presentation'",
"      </a>",
"      above):",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Type 1 hepatorenal syndrome &ndash; Type 1 hepatorenal syndrome is the more serious type; it is defined as at least a twofold increase in serum creatinine (reflecting a 50 percent reduction in creatinine clearance) to a level greater than 2.5",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (221",
"      <span class=\"nowrap\">",
"       micromol/L)",
"      </span>",
"      during a period of less than two weeks. At the time of diagnosis, some patients with type 1 hepatorenal syndrome have a urine output less than 400 to 500 mL per day.",
"     </li>",
"     <li>",
"      Type 2 hepatorenal syndrome &ndash; Type 2 hepatorenal syndrome is defined as renal impairment that is less severe than that observed with type 1 disease. The major clinical feature in patients with type 2 hepatorenal syndrome is ascites that is resistant to diuretics.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The onset of renal failure is typically insidious but can be precipitated by an acute insult, such as bacterial infection (often spontaneous bacterial peritonitis) or gastrointestinal bleeding. Diuretics do not cause hepatorenal syndrome. (See",
"      <a class=\"local\" href=\"#H5670964\">",
"       'Precipitants'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients with hepatorenal syndrome may have renal dysfunction that is substantially more severe than is suggested by the serum creatinine. (See",
"      <a class=\"local\" href=\"#H17253448\">",
"       'Problems with estimating kidney function'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Hepatorenal syndrome is diagnosed based upon clinical criteria. There is no one specific test that can establish the diagnosis. The following definition and diagnostic criteria have been proposed for the hepatorenal syndrome (see",
"      <a class=\"local\" href=\"#H7\">",
"       'Diagnosis'",
"      </a>",
"      above):",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Chronic or acute hepatic disease with advanced hepatic failure and portal hypertension.",
"     </li>",
"     <li>",
"      A serum creatinine above 1.5",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (133",
"      <span class=\"nowrap\">",
"       micromol/L)",
"      </span>",
"      that progresses over days to weeks (ie, acute or subacute kidney injury). As noted above, the rise in serum creatinine with reductions in glomerular filtration rate (GFR) may be minimal due to the marked reduction in creatinine production among such patients.",
"     </li>",
"     <li>",
"      The absence of any other apparent cause for the acute kidney injury, including shock, current, or recent treatment with nephrotoxic drugs, and the absence of ultrasonographic evidence of obstruction or parenchymal renal disease. Spontaneous bacterial peritonitis is complicated by acute kidney injury that may be reversible in 30 to 40 percent of patients. It can be associated with acute tubular necrosis (ATN), but it is also a major precipitant of the hepatorenal syndrome. Thus, ongoing infection with spontaneous bacterial peritonitis should not exclude the possibility of hepatorenal syndrome. This means that therapy for hepatorenal syndrome can commence while the bacterial infection is still being treated. In addition, hepatorenal syndrome can occur in patients with preexisting chronic kidney disease. Thus, the presence of another renal diagnosis (eg, diabetic nephropathy) does not necessarily exclude hepatorenal syndrome.",
"     </li>",
"     <li>",
"      In conjunction with excluding other apparent causes of renal disease, the following criteria also apply:",
"      <br/>",
"      <br/>",
"      Urine red cell excretion of less than 50 cells per high power field (when no urinary catheter is in place) and protein excretion less than 500",
"      <span class=\"nowrap\">",
"       mg/day.",
"       <br/>",
"       <br/>",
"       Lack",
"      </span>",
"      of improvement in renal function after volume expansion with intravenous albumin (1",
"      <span class=\"nowrap\">",
"       g/kg",
"      </span>",
"      of body weight per day up to 100",
"      <span class=\"nowrap\">",
"       g/day)",
"      </span>",
"      for at least two days and withdrawal of diuretics.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      As noted above, patients diagnosed with hepatorenal syndrome are classified as type 1 hepatorenal syndrome (more severe) or type 2 hepatorenal syndrome (less severe) based upon the rapidity of the acute kidney injury and the degree of renal impairment. Type 1 hepatorenal syndrome is present if the serum creatinine increases by at least twofold to a value greater than 2.5",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (221",
"      <span class=\"nowrap\">",
"       micromol/L)",
"      </span>",
"      during a period of less than two weeks. Less rapidly progressive disease is classified as type 2. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The diagnosis of the hepatorenal syndrome is one of",
"      <strong>",
"       exclusion",
"      </strong>",
"      , entertained only after other potential causes of acute or subacute kidney injury have been ruled out. Alternate etiologies include, but are not limited to, glomerulonephritis, prerenal disease, and ATN. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Differential diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The ideal therapy for hepatorenal syndrome is improvement of liver function from either recovery of alcoholic hepatitis, treatment of decompensated hepatitis B with effective antiviral therapy, recovery from acute hepatic failure, or liver transplantation. (See",
"      <a class=\"local\" href=\"#H97745174\">",
"       'Approach to therapy'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H97745161\">",
"       'Improving hepatic function'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      However, when improvement of liver function is not possible in the short term, medical therapy should be instituted in an attempt to reverse the acute kidney injury associated with hepatorenal syndrome. Our suggestions regarding the choice of medical therapy depend upon several factors, including: whether the patient is admitted to the intensive care unit; the availability of certain drugs, for which there is national and regional variability; and whether the patient is a candidate for liver transplantation. (See",
"      <a class=\"local\" href=\"#H97745174\">",
"       'Approach to therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In patients with hepatorenal syndrome who are",
"      <strong>",
"       admitted to the intensive care unit",
"      </strong>",
"      , we suggest initial treatment with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?16/28/16838?source=see_link\">",
"       norepinephrine",
"      </a>",
"      in combination with albumin rather than other medical therapies (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). Norepinephrine is given intravenously as a continuous infusion (0.5 to 3",
"      <span class=\"nowrap\">",
"       mg/hr)",
"      </span>",
"      with the goal of raising the mean arterial pressure by 10 mmHg, and albumin is given for at least two days as an intravenous bolus (1",
"      <span class=\"nowrap\">",
"       g/kg",
"      </span>",
"      per day [100 g maximum]). Intravenous vasopressin may also be effective, starting at 0.01",
"      <span class=\"nowrap\">",
"       units/min.",
"      </span>",
"      (See",
"      <a class=\"local\" href=\"#H5671866\">",
"       'Norepinephrine for patients in the intensive care unit'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In patients with hepatorenal syndrome who are",
"      <strong>",
"       not admitted to the intensive care unit",
"      </strong>",
"      , our suggestions depend upon the availability of certain drugs:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Where terlipressin therapy is available, we suggest initial treatment with terlipressin in combination with albumin rather than",
"      <a class=\"drug drug_general\" href=\"UTD.htm?2/35/2613?source=see_link\">",
"       midodrine",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?42/7/43128?source=see_link\">",
"       octreotide",
"      </a>",
"      , and albumin (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). Terlipressin is given as an intravenous bolus (1 to 2 mg every four to six hours), and albumin is given for two days as an intravenous bolus (1",
"      <span class=\"nowrap\">",
"       g/kg",
"      </span>",
"      per day [100 g maximum]), followed by 25 to 50 grams per day until terlipressin therapy is discontinued. (See",
"      <a class=\"local\" href=\"#H5672085\">",
"       'Terlipressin plus albumin where available'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Where terlipressin therapy is not available (principally the United States), we suggest initial treatment with a combination of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?2/35/2613?source=see_link\">",
"       midodrine",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?42/7/43128?source=see_link\">",
"       octreotide",
"      </a>",
"      , and albumin (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). Midodrine is given orally (7.5 to 15 mg by mouth three times daily), octreotide is either given as a continuous intravenous infusion (50",
"      <span class=\"nowrap\">",
"       mcg/hr)",
"      </span>",
"      or subcutaneously (100 to 200 mcg three times daily), and albumin is given for two days as an intravenous bolus (1",
"      <span class=\"nowrap\">",
"       g/kg",
"      </span>",
"      per day [100 g maximum]), followed by 25 to 50 grams per day until midodrine and octreotide therapy is discontinued. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Midodrine, octreotide, and albumin where terlipressin is not available'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In highly selected patients who fail to respond to medical therapy with the above regimens, who are awaiting liver transplantation, and who are considered well enough to undergo the procedure, transjugular intrahepatic portosystemic shunt (TIPS) is sometimes successful; however the procedure is associated with numerous complications. (See",
"      <a class=\"local\" href=\"#H5672740\">",
"       'Transjugular intrahepatic portosystemic shunt'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In patients who fail to respond to the above therapies, develop severely impaired renal function, are not considered candidates for TIPS, and either are candidates for liver transplantation or have a reversible form of liver injury and are expected to survive, we recommend dialysis as a bridge to liver transplantation or liver recovery (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). Hemodialysis is frequently difficult to perform in patients with hepatorenal syndrome, and survival is generally limited by the severity of the hepatic failure, as well as concurrent respiratory failure. (See",
"      <a class=\"local\" href=\"#H18565503\">",
"       'Dialysis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The goal of medical therapy or TIPS in patients with hepatorenal syndrome is reversal of the acute kidney injury. In addition, when patients are treated with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?16/28/16838?source=see_link\">",
"       norepinephrine",
"      </a>",
"      , terlipressin, or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?2/35/2613?source=see_link\">",
"       midodrine",
"      </a>",
"      plus",
"      <a class=\"drug drug_general\" href=\"UTD.htm?42/7/43128?source=see_link\">",
"       octreotide",
"      </a>",
"      , an immediate goal of therapy is to raise the mean arterial pressure by approximately 10 to 15 mmHg. (See",
"      <a class=\"local\" href=\"#H97745174\">",
"       'Approach to therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In patients treated with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?16/28/16838?source=see_link\">",
"       norepinephrine",
"      </a>",
"      , terlipressin, or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?42/7/43128?source=see_link\">",
"       octreotide",
"      </a>",
"      , we usually treat for a total of two weeks. However, we and others occasionally treat for longer durations (up to one month or more) if there is some but not complete improvement in renal function after two weeks of therapy. In patients who respond to therapy, we occasionally treat indefinitely with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?2/35/2613?source=see_link\">",
"       midodrine",
"      </a>",
"      to maintain a higher mean arterial pressure (or until liver transplantation or resolution of liver injury). In contrast, if a patient has no improvement in renal function after two weeks, therapy with these drugs can be considered futile. (See",
"      <a class=\"local\" href=\"#H97745174\">",
"       'Approach to therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The following therapies may prevent the development of hepatorenal syndrome in these patients (see",
"      <a class=\"local\" href=\"#H21\">",
"       'Prevention'",
"      </a>",
"      above):",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      In patients with spontaneous bacterial peritonitis, we recommend the administration of intravenous albumin (1.5",
"      <span class=\"nowrap\">",
"       g/kg)",
"      </span>",
"      at the time of diagnosis of infection and another dose of albumin (1",
"      <span class=\"nowrap\">",
"       g/kg)",
"      </span>",
"      on day 3 of antibiotic treatment (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?4/1/4121?source=see_link\">",
"       \"Treatment and prophylaxis of spontaneous bacterial peritonitis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      In selected patients with cirrhosis and ascites, we recommend chronic",
"      <a class=\"drug drug_general\" href=\"UTD.htm?16/9/16536?source=see_link\">",
"       norfloxacin",
"      </a>",
"      therapy (400",
"      <span class=\"nowrap\">",
"       mg/day)",
"      </span>",
"      (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). A discussion of which patients should receive chronic norfloxacin therapy, as well as the evidence for this graded recommendation, are presented elsewhere. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?4/1/4121?source=see_link\">",
"       \"Treatment and prophylaxis of spontaneous bacterial peritonitis\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Without therapy, most patients with hepatorenal syndrome die within weeks of the onset of the renal impairment. The outcome of patients with hepatorenal syndrome, as well as recovery of kidney function, is strongly dependent upon reversal of the hepatic failure, whether spontaneous, following medical therapy, or following successful liver transplantation. (See",
"      <a class=\"local\" href=\"#H22\">",
"       'Prognosis'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/50/29482/abstract/1\">",
"      Gin&egrave;s P, Schrier RW. Renal failure in cirrhosis. N Engl J Med 2009; 361:1279.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/50/29482/abstract/2\">",
"      Gin&egrave;s P, Guevara M, Arroyo V, Rod&eacute;s J. Hepatorenal syndrome. Lancet 2003; 362:1819.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/50/29482/abstract/3\">",
"      Wadei HM, Mai ML, Ahsan N, Gonwa TA. Hepatorenal syndrome: pathophysiology and management. Clin J Am Soc Nephrol 2006; 1:1066.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/50/29482/abstract/4\">",
"      Martin PY, Gin&egrave;s P, Schrier RW. Nitric oxide as a mediator of hemodynamic abnormalities and sodium and water retention in cirrhosis. N Engl J Med 1998; 339:533.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/50/29482/abstract/5\">",
"      Iwakiri Y. The molecules: mechanisms of arterial vasodilatation observed in the splanchnic and systemic circulation in portal hypertension. J Clin Gastroenterol 2007; 41 Suppl 3:S288.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/50/29482/abstract/6\">",
"      Fernandez-Seara J, Prieto J, Quiroga J, et al. Systemic and regional hemodynamics in patients with liver cirrhosis and ascites with and without functional renal failure. Gastroenterology 1989; 97:1304.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/50/29482/abstract/7\">",
"      Wiest R, Das S, Cadelina G, et al. Bacterial translocation in cirrhotic rats stimulates eNOS-derived NO production and impairs mesenteric vascular contractility. J Clin Invest 1999; 104:1223.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/50/29482/abstract/8\">",
"      Runyon BA, Squier S, Borzio M. Translocation of gut bacteria in rats with cirrhosis to mesenteric lymph nodes partially explains the pathogenesis of spontaneous bacterial peritonitis. J Hepatol 1994; 21:792.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/50/29482/abstract/9\">",
"      Epstein M, Berk DP, Hollenberg NK, et al. Renal failure in the patient with cirrhosis. The role of active vasoconstriction. Am J Med 1970; 49:175.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/50/29482/abstract/10\">",
"      Gin&egrave;s A, Escorsell A, Gin&egrave;s P, et al. Incidence, predictive factors, and prognosis of the hepatorenal syndrome in cirrhosis with ascites. Gastroenterology 1993; 105:229.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/50/29482/abstract/11\">",
"      Lenz K, H&ouml;rtnagl H, Druml W, et al. Ornipressin in the treatment of functional renal failure in decompensated liver cirrhosis. Effects on renal hemodynamics and atrial natriuretic factor. Gastroenterology 1991; 101:1060.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/50/29482/abstract/12\">",
"      Esler M, Dudley F, Jennings G, et al. Increased sympathetic nervous activity and the effects of its inhibition with clonidine in alcoholic cirrhosis. Ann Intern Med 1992; 116:446.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/50/29482/abstract/13\">",
"      Roulot D, Moreau R, Gaudin C, et al. Long-term sympathetic and hemodynamic responses to clonidine in patients with cirrhosis and ascites. Gastroenterology 1992; 102:1309.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/50/29482/abstract/14\">",
"      Schroeder ET, Anderson GH Jr, Smulyan H. Effects of a portacaval or peritoneovenous shunt on renin in the hepatorenal syndrome. Kidney Int 1979; 15:54.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/50/29482/abstract/15\">",
"      R&ouml;ssle M, Gerbes AL. TIPS for the treatment of refractory ascites, hepatorenal syndrome and hepatic hydrothorax: a critical update. Gut 2010; 59:988.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/50/29482/abstract/16\">",
"      Castells A, Sal&oacute; J, Planas R, et al. Impact of shunt surgery for variceal bleeding in the natural history of ascites in cirrhosis: a retrospective study. Hepatology 1994; 20:584.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/50/29482/abstract/17\">",
"      Akriviadis E, Botla R, Briggs W, et al. Pentoxifylline improves short-term survival in severe acute alcoholic hepatitis: a double-blind, placebo-controlled trial. Gastroenterology 2000; 119:1637.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/50/29482/abstract/18\">",
"      Better OS. Renal and cardiovascular dysfunction in liver disease. Kidney Int 1986; 29:598.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/50/29482/abstract/19\">",
"      Arroyo V, Gin&egrave;s P, Gerbes AL, et al. Definition and diagnostic criteria of refractory ascites and hepatorenal syndrome in cirrhosis. International Ascites Club. Hepatology 1996; 23:164.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/50/29482/abstract/20\">",
"      BALDUS WP, FEICHTER RN, SUMMERSKILL WH. THE KIDNEY IN CIRRHOSIS. I. CLINICAL AND BIOCHEMICAL FEATURES OF AZOTEMIA IN HEPATIC FAILURE. Ann Intern Med 1964; 60:353.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/50/29482/abstract/21\">",
"      Esrailian E, Pantangco ER, Kyulo NL, et al. Octreotide/Midodrine therapy significantly improves renal function and 30-day survival in patients with type 1 hepatorenal syndrome. Dig Dis Sci 2007; 52:742.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/50/29482/abstract/22\">",
"      Salerno F, Gerbes A, Gin&egrave;s P, et al. Diagnosis, prevention and treatment of hepatorenal syndrome in cirrhosis. Gut 2007; 56:1310.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/50/29482/abstract/23\">",
"      Wu CC, Yeung LK, Tsai WS, et al. Incidence and factors predictive of acute renal failure in patients with advanced liver cirrhosis. Clin Nephrol 2006; 65:28.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/50/29482/abstract/24\">",
"      Follo A, Llovet JM, Navasa M, et al. Renal impairment after spontaneous bacterial peritonitis in cirrhosis: incidence, clinical course, predictive factors and prognosis. Hepatology 1994; 20:1495.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/50/29482/abstract/25\">",
"      Sort P, Navasa M, Arroyo V, et al. Effect of intravenous albumin on renal impairment and mortality in patients with cirrhosis and spontaneous bacterial peritonitis. N Engl J Med 1999; 341:403.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/50/29482/abstract/26\">",
"      Verna EC, Brown RS, Farrand E, et al. Urinary neutrophil gelatinase-associated lipocalin predicts mortality and identifies acute kidney injury in cirrhosis. Dig Dis Sci 2012; 57:2362.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/50/29482/abstract/27\">",
"      Fagundes C, P&eacute;pin MN, Guevara M, et al. Urinary neutrophil gelatinase-associated lipocalin as biomarker in the differential diagnosis of impairment of kidney function in cirrhosis. J Hepatol 2012; 57:267.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/50/29482/abstract/28\">",
"      Wong F, Nadim MK, Kellum JA, et al. Working Party proposal for a revised classification system of renal dysfunction in patients with cirrhosis. Gut 2011; 60:702.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/50/29482/abstract/29\">",
"      Mart&iacute;n-Llah&iacute; M, Guevara M, Torre A, et al. Prognostic importance of the cause of renal failure in patients with cirrhosis. Gastroenterology 2011; 140:488.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/50/29482/abstract/30\">",
"      Trawal&eacute; JM, Paradis V, Rautou PE, et al. The spectrum of renal lesions in patients with cirrhosis: a clinicopathological study. Liver Int 2010; 30:725.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/50/29482/abstract/31\">",
"      Kanel GC, Peters RL. Glomerular tubular reflux--a morphologic renal lesion associated with the hepatorenal syndrome. Hepatology 1984; 4:242.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/50/29482/abstract/32\">",
"      Linas SL, Schaefer JW, Moore EE, et al. Peritoneovenous shunt in the management of the hepatorenal syndrome. Kidney Int 1986; 30:736.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/50/29482/abstract/33\">",
"      Diamond JR, Yoburn DC. Nonoliguric acute renal failure associated with a low fractional excretion of sodium. Ann Intern Med 1982; 96:597.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/50/29482/abstract/34\">",
"      Laffi G, Daskalopoulos G, Kronborg I, et al. Effects of sulindac and ibuprofen in patients with cirrhosis and ascites. An explanation for the renal-sparing effect of sulindac. Gastroenterology 1986; 90:182.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/50/29482/abstract/35\">",
"      Amini M, Runyon BA. Alcoholic hepatitis 2010: a clinician's guide to diagnosis and therapy. World J Gastroenterol 2010; 16:4905.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/50/29482/abstract/36\">",
"      Garg H, Sarin SK, Kumar M, et al. Tenofovir improves the outcome in patients with spontaneous reactivation of hepatitis B presenting as acute-on-chronic liver failure. Hepatology 2011; 53:774.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/50/29482/abstract/37\">",
"      Velez JC, Nietert PJ. Therapeutic response to vasoconstrictors in hepatorenal syndrome parallels increase in mean arterial pressure: a pooled analysis of clinical trials. Am J Kidney Dis 2011; 58:928.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/50/29482/abstract/38\">",
"      Singh V, Dhungana SP, Singh B, et al. Midodrine in patients with cirrhosis and refractory or recurrent ascites: a randomized pilot study. J Hepatol 2012; 56:348.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/50/29482/abstract/39\">",
"      Badalamenti S, Graziani G, Salerno F, Ponticelli C. Hepatorenal syndrome. New perspectives in pathogenesis and treatment. Arch Intern Med 1993; 153:1957.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/50/29482/abstract/40\">",
"      Arroyo V, Guevara M, Gin&egrave;s P. Hepatorenal syndrome in cirrhosis: pathogenesis and treatment. Gastroenterology 2002; 122:1658.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/50/29482/abstract/41\">",
"      Gonwa TA, Morris CA, Goldstein RM, et al. Long-term survival and renal function following liver transplantation in patients with and without hepatorenal syndrome--experience in 300 patients. Transplantation 1991; 51:428.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/50/29482/abstract/42\">",
"      Veldt BJ, Lain&eacute; F, Guillygomarc'h A, et al. Indication of liver transplantation in severe alcoholic liver cirrhosis: quantitative evaluation and optimal timing. J Hepatol 2002; 36:93.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/50/29482/abstract/43\">",
"      Villeneuve JP, Condreay LD, Willems B, et al. Lamivudine treatment for decompensated cirrhosis resulting from chronic hepatitis B. Hepatology 2000; 31:207.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/50/29482/abstract/44\">",
"      Duvoux C, Zanditenas D, H&eacute;zode C, et al. Effects of noradrenalin and albumin in patients with type I hepatorenal syndrome: a pilot study. Hepatology 2002; 36:374.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/50/29482/abstract/45\">",
"      Kiser TH, Fish DN, Obritsch MD, et al. Vasopressin, not octreotide, may be beneficial in the treatment of hepatorenal syndrome: a retrospective study. Nephrol Dial Transplant 2005; 20:1813.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/50/29482/abstract/46\">",
"      Singh V, Ghosh S, Singh B, et al. Noradrenaline vs. terlipressin in the treatment of hepatorenal syndrome: a randomized study. J Hepatol 2012; 56:1293.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/50/29482/abstract/47\">",
"      Alessandria C, Ottobrelli A, Debernardi-Venon W, et al. Noradrenalin vs terlipressin in patients with hepatorenal syndrome: a prospective, randomized, unblinded, pilot study. J Hepatol 2007; 47:499.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/50/29482/abstract/48\">",
"      Guevara M, Gin&egrave;s P, Fern&aacute;ndez-Esparrach G, et al. Reversibility of hepatorenal syndrome by prolonged administration of ornipressin and plasma volume expansion. Hepatology 1998; 27:35.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/50/29482/abstract/49\">",
"      G&uuml;lberg V, Bilzer M, Gerbes AL. Long-term therapy and retreatment of hepatorenal syndrome type 1 with ornipressin and dopamine. Hepatology 1999; 30:870.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/50/29482/abstract/50\">",
"      Gluud LL, Kjaer MS, Christensen E. Terlipressin for hepatorenal syndrome. Cochrane Database Syst Rev 2006; :CD005162.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/50/29482/abstract/51\">",
"      Mart&iacute;n-Llah&iacute; M, P&eacute;pin MN, Guevara M, et al. Terlipressin and albumin vs albumin in patients with cirrhosis and hepatorenal syndrome: a randomized study. Gastroenterology 2008; 134:1352.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/50/29482/abstract/52\">",
"      Sanyal AJ, Boyer T, Garcia-Tsao G, et al. A randomized, prospective, double-blind, placebo-controlled trial of terlipressin for type 1 hepatorenal syndrome. Gastroenterology 2008; 134:1360.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/50/29482/abstract/53\">",
"      Hadengue A, Gadano A, Moreau R, et al. Beneficial effects of the 2-day administration of terlipressin in patients with cirrhosis and hepatorenal syndrome. J Hepatol 1998; 29:565.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/50/29482/abstract/54\">",
"      Neri S, Pulvirenti D, Malaguarnera M, et al. Terlipressin and albumin in patients with cirrhosis and type I hepatorenal syndrome. Dig Dis Sci 2008; 53:830.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/50/29482/abstract/55\">",
"      Solanki P, Chawla A, Garg R, et al. Beneficial effects of terlipressin in hepatorenal syndrome: a prospective, randomized placebo-controlled clinical trial. J Gastroenterol Hepatol 2003; 18:152.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/50/29482/abstract/56\">",
"      Gluud LL, Christensen K, Christensen E, Krag A. Terlipressin for hepatorenal syndrome. Cochrane Database Syst Rev 2012; 9:CD005162.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/50/29482/abstract/57\">",
"      Kalambokis G, Economou M, Fotopoulos A, et al. The effects of chronic treatment with octreotide versus octreotide plus midodrine on systemic hemodynamics and renal hemodynamics and function in nonazotemic cirrhotic patients with ascites. Am J Gastroenterol 2005; 100:879.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/50/29482/abstract/58\">",
"      Angeli P, Volpin R, Gerunda G, et al. Reversal of type 1 hepatorenal syndrome with the administration of midodrine and octreotide. Hepatology 1999; 29:1690.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/50/29482/abstract/59\">",
"      Pomier-Layrargues G, Paquin SC, Hassoun Z, et al. Octreotide in hepatorenal syndrome: a randomized, double-blind, placebo-controlled, crossover study. Hepatology 2003; 38:238.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/50/29482/abstract/60\">",
"      Ochs A, R&ouml;ssle M, Haag K, et al. The transjugular intrahepatic portosystemic stent-shunt procedure for refractory ascites. N Engl J Med 1995; 332:1192.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/50/29482/abstract/61\">",
"      Somberg KA, Lake JR, Tomlanovich SJ, et al. Transjugular intrahepatic portosystemic shunts for refractory ascites: assessment of clinical and hormonal response and renal function. Hepatology 1995; 21:709.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/50/29482/abstract/62\">",
"      Wong F, Sniderman K, Liu P, Blendis L. The mechanism of the initial natriuresis after transjugular intrahepatic portosystemic shunt. Gastroenterology 1997; 112:899.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/50/29482/abstract/63\">",
"      Brensing KA, Textor J, Strunk H, et al. Transjugular intrahepatic portosystemic stent-shunt for hepatorenal syndrome. Lancet 1997; 349:697.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/50/29482/abstract/64\">",
"      Guevara M, Gin&egrave;s P, Bandi JC, et al. Transjugular intrahepatic portosystemic shunt in hepatorenal syndrome: effects on renal function and vasoactive systems. Hepatology 1998; 28:416.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/50/29482/abstract/65\">",
"      Malinchoc M, Kamath PS, Gordon FD, et al. A model to predict poor survival in patients undergoing transjugular intrahepatic portosystemic shunts. Hepatology 2000; 31:864.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/50/29482/abstract/66\">",
"      Wong LP, Blackley MP, Andreoni KA, et al. Survival of liver transplant candidates with acute renal failure receiving renal replacement therapy. Kidney Int 2005; 68:362.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/50/29482/abstract/67\">",
"      Wilkinson SP, Weston MJ, Parsons V, Williams R. Dialysis in the treatment of renal failure in patients with liver disease. Clin Nephrol 1977; 8:287.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/50/29482/abstract/68\">",
"      Witzke O, Baumann M, Patschan D, et al. Which patients benefit from hemodialysis therapy in hepatorenal syndrome? J Gastroenterol Hepatol 2004; 19:1369.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/50/29482/abstract/69\">",
"      Epstein M. Hepatorenal syndrome: emerging perspectives. Semin Nephrol 1997; 17:563.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/50/29482/abstract/70\">",
"      Epstein M. Peritoneovenous shunt in the management of ascites and the hepatorenal syndrome. Gastroenterology 1982; 82:790.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/50/29482/abstract/71\">",
"      Stanley MM, Ochi S, Lee KK, et al. Peritoneovenous shunting as compared with medical treatment in patients with alcoholic cirrhosis and massive ascites. Veterans Administration Cooperative Study on Treatment of Alcoholic Cirrhosis with Ascites. N Engl J Med 1989; 321:1632.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/50/29482/abstract/72\">",
"      Gin&egrave;s P, Arroyo V, Vargas V, et al. Paracentesis with intravenous infusion of albumin as compared with peritoneovenous shunting in cirrhosis with refractory ascites. N Engl J Med 1991; 325:829.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/50/29482/abstract/73\">",
"      Tobe SW, Morali GA, Greig PD, et al. Peritoneovenous shunting restores atrial natriuretic factor responsiveness in refractory hepatic ascites. Gastroenterology 1993; 105:202.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/50/29482/abstract/74\">",
"      Briglia AE, Anania FA. Hepatorenal syndrome. Definition, pathophysiology, and intervention. Crit Care Clin 2002; 18:345.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/50/29482/abstract/75\">",
"      Gin&egrave;s P, Arroyo V. Hepatorenal syndrome. J Am Soc Nephrol 1999; 10:1833.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/50/29482/abstract/76\">",
"      Epstein M. Treatment of refractory ascites. N Engl J Med 1989; 321:1675.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/50/29482/abstract/77\">",
"      Greig PD, Langer B, Blendis LM, et al. Complications after peritoneovenous shunting for ascites. Am J Surg 1980; 139:125.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/50/29482/abstract/78\">",
"      Smadja C, Franco D. The LeVeen shunt in the elective treatment of intractable ascites in cirrhosis. A prospective study on 140 patients. Ann Surg 1985; 201:488.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/50/29482/abstract/79\">",
"      Salerno F, Navickis RJ, Wilkes MM. Albumin infusion improves outcomes of patients with spontaneous bacterial peritonitis: a meta-analysis of randomized trials. Clin Gastroenterol Hepatol 2013; 11:123.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/50/29482/abstract/80\">",
"      Fern&aacute;ndez J, Navasa M, Planas R, et al. Primary prophylaxis of spontaneous bacterial peritonitis delays hepatorenal syndrome and improves survival in cirrhosis. Gastroenterology 2007; 133:818.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/50/29482/abstract/81\">",
"      Tyagi P, Sharma P, Sharma BC, et al. Prevention of hepatorenal syndrome in patients with cirrhosis and ascites: a pilot randomized control trial between pentoxifylline and placebo. Eur J Gastroenterol Hepatol 2011; 23:210.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/50/29482/abstract/82\">",
"      Whitfield K, Rambaldi A, Wetterslev J, Gluud C. Pentoxifylline for alcoholic hepatitis. Cochrane Database Syst Rev 2009; :CD007339.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/50/29482/abstract/83\">",
"      Alessandria C, Ozdogan O, Guevara M, et al. MELD score and clinical type predict prognosis in hepatorenal syndrome: relevance to liver transplantation. Hepatology 2005; 41:1282.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/50/29482/abstract/84\">",
"      Cassinello C, Moreno E, Gozalo A, et al. Effects of orthotopic liver transplantation on vasoactive systems and renal function in patients with advanced liver cirrhosis. Dig Dis Sci 2003; 48:179.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/50/29482/abstract/85\">",
"      Marik PE, Wood K, Starzl TE. The course of type 1 hepato-renal syndrome post liver transplantation. Nephrol Dial Transplant 2006; 21:478.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 2308 Version 9.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-61.55.141.10-11D65C23BF-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f28_50_29482=[""].join("\n");
var outline_f28_50_29482=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H97742010\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9884469\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      CLINICAL PRESENTATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5670964\">",
"      Precipitants",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17253448\">",
"      Problems with estimating kidney function",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      DIFFERENTIAL DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Acute tubular necrosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Prerenal disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H97745174\">",
"      Approach to therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H97745161\">",
"      Improving hepatic function",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5671866\">",
"      Norepinephrine for patients in the intensive care unit",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5672465\">",
"      Patients not in the intensive care unit",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5672085\">",
"      - Terlipressin plus albumin where available",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Midodrine, octreotide, and albumin where terlipressin is not available",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5672923\">",
"      Patients who do not respond to initial medical therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5672740\">",
"      - Transjugular intrahepatic portosystemic shunt",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18565503\">",
"      - Dialysis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Other therapies",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      - Peritoneovenous shunt",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      PREVENTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      PROGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H97742010\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"NEPH/2308\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEPH/2308|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?36/51/37693\" title=\"figure 1\">",
"      Hormonal response to cirrhosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?38/9/39069\" title=\"figure 2\">",
"      Ornipressin on GFR in cirrhosis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   CALCULATORS",
"  </h1>",
"  <div id=\"relatedCalculators\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"calc calc_professional\" href=\"UTD.htm?25/13/25809?source=related_link\" title=\"calculator 1\">",
"      Calculator: Fractional excretion of sodium",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"calc calc_professional\" href=\"UTD.htm?24/28/25025?source=related_link\" title=\"calculator 2\">",
"      Calculator: Fractional excretion of sodium (SI units)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/40/38538?source=related_link\">",
"      Acute liver failure in adults: Management and prognosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/43/698?source=related_link\">",
"      Alcoholic hepatitis: Natural history and management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/45/36570?source=related_link\">",
"      Assessment of kidney function",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/19/1337?source=related_link\">",
"      Clinical presentation and diagnosis of IgA nephropathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/40/28295?source=related_link\">",
"      Continuous renal replacement therapy in acute kidney injury (acute renal failure)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/13/38105?source=related_link\">",
"      Epidemiology, clinical features, and diagnosis of nonalcoholic fatty liver disease in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/54/12138?source=related_link\">",
"      Etiology and diagnosis of prerenal disease and acute tubular necrosis in acute kidney injury (acute renal failure)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/17/8472?source=related_link\">",
"      Fractional excretion of sodium, urea, and other molecules in acute kidney injury (acute renal failure)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/35/34359?source=related_link\">",
"      Indications for the use of transjugular intrahepatic portosystemic shunts",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/44/19145?source=related_link\">",
"      Initial therapy of ascites in patients with cirrhosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/0/24582?source=related_link\">",
"      NSAIDs: Acute kidney injury (acute renal failure) and nephrotic syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/59/17337?source=related_link\">",
"      Overview of the complications, prognosis, and management of cirrhosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/1/21527?source=related_link\">",
"      Pathogenesis of ascites in patients with cirrhosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/28/44488?source=related_link\">",
"      Renal disease associated with hepatitis B virus infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/30/37353?source=related_link\">",
"      Renal disease associated with hepatitis C virus infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/28/34250?source=related_link\">",
"      Renal function and nonrenal solid organ transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/1/4121?source=related_link\">",
"      Treatment and prophylaxis of spontaneous bacterial peritonitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/40/35465?source=related_link\">",
"      Treatment of diuretic-resistant ascites in patients with cirrhosis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f28_50_29483="Lipids - Standard vs SI units";
var content_f28_50_29483=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PI%2F76734&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PI%2F76734&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Cholesterol and triglyceride measurements in the United States and elsewhere",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\" rowspan=\"2\">",
"        &nbsp;",
"       </td>",
"       <td class=\"subtitle1\">",
"        <p>",
"         Measurement used within the United States",
"         <br/>",
"         Milligrams/deciliter (mg/dL)",
"        </p>",
"       </td>",
"       <td class=\"subtitle1\">",
"        <p>",
"         Measurement used most places outside the United States",
"         <br/>",
"         Millimoles/liter (mmol/Liter)",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2\">",
"        Level to aim for",
"       </td>",
"       <td class=\"subtitle2\">",
"        Level to aim for",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Total cholesterol",
"        </strong>",
"       </td>",
"       <td>",
"        Below 200",
"       </td>",
"       <td>",
"        Below 5.17",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         LDL cholesterol",
"        </strong>",
"       </td>",
"       <td>",
"        Below 130 - or much lower if at risk of heart attack and stroke",
"       </td>",
"       <td>",
"        Below 3.36 - or much lower if at risk of heart attack and stroke",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         HDL cholesterol",
"        </strong>",
"       </td>",
"       <td>",
"        Above 60",
"       </td>",
"       <td>",
"        Above 1.55",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Triglycerides",
"        </strong>",
"       </td>",
"       <td>",
"        Below 150",
"       </td>",
"       <td>",
"        Below 1.7",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    Cholesterol is measured differently in the United States than it is in most other countries. This table shows values used within and outside the United States. It includes the cholesterol and triglyceride levels that most people who do not have heart disease should aim for.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f28_50_29483=[""].join("\n");
var outline_f28_50_29483=null;
var title_f28_50_29484="Indications for pulmonary tests";
var content_f28_50_29484=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F52884&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F52884&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Indications for pulmonary function tests",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <colgroup span=\"2\" width=\"50%\">",
"     </colgroup>",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Test",
"       </td>",
"       <td class=\"subtitle1\">",
"        Indication",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"3\">",
"        Spirometry",
"       </td>",
"       <td>",
"        Evaluate dyspnea",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Symptomatic smokers over age 45 to detect COPD",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Monitor recovery from exacerbation of asthma, COPD",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td rowspan=\"2\">",
"        Spirometry with bronchodilator",
"       </td>",
"       <td>",
"        Chronic cough or chest tightness",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Suspected asthma or COPD",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td class=\"sublist1_start\" rowspan=\"6\">",
"        <p>",
"         Diffusing capacity for carbon monoxide",
"        </p>",
"        <p>",
"         (DLCO or transfer factor)",
"        </p>",
"       </td>",
"       <td>",
"        Differential diagnosis of abnormal spirometry",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Obstruction: asthma versus COPD or bronchiolitis obliterans",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Restriction: interstitial lung disease versus chest wall",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Diffuse opacities on chest radiograph",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Suspected pulmonary vascular disease",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Evaluate dyspnea",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        Lung volumes",
"       </td>",
"       <td>",
"        Low FVC on spirometry: restriction versus hyperinflation or mixed",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td rowspan=\"3\">",
"        Oximetry with exercise or sleep",
"       </td>",
"       <td>",
"        Dyspnea on exertion, disability evaluation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Check adequacy of supplemental oxygen",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Screen for abnormal breathing during sleep",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        Bronchoprovocation challenge",
"       </td>",
"       <td>",
"        Suspected asthma but normal spirometry",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td rowspan=\"2\">",
"        Respiratory pressures",
"       </td>",
"       <td>",
"        Suspected muscle weakness or diaphragm paralysis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Monitoring of myasthenia, ALS, polio",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td class=\"sublist1_start\" rowspan=\"3\">",
"        Flow volume loop",
"       </td>",
"       <td>",
"        Inspiratory stridor",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Suspected upper airway obstruction: vocal cord paralysis, tracheal stenosis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Evaluate unexplained dyspnea",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     COPD: chronic obstructive pulmonary disease; FVC: forced vital capacity; ALS: amyotrophic lateral sclerosis.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f28_50_29484=[""].join("\n");
var outline_f28_50_29484=null;
var title_f28_50_29485="Contents: Critical care calculators";
var content_f28_50_29485=[" <script type=\"text/javascript\">",
"  $$.inlineInitCustomer(",
"	false);",
"	var quirksmode = document.compatMode == \"CSS1Compat\";",
"	if (quirksmode) {",
"		$(\"html\").addClass(\"ie-standards\");",
"	}",
" </script>",
" <div id=\"message-wrap\">",
"  <div id=\"message-bg\">",
"  </div>",
"  <iframe id=\"message-bk\">",
"  </iframe>",
"  <dl id=\"message-container\">",
"   <dt id=\"message-title\">",
"   </dt>",
"   <dd id=\"message-body\">",
"   </dd>",
"   <dd id=\"message-controls\">",
"   </dd>",
"  </dl>",
" </div>",
" <div id=\"topPanel\">",
"  <div id=\"header\">",
"   <div id=\"header_container\">",
"    <h2 id=\"logo\">",
"     <a href=\"./toc\">",
"      Wolters Kluwer Health UpToDate",
"     </a>",
"    </h2>",
"    <div id=\"header_right\">",
"     <div id=\"searchpanel\">",
"      <a href=\"/login\" id=\"loginbutton\">",
"       Log in",
"      </a>",
"      <div id=\"cmsSearchBox\">",
"       <div class=\"header-search\">",
"        <form action=\"./search\" id=\"cmssearch\" method=\"get\" name=\"SearchForm\">",
"         <div class=\"header-search-left\">",
"          <input autocomplete=\"off\" class=\"searchfield\" id=\"cmsTxtBox\" name=\"search\" placeholder=\"Search UpToDate\" type=\"text\"/>",
"         </div>",
"         <div class=\"header-search-right\">",
"          <input alt=\"Search\" id=\"cmsSearchSubmit\" src=\"/sites/all/themes/uptodate/images/search_button.png\" type=\"image\"/>",
"         </div>",
"         <div class=\"clear\">",
"         </div>",
"        </form>",
"       </div>",
"      </div>",
"      <div id=\"cms_lang_dropdown\">",
"       <form accept-charset=\"UTF-8\" action=\"/\" id=\"lang-dropdown-form\" method=\"post\">",
"        <div class=\"form-item form-type-select form-item-lang-dropdown-select\">",
"         <select class=\"lang-dropdown-select-element form-select\" id=\"edit-lang-dropdown-select\" name=\"lang_dropdown_select\" style=\"width:100px\">",
"          <option selected=\"selected\" value=\"en\">",
"           English",
"          </option>",
"          <option value=\"ja\">",
"           ���������������������������",
"          </option>",
"         </select>",
"        </div>",
"        <input name=\"lang_dropdown_type\" type=\"hidden\" value=\"language\">",
"         <input name=\"en\" type=\"hidden\" value=\"/\">",
"          <input name=\"ja\" type=\"hidden\" value=\"/ja\">",
"           <noscript>",
"            <div>",
"             <input class=\"form-submit\" id=\"edit-submit\" name=\"op\" type=\"submit\" value=\"Go\"/>",
"            </div>",
"           </noscript>",
"           <input name=\"form_build_id\" type=\"hidden\" value=\"form-on4lUWpxHun_wp6revUkjCG6rK2IBuCGME9Cw0HXeok\">",
"            <input name=\"form_id\" type=\"hidden\" value=\"lang_dropdown_form\">",
"            </input>",
"           </input>",
"          </input>",
"         </input>",
"        </input>",
"       </form>",
"      </div>",
"      <div class=\"clear\">",
"      </div>",
"     </div>",
"     <ul id=\"utility\">",
"      <li class=\"first\">",
"       <a href=\"/home/about-us\">",
"        About Us",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/news-events\">",
"        News &amp; Events",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/contact-us\">",
"        Contact Us",
"       </a>",
"      </li>",
"      <li class=\"last\">",
"       <a href=\"/help\">",
"        Help",
"       </a>",
"      </li>",
"     </ul>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"nav\">",
"    <ul>",
"     <li id=\"productTab\">",
"      <a href=\"/home/product\">",
"       Product",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"editoralTab\">",
"      <a href=\"/home/editorial\">",
"       Editorial",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"whyUptodateTab\">",
"      <a href=\"/home/why-uptodate\">",
"       Why UpToDate",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"supscriptionOptionsTab\">",
"      <a href=\"/home/subscription-options\">",
"       Subscription Options",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"/store\">",
"       Subscribe",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"wkhcsTab\">",
"      <a href=\"/home/wolters-kluwer-health-clinical-solutions\">",
"       Wolters Kluwer Health Clinical Solutions",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"    </ul>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"greyBar\">",
"    <div id=\"greyBarTitle\">",
"     <span class=\"emphasis\">",
"      <a href=\"UTD.htm?3/3/3134\">",
"       Contents",
"      </a>",
"     </span>",
"     <img src=\"./../images/space_arrows.myextg\">",
"      <a href=\"UTD.htm?8/24/8590\">",
"       Pulmonary, Critical Care, and Sleep Medicine",
"      </a>",
"      <img src=\"./../images/space_arrows.myextg\">",
"       Critical care calculators",
"      </img>",
"     </img>",
"    </div>",
"    <div id=\"greyBarButtons\">",
"     <div id=\"printGB\">",
"      <a class=\"icontxt\" href=\"?view=print\">",
"       <img align=\"middle\" alt=\"Print this page\" border=\"0\" height=\"20\" src=\"./../images/icn_print.myextg\" width=\"24\"/>",
"      </a>",
"      <a class=\"icontxt\" href=\"?view=print\" title=\"Print this page\">",
"       Print",
"      </a>",
"     </div>",
"    </div>",
"   </div>",
"   <!-- menuMessage.jsp -->",
"   <!-- /menuMessage.jsp -->",
"  </div>",
"  <!-- header -->",
" </div>",
" <!-- topPanel -->",
" <div id=\"leftPanel\">",
"  <ul>",
"   <li>",
"    <a href=\"UTD.htm?3/45/3806\">",
"     Specialties",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?18/22/18798\">",
"     Patient Information",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?3/13/3294\">",
"     What's New",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?0/37/606\">",
"     Calculators",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?0/40/654\">",
"     Authors and Editors",
"    </a>",
"   </li>",
"  </ul>",
" </div>",
" <!-- leftPanel -->",
" <div id=\"rightPanel\">",
"  <noscript>",
"   <div id=\"javascriptDisabled\">",
"    It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"   </div>",
"  </noscript>",
"  <div id=\"printHeader\">",
"   <div id=\"printHeaderLogo\">",
"    <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"    </img>",
"   </div>",
"   <div id=\"printHeaderText\">",
"    Official reprint from UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"    <a href=\"file://www.uptodate.com\">",
"     www.uptodate.com",
"    </a>",
"    <br>",
"     &copy;2013 UpToDate",
"     <sup>",
"      &reg;",
"     </sup>",
"    </br>",
"   </div>",
"   <div id=\"printHeaderLinks\">",
"    <a href=\"#\" id=\"printHeaderPrint\" rel=\"\" title=\"Click here to print\">",
"     Print",
"    </a>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"     Back",
"    </a>",
"   </div>",
"  </div>",
"  <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" id=\"tocTable\" width=\"100%\">",
"   <trs>",
"    <tds>",
"     <h1>",
"      Contents:",
"			Critical care calculators",
"     </h1>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds valign=\"top\">",
"     <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" width=\"100%\">",
"      <trs>",
"       <tds>",
"        <strong>",
"         Medical Equations",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?2/41/2706\">",
"           Calculator: Ideal body weight (method of Devine) and dosing weight for adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?28/26/29089\">",
"           Calculator: Lean body weight (adult female)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?28/21/29009\">",
"           Calculator: Lean body weight (adult male)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?1/6/1123\">",
"           Calculator: Right to Left Shunt Fraction Qs/Qt",
"          </a>",
"         </li>",
"        </ul>",
"       </tds>",
"      </trs>",
"     </div>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"     <img height=\"10\" src=\"./../images/spacer.myextg\" width=\"1\"/>",
"    </tds>",
"   </trs>",
"  </div>",
"  <div id=\"footer\">",
"   <div id=\"footerNav\">",
"    <ul>",
"     <li>",
"      <a href=\"file://www.wolterskluwerhealth.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Wolters Kluwer Health",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.factsandcomparisons.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Facts &amp; Comparisons&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medispan.com\" rel=\"nofollow\" target=\"_blank\">",
"       Medi-Span&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationordersets.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Order Sets",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationmedical.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Medical",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://pharmacyonesource.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Pharmacy OneSource&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medicom.com.cn/\" rel=\"nofollow\" target=\"_blank\">",
"       Medicom",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.lexi.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Lexicomp",
"      </a>",
"     </li>",
"     <li class=\"last\">",
"      <a href=\"/home/privacy-policy\">",
"       Privacy Policy",
"      </a>",
"     </li>",
"    </ul>",
"   </div>",
"   <div id=\"footerLogo\">",
"    <a href=\"./toc\">",
"     Wolters Kluwer Health | UpToDate",
"    </a>",
"   </div>",
"   <div id=\"supportFooter\">",
"    <span class=\"sfInfo\">",
"     &copy; 2013 UpToDate, Inc. All rights reserved.",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Release: 21.3 - C21.34",
"    </span>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <span class=\"sfInfo\">",
"     <a href=\"/home/terms-use\">",
"      Terms of Use",
"     </a>",
"    </span>",
"    <br/>",
"    <span class=\"sfInfo\">",
"     Licensed to:",
"     <span class=\"emphasis\">",
"      UpToDate Marketing Professional",
"     </span>",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Support Tag: [0605-95.154.198.148-64FFA1F2DA-14]",
"     <br/>",
"    </span>",
"   </div>",
"  </div>",
" </div>",
" <!-- rightPanel -->",
"</body>"].join("\n");
var script_f28_50_29485=[""].join("\n");
var outline_f28_50_29485=null;
var title_f28_50_29486="Hypoxic ventilatory response";
var content_f28_50_29486=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F81924&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F81924&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Hypoxic ventilatory response",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 393px; height: 314px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Ventilatory response to decreasing inspired oxygen concentration in two subjects. End-tidal PCO",
"    <sub>",
"     2",
"    </sub>",
"    is held constant. The left panel shows the linear response of ventilation plotted against oxygen saturation. On the right is the more traditional hyperbolic response, obtained from plotting ventilation against alveolar PO",
"    <sub>",
"     2",
"    </sub>",
"    .",
"    <div class=\"footnotes\">",
"     VE: minute ventilation; SO",
"     <sub>",
"      2",
"     </sub>",
"     : oxygen saturation; PO",
"     <sub>",
"      2",
"     </sub>",
"     : partial pressure of oxygen; PCO",
"     <sub>",
"      2",
"     </sub>",
"     : partial pressure of carbon dioxide.",
"    </div>",
"    <div class=\"reference\">",
"     Redrawn from: Rebuck AS, Campbell EJM, Am Rev Respir Dis 1974; 109:345.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f28_50_29486=[""].join("\n");
var outline_f28_50_29486=null;
var title_f28_50_29487="IMV versus PV";
var content_f28_50_29487=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F71301&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F71301&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 584px\">",
"   <div class=\"ttl\">",
"    Intermittent mandatory ventilation (IMV) versus pressure support ventilation (PSV)",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 564px; height: 568px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <strong>",
"     A)",
"    </strong>",
"    Changes in pressure-time product (PTP) per minute,",
"    <strong>",
"     B)",
"    </strong>",
"    PTP per breath, and",
"    <strong>",
"     C)",
"    </strong>",
"    frequency as intermittent mandatory ventilation (IMV) and pressure support (PS) were progressively increased. PS of 100 percent represents the level necessary to achieve a tidal volume equivalent to that during assist-control ventilation (10 mL/kg); IMV of 100 percent is the same ventilator rate as during assist-control ventilation. From zero assistance to 60 percent, decrease in PTP/min was greater with PS than with IMV. From 60 to 100 percent assistance, the opposite was observed - the decrease in PTP/min was greater with IMV than with PS. PTP per breath decreased linearly as the rate of IMV was increased to 60 percent. PTP per breath decreased linearly as the amount of PS was increased to 60 percent, but little thereafter. Frequency decreased linearly as PS was increased. In contrast, frequency changed little as the rate of IMV was increased, until a high level of assistance was provided.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Tobin MJ, Jubran, A, Laghi, F. Patient-Ventilator Interaction. Am J Respir Crit Care Med 2001; 163:1059. Copyright &copy;2001 American Thoracic Society.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f28_50_29487=[""].join("\n");
var outline_f28_50_29487=null;
